  
 
PROTOCOL : 1042- SE-3003  
TITLE:  A double -blind , randomized, placebo -controlled study to evaluate the 
efficacy and safety  of intravenous ganaxolone in status epilepticus  
DRUG:  Ganaxolone   
IND:  129433  
EUDRACT NO.:  TBD  
  
SPONSOR:  Marinus  Pharmaceuticals, Inc.  
5 Radnor Corporate Center 
100 Matsonford Road, Suite 500 
Radnor, PA 19087 USA  
PROTOCOL 
HISTORY:  Amendment 5:  06May2024, Version 6.0  
Amendment 4: 13Oct 2023, Version 5.0 
Amendment 3: 10June2022, Version 4.0  
Amendment 2: 19November2021, Version 3.0 
Amendment 1:  14July2020, Version 2.0  
Original Protocol : 13April 2020 , Version 1.0  
 
 
This document contains confidential and proprietary information of Marinus  and is disclosed pursuant to 
confidentiality and non -disclosure obligations . This information should be used solely for the purposes for which it 
was provided and should not be copied, shared with, or disclosed to any third party without the express written 
consent of Marinus . 
 
 
Confidential  Page 4 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
EMERGENCY CONTACT INFORMATION 
In the event of a serious adverse event  (SAE ), the investigator must fax or e- mail the Marinus 
Serious Adverse Even t form within 24 hours to the Marinus Drug Safety vendor. A copy of this 
form must also be sent to the contract research organization ( CRO)/ Medical Monitor by e- mail 
using the details below.  
Email:  
Fax: 
In addition, f or protoc ol or safety related issues the investigator must contact the Medical 
Monitor: 
Medical Monitor:  
, MD , PhD  
, Clinical Development  
Marinus Pharmaceuticals, Inc.  
Email:  
Mobile Telephone Number:  (primary contact method via text or call  to this 
number and followed by e -mail) 
If unavailable : 
, MD  
, Clinical Development  
Marinus Pharmaceuticals, Inc.  
Email:  
Mobile Telephone Number: (primary contact method via text or call  to this 
number followed by e- mail) 
 

 
Confidential  Page 5 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
ADDITIONAL CONTACT INFORMATION  
In case of any other issues including non-safety  related issues or if the Medical Monitor is unable 
to be reached, the Investigator must contact the Mari nus Program or Clinical Trial Manager:   
Marinus Trial  Manager: 
 
 
Marinus Pharmaceutical s, Inc. 
Email:  
Mobile Telephone Number: (primary contact method  via text or call ) 
 
Marinus Program Manager: 
, PharmD  
, Clinical Development Operations 
Marinus Pharmaceuticals, Inc.  
Email:  
Mobile Telephone Number: (primary contact method via text or call) 
 

 
Confidential  Page 6 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
TABLE OF CONTENTS  
PROTOCOL SIGNATURE PAGE  .................................................................................................2 
SUMMARY OF CHANGES FROM PREVIOUS VERSION  ........................................................3 
EMERGENCY CONTACT INFORMATION  ................................................................................4 
ADDITIONAL CONTACT INFORMATION  ................................................................................5 
LIST OF TABLES  .........................................................................................................................11 
LIST OF FIGURES  .......................................................................................................................11 
ABBREVIATIONS  .......................................................................................................................12 
STUDY SYNOPSIS  ......................................................................................................................14 
STUDY SCHEDULE(S)  ...............................................................................................................27 
1 BACKGROUND INFORMATION  .......................................................................................33 
1.1 Indication and Current Treatment Options ........................................................................33 
1.2 Product Background and Clinical Information ..................................................................34 
2 STUDY OBJECTIVES AND PURPOSE  ..............................................................................37 
2.1 Rationale for the study  .......................................................................................................37 
2.2 Study Objectives ................................................................................................................39 
2.2.1 Primary Objective  ........................................................................................................39 
2.2.2 Secondary Objectives  ...................................................................................................39 
2.2.3 Exploratory Objectives  ................................................................................................39 
3 STUDY DESIGN  ...................................................................................................................39 
3.1 Study Design and Flow Chart ............................................................................................39 
3.1.1 Double-blind Phase ......................................................................................................39 
3.1.2 Open -label Phase .........................................................................................................40 
3.2 Interim Analysis  .................................................................................................................41 
3.3 Duration and Study Completion Definition .......................................................................41 
3.4 Sites and Regions ...............................................................................................................41 
4 STUDY POPULATION  .........................................................................................................41 
4.1 Inclusion Criteria  ...............................................................................................................41 
4.2 Exclusion Criteria  ..............................................................................................................42 
4.3 Restrictions  ........................................................................................................................43 
4.4 Reproductive Potential .......................................................................................................43 
4.4.1 Female Contraception  ..................................................................................................43 
4.4.2 Male Co
ntraception  ......................................................................................................44 
4.5 Discontinuation of Participants  ..........................................................................................44 
4.5.1 Investigational product discontinuation .......................................................................44 
4.5.1.1 Reasons for IP discontinuation include, but are not limited to, the 
following:  ...............................................................................................................45 
4.5.1.2 Study Withdrawal ..................................................................................................45 
4.5.2 Participant Withdrawal Criteria  ...................................................................................45 
4.5.3 Reasons for Study Discontinuation ..............................................................................46 
4.5.4 Participants Lost to Follow -up Prior to Last Scheduled Visit .....................................46 
 
Confidential  Page 7 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
5 PRIOR AND CONCOMITANT TREATMENT  ...................................................................46 
5.1 Prior Treatment  ..................................................................................................................46 
5.2 Concomitant Treatment  .....................................................................................................47 
5.2.1 Permitted Treatment  .....................................................................................................48 
5.2.2 Prohibited Treatment ...................................................................................................48 
6 INVESTIGATIONAL PRODUCT  ........................................................................................48 
6.1 Identity of Investigational Product .....................................................................................48 
6.1.1 Blinding the Treatment Assignment  ............................................................................49 
6.1.2 Double-Blind Phase .....................................................................................................49 
6.1.3 Open -Label Phase ........................................................................................................49 
6.2 Administration of Investigational Product(s)  .....................................................................49 
6.2.1 Interactive Response Technology for Investigational Product Management ..............49 
6.2.2 Allocation of Participants to Treatment .......................................................................49 
6.2.2.1 Double-Blind Phase ...............................................................................................49 
6.2.2.2 Open -Label Phase ..................................................................................................49 
6.2.3 Dosing ..........................................................................................................................50 
6.2.3.1 Participants weighing at least 40  kg: .....................................................................51 
6.2.3.2 Participants weighing <40  kg will be dosed on a per kilogram basis: ...................52 
6.2.4 Investigational Product Infusion Precautions ..............................................................53 
6.2.5 Medical Oversight  ........................................................................................................54 
6.2.6 Investigational Product Tapering (One or More May Apply) .....................................54 
6.2.7 Dose Adjustments and Interruptions ............................................................................54 
6.2.8 Unblinding the Treatment Assignment ........................................................................55 
6.2.8.1 Double-Blind Phase ...............................................................................................55 
6.3 Labeling, Packaging, Storage, and Handling .....................................................................55 
6.3.1 Labeling .......................................................................................................................55 
6.3.2 Packaging .....................................................................................................................56 
6.3.3 Storage .........................................................................................................................56 
6.4 Investigational Product Accountability  ..............................................................................56 
6.5 Participant Compliance  ......................................................................................................57 
7 STUD
Y PROCEDURES  ........................................................................................................58 
7.1 Study Schedule...................................................................................................................58 
7.1.1 Screening Period ..........................................................................................................58 
7.1.1.1 Screening ................................................................................................................58 
7.1.1.2 Screen Failures  .......................................................................................................58 
7.1.2 Treatment Period  ..........................................................................................................59 
7.1.2.1 Investigational Product Initiation Through Taper (Day 1 to Day 2) .....................59 
7.1.3 Follow-up Period (starting at IP discontinuation through Week 4) .............................59 
7.1.4 Additional Care of Participants After the Study  ..........................................................59 
7.2 Study Evaluations and Procedures .....................................................................................60 
7.2.1 Demographic and Other Baseline Characteristics  .......................................................60 
 
Confidential  Page 8 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
7.2.2 Efficacy  ........................................................................................................................60 
7.2.2.1 Electroencephalogram (EEG) ................................................................................60 
7.2.2.2 Status Epilepticus Severity Score (STESS)  ...........................................................60 
7.2.2.3 Clinical Global Impression of Severity and Improvement (CGI-S and 
CGI-I, respectively)  ...............................................................................................61 
7.2.2.4 Richmond Agitation and Sedation Scale (RASS) ..................................................61 
7.2.2.5 The Full Outline of UnResponsiveness (FOUR) Score .........................................61 
7.2.2.6 Seizure Description Questionnaire  ........................................................................61 
7.2.2.7 Status Epilepticus Cessation Questionnaire  ...........................................................61 
7.2.2.8 Super Refractory Status Epilepticus Questionnaire  ...............................................61 
7.2.2.9 Modified Rankin Scale (mRS) ...............................................................................61 
7.2.2.10 EuroQol (EQ-5D- 5L) .............................................................................................62 
7.2.3 Safety  ...........................................................................................................................62 
7.2.3.1 Medical, Seizure or SE, and Medication History ..................................................62 
7.2.3.2 Physical Examination .............................................................................................62 
7.2.3.3 Adverse Event Collection ......................................................................................63 
7.2.3.4 Vital Signs  ..............................................................................................................63 
7.2.3.5 Electrocardiography (ECG) ...................................................................................63 
7.2.3.6 Cardiodynamic 12- Lead Electrocardiography (ECG) Monitoring  ........................63 
7.2.3.7 Clinical Laboratory Evaluations  ............................................................................64 
7.2.4 Others  ...........................................................................................................................66 
7.2.4.1 Clinical Pharmacology Blood Sample Collection and Handling Procedures ........66 
7.2.4.2 Shipment of Plasma Pharmacokinetic Samples  .....................................................66 
7.2.4.3 Plasma Drug Assay Methodology .........................................................................66 
7.3 Healthcare Utilization Questionnaires  ...............................................................................68 
8 ADVERSE AND SERIOUS ADVERSE EVENTS ASSESSMENT  ....................................69 
8.1 Definition of Adverse Events, Period of Observation, Recording of Adverse 
Events ..............................................................................................................................69 
8.1.1 Severity Categorization  ................................................................................................69 
8.1.2 Relationship Categorization  .........................................................................................70 
8.1.3 Outcome Categorization ..............................................................................................70 
8.1.4 Symptoms of the Disease Under Study  .......................................................................70 
8.1.5 Clinical Laboratory and Other Safety Evaluations  ......................................................71 
8.1.6 Pre
gnancy .....................................................................................................................71 
8.1.7 Medication Errors and Other Reportable Information  .................................................72 
8.2 Serious Adverse Event Procedures  ....................................................................................72 
8.2.1 Reference Safety Information  ......................................................................................72 
8.2.2 Reporting Procedures ...................................................................................................72 
8.2.3 Serious Adverse Event Definition  ...............................................................................73 
8.2.4 Serious Adverse Event Collection Time Frame  ...........................................................73 
8.2.5 Serious Adverse Event Onset and Resolution Dates  ...................................................73 
 
Confidential  Page 9 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
8.2.6 Fatal Outcome  ..............................................................................................................74 
8.2.7 Regulatory Agency, Institutional Review Board, Ethics Committee, and Site 
Reporting ....................................................................................................................74 
9 DATA MANAGEMENT  .......................................................................................................75 
9.1 Data Collection  ..................................................................................................................75 
9.2 Clinical Data Management  ................................................................................................75 
9.3 Data Monitoring Committee (DMC) .................................................................................75 
10 STATISTICAL CONSIDERATIONS ...................................................................................75 
10.1 Statistical Analysis Process  ................................................................................................75 
10.2 Sample Size Determination  ................................................................................................76 
10.3 Analysis Populations ..........................................................................................................76 
10.4 Statistical Analyses  ............................................................................................................76 
10.4.1 Primary Endpoints (Double -Blind Phase) ...................................................................76 
10.4.2 Key Secondary Endpoints (Double-Blind Phase) ........................................................77 
10.4.3 Other Secondary Endpoints .........................................................................................77 
10.4.4 Healthcare Utilization Endpoints  .................................................................................78 
10.4.5 Open -Label Endpoints  .................................................................................................78 
10.5 Safety Analyses  ..................................................................................................................78 
10.6 Pharmacokinetic Analyses .................................................................................................79 
10.7 Interim Analyses  ................................................................................................................79 
11 SPONSOR’S AND INVESTIGATOR’S RESPONSIBILITIES ...........................................79 
11.1 Sponsor’s Responsibilities .................................................................................................80 
11.1.1 Good Clinical Practice (GCP) Compliance  .................................................................80 
11.1.2 Public Posting of Study Information ............................................................................80 
11.1.3 Submission of Summary of Clinical Study Report to Competent Authorities of 
Member States Concerned and Ethics Committees ....................................................80 
11.1.4 Study Suspension, Termination, and Completion........................................................80 
11.2 Investigator’s Responsibilities  ...........................................................................................81 
11.2.1 Good Clinical Practice Compliance  .............................................................................81 
11.2.2 Protocol Adherence and Investigator Agreement  ........................................................81 
11.2.3 Documentation and Retention of Records ...................................................................82 
11.2.3.1 Case Report Forms  .................................................................................................82 
11.2.3.2 Rec
ording, Access, and Retention of Source Data and Study Documents ............82 
11.2.3.3 Audit/Inspection  .....................................................................................................83 
11.2.3.4 Financial Disclosure  ...............................................................................................83 
11.3 Ethical Considerations  .......................................................................................................83 
11.3.1 Informed Consent.........................................................................................................83 
11.3.2 Institutional Review Board or Ethics Committee  ........................................................84 
11.4 Privacy and Confidentiality  ...............................................................................................84 
11.5 Study Results/Publication Policy .......................................................................................85 
12 REFERENCES .......................................................................................................................87 
 
Confidential  Page 10 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
13 APPENDICES ........................................................................................................................91 
 
  
 
Confidential  Page 11 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
LIST OF TABLES  
Table 1.  Schedule of Assessments (Double Blind and Open- Label Phases)  .......................27  
Table 2.  Investigational Product Infusion and Pharmacokinetic Sample Collection (Double 
Blind and Open- Label Phases) ...............................................................................32  
Table  3. Enrollment in Study 1042- SE-2001 Dose Level Cohorts ......................................38  
Table 4.  Dosing for Participants ≥40 kg (on a mg/hour basis)  ............................................52  
Table 5.  Dosing for Participants <40 kg (on a mg/kg/hour basis) .......................................53  
Table 6.  Clinical Laboratory Tests  .......................................................................................65  
Table  7. Volume of Blood to Be Drawn from Each Participant ..........................................67  
Table  8. Volume of Blood to Be Drawn from Each Participant (Pediatric Institution Sample Volumes)  ...................................................................................................67
 
 
LIST OF FIGURES  
Figure 1.  Study Design Flow Chart .......................................................................................40  
 
 
Confidential  Page 12 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
ABBREVIATIONS  
AE adverse event  
AED  antiepileptic drug  
ALT  alanine aminotransferase  
AST  aspartate aminotransferase  
BID twice daily  
BMI  body mass index  
CGI-I Clinical Global Impression -Improvement  
CGI-S Clinical Global Impression -Severity  
CRA  clinical research associate  
CRO  contract research organization  
CSE convulsive status epilepticus  
DMC  data monitoring committee  
EC Ethics Committee  
ECG  electrocardiography  
eCRF  electronic case report form  
EEG  electroencephalography  
eGFR  estimated glomerular filtration rate  
EMA  European Medicines Agency  
ESE established status epilepticus  
ESETT  Established Status Epilepticus Treatment Trial  
EU European Union  
Euro QOL  Euro Quali ty of Life  
FCBP  Females of childbearing potential  
FDA  United States Food and Drug Administration  
FOUR Score  Full Outline of Un Responsiveness Score  
GABA  gamma -aminobutyric acid  
GCP  Good Clinical Practice  
GCSE  generalized convulsive status epilepticus   
GNX  ganaxolone  
HIPAA  Health Insurance Portability and Accountability Act  
IB Investigator’s Brochure  
ICF informed consent form 
ICH International Council for Harmonisation  
ICU Intensive Care Unit  
ILAE  International League Against Epilepsy  
IV intravenous  
IM intramuscular  
IP investigational product  
IRB Institutional Review Board  
ITT Intent to treat  
LAR  legal authorized representative  
MRI  Magnetic Resonance Imaging  
mRS Modified Rankin Scale  
NCSE  non-convulsive status epilepticus  
 
Confidential  Page 13 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
NLT  not less than  
PND  Postnatal Day  
RASS   Richmond Agitation and Sedation Scale  
PK pharmacokinetic  
RSE refractory status epilepticus  
SAE  serious adverse event  
SAP Statistical Analysis Plan 
SE status epilepticus  
SRSE  super refractory status epilepticus  
STESS  Status Epilepticus Severity Scale  
ULN  upper limit of normal  
 
Confidential  Page 14 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
STUDY SYNOPSIS  
Protocol number : 1042 -SE-3003  Drug : GGG anaxolone  
Title of the study:  A double -blind , randomized, placebo -controlled study to evaluate the efficacy and safety of 
intravenous ganaxolone in status epilepticus  
Number of participant s (total and for each treatment arm):  
The term “participant” will be used in place of “ subject ” in accordance with the Food and Drug Administration 
(FDA) glossary , which states these may be used interchangeably.  The double -blind  phase  of the study plans to  
screen approximately 160  patients  aged  12 years of age and older with status epilepticus (SE)  to randomize 
approximately 124 participants . Participants will be randomized in a 1:1 ratio to receive ganaxolone IV solution 
or placebo added to SE standard of care.  Should the interim analysis result in demonstration of efficacy , the study 
will transition  to an open -label treatment with all participants receiving  ganaxolone IV solution added to SE 
standard of care . 
Investigator(s): Multicenter study  
Site(s) and Region (s):  
Multicenter study to be conducted in the United States, Canada, and Australia at approximately 100 sites  
Study period (planned) : August 2020 to December  2024 Clinical phase : 3 
Objectives:  
Primary:  
• To evaluate the efficacy and safety  of ganaxolone IV for the treatment of SE after failure of two or more 
antiseizure medications . 
Secondary :  
• To assess the time to  SE cessation following ganaxolone administration . 
• To evaluate the sustained efficacy of ganaxolone IV beyond the  48-hour treatment period  as assessed by 
prevention of progression to IV anesthesia  for the treatment of SE .  
Exploratory :  
• To determine the effect  of ganaxolone on healthcare resource utilization . 
• To assess the effect of ganaxolone on doses of other antiseizure treatments  and changes in seizure burden. 
• To evaluate the effect of ganaxolone on quality of life , functional  status , and level of responsiveness . 
Rationale:  
Status epilepticus is defined as a prolonged, self -sustaining seizure or  recurrent seizures without intervening 
recovery of consciousness.1 The International League Against Epilepsy (ILAE) further defined SE as a condition 
resulting either from the failure of mechanisms responsible for seizure termination or from the initiation of 
mechanisms leading to prolonged seizures.2 SE duration is typically defined as 5  minutes for convulsive  (CSE) 
and 10 minutes for nonconvulsive (NC SE).3 The ILAE has proposed definitions that encompass the time at which 
seizures become self -sustaining (t1) and a time when neurologic damage results (t2).2 For generalized convulsive 
status epilepticus (GCSE), these are 5 and 30 minutes, respectively; for NCSE, they are 10 and 60 minutes.  
Status epilepticus  is a neurological emergency that requires urgent  treatment to stop seizures and avoid 
neurologic sequelae.4 Mortality can range from 3% to 40% depending on etiology, age, SE type, and duration.5,6,7 
Convulsive SE is associated with complications that include cardiac arrhythmias, rhabdomyolysis, pulmonary 
edema, electrolyte and glucose imbalances and body temperature disturbances. Approximately one third of patients with refractory status epilepticus (RSE) and super  refractory SE (SRSE) wi ll die and one -third  will 
recover with chronic neurologic sequelae . 
 
Confidential  Page 15 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
Benzodiazepines are the agents of choice for first -line treatment of SE, but may cause respiratory depression and 
hypotension, requiring the use of supportive therapies.8 Approximately 35 % to 45% of patients fail first -line 
treatment with benzodiazepines and are then considered to have established status epilepticus  (ESE). T he recently 
published findings from the Established Status Epilepticus Treatment Trial ( ESETT) , comparing the efficacy and 
safety of three commonly administered second -line IV antiepileptic drug ( AEDs ; fosphenytoin, levetiracetam and 
valproic acid) found that SE was  not controlled in over 50% of  ESE patients and that none of the medications 
tested was superior to the others.9 
When a patient fails to respond to a benzodiazepine and the initial second- line IV AED, they are classified as 
having refractory SE (RSE).  Refractory SE develops in 31% to 50% of patients with SE and has a mortality of 16 
to 39%.1,10,11 Because SE tends to become more refractory as it progresses, patients who fail second -line IV 
AEDs may require treatment with an IV anesthetic.12,13 Third -line agents such as pentobarbital, midazolam and 
propofol are administered at anesthetic doses to induce coma that is maintained for 24 hours or longer, after 
which the dose of anesthetic agent is reduced to determine whether seizure activity has bee n aborted. IV 
anesthesia is an independent risk factor for increased morbidity and mortality in SE, with longer duration of anesthesia associated with a worse prognosis.
14,15,16 
Few drugs are approved for the treatment of SE and the re is a need for more evidence -based, efficacious 
therapies . Treatment resistance in SE has been partially attributed to the internalization of post -synaptic γ -
aminobutyric acid (GABA) A receptors and externalization of glutamate receptors.10,12 With the down -regulation 
of GABA A-mediated synaptic inhibition that occurs in SE, antiepileptic treatments relying on enhancement of 
synaptic GABA A neurotransmission become less effective.  
Ganaxolone is a potent positive allosteric modulator of GABA A receptors that binds at a site distinct from that 
responsible for the action of benzodiazepines and barbiturates.17 Unlike benzodiazepines, neuroactive steroids 
such as ganaxolone  bind to both synaptic and extrasynaptic GABA A receptors.18 By enhancing GABA A receptor 
function, especially through its action at extrasynaptic GABA A receptors, ganaxolone provides an alternative 
mechanism in the treatment of seizures . Thus, ganaxolone may serve as a novel and effective therapy in the 
management of SE.  
The ganaxolone to be used for this study is a proprietary IV formulation solubilized by Captisol® (betadex 
sulfobutyl ether sodium) . Dosing targets plasma concentrations of ganaxolone  that mimic those associated with 
anticonvulsant effects in preclinical animal models of SE and that are expected to demonstrate anticonvulsant 
properties in humans . The dose of Captisol® will not exceed 50 g /day (1.25 g/kg/day in participants weighing 
<40 kg) which corresponds  to a maximum ganaxolone dose of 833 mg/day (20.825  mg/kg/day  in participants 
weighing <40 kg ). 
Investigational Product, Dose, and Mode of Administration: 
Once consent/assent has been obtained or deferred where allowed by law , ganaxolone IV solution or placebo, 
referred to as investigational product (IP) throughout this document, will be added to standard of care .  
Participants must have received any two or more of the following  agents for treatment  of the current episode of 
SE, administered at an adequate dose and for a sufficient duration, in the judgment of the investigator, to 
demonstrate efficacy:  
• Benzodiazepines, 
• IV Fosphenytoin/phenytoin,  
• IV Valproic acid,  
• IV Levetiracetam,  
• IV Lacosamide ,  
• IV Brivaracetam , or 
• IV Phenobarbital . 
Fosphenytoin and phenytoin will be counted as 1 AED. Levetiracetam and brivaracetam will be counted as 
2 AEDs. 
Investigational product for administration will be provided to the site as individual 500 mL bottles of 1 mg / mL of 
ganaxolone, or placebo. Each bottle contains not less than (NLT) 425 mL  of IP . 
 
Confidential  Page 16 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
Investigational product should be administered through a dedicated peripheral or central IV line  or a dedicated 
lumen of a multi- lumen catheter. Note: At any time, the infusion rate of IP may be temporarily decreased or 
permanently stopped for safety reasons.  
The total time of IP administration will be 48 hours (36 hours IP administration and 12 hours of IP taper). The 
investigator will confirm that the participant  meets clinical and electroencephalographic  (EEG ) criteria for SE 
during the 60 -minute period prior to IP initiation and will reconfirm that ongoing ictal activity is present within 
30 minutes immediately prior to IP  initiation . The dosing of IP will be as follow s: 
Participants weighing at least 40  kg: 
• A 30 mg bolus dose (over ~3 minutes) will be administered with a continuous infusion of 80 mg/hour for 
2 hours followed by a continuous infusion rate of 40 mg/hour for 10 hours, and then 20 mg/hour for the 
remaining 12 hours of Day 1 (time 0 to 24 hours) .  
• On Day 2, from 24 to 36 hours following IP initiation, the continuous infusion rate of 20 mg/hour can be 
increased up to a maximum rate of 45 mg/hour until the start of the taper at 36 hours. The infusion rate will 
be determined by  the investigator to best manage seizure relapse and cannot exceed a rate of 45 mg/hour 
between 24 and 36 hours following  IP initiation.  
• To taper IP, beginning 36 hour s following  IP initiation, the infusion rate will be reduced by 33.3% every 
4 hours until the infusion is stopped or until the infusion rate becomes too low to sustain the IV line.  
Note: If, according to the investigator’s clinical judgment, IP taper needs to start sooner than 36 hours after 
initiation, the infusion rate will be decreased by 33.3% of the rate at the beginning of the IP taper every 4 hours.  
• At the time the IP infusion is discontinued, the participant will progress to the  follow -up period 
assessments/procedures.  
Participants weighing <40  kg will be  dosed on a per- kilogram basis: 
• A 0.75 mg/kg bolus dose (over ~3 minutes) will be administered with a continuous infusion at a dose of 
2 mg/kg/hour for 2 hours followed by a continuous infusion dose of 1 mg/kg/hour for 10 hours, and 
0.5 mg/kg/hour for the  remaining 12 hours of Day 1 (time 0 to 24 hours) . 
• On Day 2, 24 to 36 hours following  IP initiation, the continuous infusion rate of 0. 5 mg/kg/hour can be 
increased up to a maximum of 1.125 mg/kg/hour until the start of IP taper at 36 hours. The infusion rate will 
be determined by  the investigator  to best manage seizure relapse and cannot exceed a rate of 1.125 
mg/kg/hour during hours 24 to 36 of Day 2.  
• To taper IP, beginning 36 hour s following  IP initiation, the infusion rate will be reduced by 33.3% every 
4 hours until the infusion is stopped or until the infusion rate becomes too low to sustain the IV line.  
Note: If, according to the investigator’s clinical judgment, IP taper needs to start sooner than 36 hours after 
initiation, the infusion rate will be decreased by 33.3% of the rate at the beginning of the IP taper every 4 hours.  
• At the time the IP infusion is discontinued , the participant will progress to the follow -up period 
assessments/procedures.  
Investigational product infusion precautions:  
Throughout the study, heart rate and rhythm, blood pressure, and oxygen saturation will be monitored. 
Investigational product may be temporarily or permanently discontinued, if clinically indicated, for treatment of 
persistent hypotension (sustained systolic blood pressure 90 mmHg), cardiac arrhythmia or oxygen desaturation.  
Investigational product may also be terminated for any serious adverse event during infusion that the treating physician believes is IP related and necessary for participant safety.  Investigational product d iscontinuation does 
not affect  continued participation in the study. All participants should be followed , regardless of early  
discontinuation of IP,  until the final study follow -up visit/contact unless  consent is withdrawn.  
Medical oversight:  
Participants will require close medical monitoring as defined by local institutional practice guidelines for the 
treatment of patients with the diagnosis of seizures and/or status epilepticus . 
Telemedicine : 
 
Confidential  Page 17 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
Telemedicine is an acceptable practice for conducting protocol -driven assessments/procedures  as defined by local 
institutional practice guidelines . 
Investigational product discontinuation (one or more may apply) : 
• Scenarios for stopping IP without a taper may include:  
o Participants who receive IP for less than 2 hours . 
o Investigational product infusion is discontinued or interrupted (e.g., for safety concerns related or 
not related to IP or due to planned medical procedures), and a decision is made not to restart the 
infusion . 
o If at any time during IP administration the participant progresses to an anesthetic with the primary intent specifically to treat seizures or achieve burst suppression . 
o For other safety reasons based on the investigator’s clinical judgment . 
Dose adjustments and interruptions:  
Investigational product dose (infusion rate) decreases , and interruptions are discouraged during treatment. 
However, if there is an urgent medical need (e.g., severe hypotension, severe sedation) or standard of care  
requires a procedure for which the infusion rate would need to be temporarily decreased or interrupted (e.g., 
MRI) it should be kept as short as possible and should not exceed 2 hours. If the interruption is > 2 hours , the 
Medical Monitor should be consulted before restarting the infusion.  
Note:  
• After a dose (infusion rate) decrease or interruption, the investigator’s clinical judgment of risk/benefit will 
determine IP administration or discontinuation.  
• Investigational product discontinuation does not affect continued participation in the study. All participants 
should be followed , regardless of early  discontinuation of IP,  until they reach the final study follow -up 
visit/contact unless  consent is withdrawn.  
• In cases when IP discontinuation is being considered (e.g., severe sedation), when possible, the Medical 
Monitor should be contacted prior to infusion termination.   
• If the decision is made to restart IP, the infusion should be restarted at the rate matching the rate at the 
corresponding nominal time, counted from the start of the IP infusion on Day 1. Investigational product bolus or “catch -up” dose to deliver the IP that was missed during the interruption should not be administered.  
Dose (infusion rate) increases above those specified in the protocol are not allowed at any time during infusion. This is to ensure daily Captisol
® and ganaxolone limits are maintained at ≤50 g/day (1.25 g/kg/day in participants 
weighing <40 kg ) and ≤83 3 mg/day  (20.825  mg/kg/day  in participants weighing <40 kg ), respectively.  
Methodology:  
This is a double -blind, randomized, placebo -controlled study to evaluate the efficacy and safety  of ganaxolone IV 
solution in SE , with the option to transition  the study to an open -label  phase to obtain additional safety data . 
Screening, duration of the treatment , and follow -up period s, as well as the study schedule , remain the same for 
participants enrolled under either the double -blind or open- label phases.   
As previously described, IP will be added to standard of care  after failure of two or more  antiseizure treatments  
(benzodiazepine and one IV AED or two IV AEDs).  
Potential participants may be identified in the emergency department, ICU , or other units in the hospital, and will 
be consented/assented and then screened for inclusion/exclusion criteria prior to being randomized to start IP 
treatment . Investigational product will be administered as a 3 -minute bolus that will be started with a continuous 
IV infusion of IP  lasting for 36 hours and followed by a 12 - hour taper. After the IP has been discontinued , the 
follow -up period  assessments/procedures will be collected  every 24 hours through 120 hours (or until hospital 
discharge) and at the time of hospital discharge followed by weekly follow -up visits/contacts  at Week 1, 2, 3 and 
4.  
Week s 1, 2, 3, and 4 visits can be conducted as inpatient visit s, if the participant is still in the hospital or as a 
telephone contact if the participant has been discharged. Attempts should be made to have discharged participants 
return for one of these visits to be in person. In total, each participant will be followed for approximately 4 weeks 
following  IP initiation.  
 
Confidential  Page 18 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
An interim analysis will be conducted when  approximately  two-thirds  of the ITT population  have completed  
72 hours of efficacy  assessments (approximately  41 participants per arm) . Enrollment in the double -blind phase 
will continue until the  DMC provides a recommendation regarding study continuation. Based upon the interim 
analysis results , recommendation from the DMC , and agreement from the S ponsor,  the double -blind study will 
either continue without modification or will transition  to enrollment in an open-l abel phase . All participants  
enrolled subsequently will receive open --label ganaxolone IV solution added to  SE standard of care . 
Approximately 60 to 100 study participants will receive ganaxolone IV in the double -blind and open -label phases 
combined.  
Screening  
Procedures specific to this protocol will not be performed until written informed consent/assent from the 
prospective participant/participant’s parent/guardian/legally authorized representative (LAR) has been 
appropriately obtained according to institution policy. As many of the participants will not be able to provide 
consent/assent, a parent/guardian/LAR may provide consent on behalf of the participant . Where allowed by law, 
if the patient lacks the capacity to make informed decisions regarding his/her me dical treatment options, the 
treating clinician may follow their deferred consenting practices. As soon as the participant is able, according to 
institution guidelines, consent/assent will be obtained. Consent/assent for participants who are known to be at risk 
for SE may be obtained prior to the occurrence of SE.   
Standard of care a ssessments conducted  prior to obtaining informed consent,  that the investigator judges to be 
clinically relevant to the participant’s current condition, can be utilized in the study and do not need to be 
repeated. For medically unstable participants , screening activities (e.g., labs or vital signs) should be collected as 
close to IP initiation as possible . 
Treatment and Follow -up 
Investigational Product Dosing  
Approximately 160 participants will be enrolled in the double -blind phase of the study. For the double -blind 
phase , participants will be randomized (1:1) to receive either ganaxolone IV solution or placebo added to SE 
standard of care . In the open- label phase, all enrolled participants will receive ganaxolone IV solution added to 
SE standard of care. Investigational product will be given as a bolus plus continuous infusion. Following  IP 
initiation, the standard duration of treatment is 2 days (48 hours) which includes a 12- hour taper.  
Safety and Assessments  
Investigational product will be given in addition to standard of care for SE and other medical or surgical 
interventions deemed appropriate by the investigator.  Safety and tolerability will be monitored including  but not 
limited to the following:  
1. Physical examination should be completed:  
a. Predose (screening) or, if unable to perform  predose , conduct within 2 hours following  IP initiation, 
and at 36 hours , if clinically indicated , following IP initiation , 
b. At the time of IP discontinuation (+/ - 1 hour), either at the end of the taper or if the IP 
administration is stopped without a taper,  
c. 24 hours (+/- 1 hour) following  IP discontinuation, and  
d. At the time of hospital discharge.  
e. For participants who terminate early  from the study, at the time  of early termination  (whenever 
possible) .  
f. At any other time based on the clinical judgment of the investigator . 
2. Status Epilepticus Severity Score (STESS)  shoul d be collected predose (screening).  
3. Vital signs  should be collected:  
a. Predose (screening), 60 minutes (+/ - 15 min), 2 (+/ - 15 min), 6, 10 , 24, and 36 hours (+/- 2 hour) 
following  IP initiation,  
b. At the time of IP discontinuation (+/ - 1 hour), either at the end of the taper or if the IP 
administration is stopped without a taper,  
c. 24 hours (+/- 2 hour) following  IP discontinuation, and  
d. At the time of hospital discharge.  
 
Confidential  Page 19 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
e. For participants who terminate early  from the study, at the time  of early termination  (whenever 
possible) . 
f. At any other time based on the clinical judgment of the investigator . 
4. Weight and height  shoul d be collected predose (screening) for calculation of the BMI inclusion criterion, 
if feasible. If unable to collect predose, collect prior to the end of the first 24 hours of the follow -up 
period.  
5. Richmond Agitation and Sedation Scale (RASS) and the Full Outline of UnResponsiveness (FOUR) 
Score Scale should be collected : 
a. Predose (screening),  
b. 60 minutes  (+/- 15 min) , 2, 6, 10 (+/- 30 min) , 24 and 36 hours  (+/- 1 hour) following  IP initiation,  
c. At the time of IP discontinuation (+/- 1 hour), either at the end of the taper or if the IP 
administration is stopped without a taper,  
d. 24 (+/- 1 hour) , 48, 72, 96, and 120 hours (+/- 2 hours) following  IP discontinuation, and  
e. At the time of hospital discharge.  
f. At the weekly follow -up visits  (Week 1, 2, 3, or 4)  for hospitalized  participants  and for participants  
who have been discharged  (whenever possible) . 
g. For participants who terminate early  from the study, at the time of early termination  (whenever 
possible) .  
6. Electrocardiogram  (ECG),  the participant should have a safety 12 lead ECG:  
a. Predose (screening), 2 (+/ - 30 min) following  IP initiation,  
b. At the time of IP discontinuation (+/ - 1 hour), either at the end of the taper or if the IP 
administration is stopped without a taper,  
c. 24 hours (+/- 1 hour) following  IP discontinuation, and  
d. At the time of hospital discharge.  
e. For participants who terminate early  from the study, at the time of early termination  (whenever 
possible).  
f. At any other time based on the clinical judgment of the investigator.  
7. Cardiodynamic  12 l ead ECG monitoring: Select sites will participate in a sub study using a continuous 
12 lead ECG recorder which should begin approximately 60 minutes prior to the initiation of IP and 
continue for 36 hours following  IP initiation.  
8. Clinical laboratory measures , hem a tology, serum chemistry (including creatinine, blood urea nitrogen 
[BUN], estimated glomerular filtration rate [eGFR] calculation  (if available) , creatinine clearance 
calculation  (if available) , and concomitant AED levels (fosphenytoin/phenytoin,  valproic acid, 
levetiracetam, lacosamide, phenobarbital , or brivaracetam, if collected per standard of care ), and  
Urinalysis  (including urine protein and microscopic , if a ny abnormal value is observed on the urine 
dipstick test ), should be collected:  
a. Predose (screening), if unable t o collect predose , collect within 2 hours following  IP initiation,  
b. At the time of IP discontinuation (+/ - 1 hour); either at the end of the taper or if the IP 
administration is stopped without a taper,  
c. 24 hours (+/- 1 hour) following  IP discontinuation, and  
d. At the time of hospital discharge . 
e. At the weekly follow -up visits (Week 1, 2, 3, or 4) for hospitalized participants and for participants 
who have been discharged  (whenever possible ). 
f. For participants who terminate early from the study, at the time of early termination (whenever 
possible).   
g. In the event of a n SAE . 
h. At any other time based on the clinical judgment of the investigator.  
Urine chemistry samp l es for N -acetyl -β-D- glucosaminidase [NAG] , β2-microglobulin , and creatinine  
should be collected:  
 
Confidential  Page 20 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
a. Predose (screening), if unable to collect predose, collect w ithin 2 hours following IP initiation,  
b. 24 hours (+/- 1 hour) following IP discontinuation, and 
c. At the time of hospital discharge.  
d. At the weekly follow -up visits (Week 1, 2, 3, or 4) for hospitalized participants and for participants 
who have been discharge d (whenever possible) . 
e. For participants who terminate early from the study, at the time of early termination (whenever 
possible).  
Urine samples will be stored frozen unless otherwise dictated or revised in the Biospecimen Manual . 
Coagulation  (incl uding fibrinogen, activated partial prothrombin time [APTT], prothrombin time [PT] 
and internatio nal normalized ratio [INR]) samples should be collected:  
a. Predose (screening), if unabl e to collect predose , collect within 2 hours following  IP initiation,  
b. 24 hours (+/- 1 hour) following  IP discontinuation, and  
c. At the time of hospital discharge.  
d. For participants who terminate early from the study, at the time of early termination (whenever 
possible).  
e. At any other time based on the clinical judgment of the investigator . 
9. Drugs of abuse  tes ting should be collected predose (screening)  per institution  standard of care. Alcohol 
testing should be collected if  medically  indicated . Sample s can be urine or serum. If unable to collect 
predose, collect as soon as possible following IP initiation . Enrollment is not contingent upon results. 
However, if a participant has a positive test result, it will be at the investigator’s discretion to weigh the 
risks versus benefits for enrollment  or continued participation.  
10. Pregnancy  test  for females of childbearing potential, should be collected predose (screening).  Samples 
can be urine or serum . If unable  to collect predose, collect as soon as possible following IP in itiation . 
Enrollment is not contingent upon results. However, if a participant has a positive test result, it will be  at 
the investigator’s discretion to weigh the risks versus benefits for enrollment or continued participation. 
If the institution requires the pregnancy test results to be obtained prior to IP initiation , the institution ’s 
guideline s will be followed.   
11.  Electroencephalogram  is required for confirmation of CSE and NCSE diagnosis.  Ideally, continuous 
EEG monitoring should start at least 60 minutes before IP initiation and continue through the end of the 
first 24 hours of the follow -up period.  
Sites will be offered the use of a rapid EEG device to assist with screening of par ticipants  with NCSE. It 
is preferred that a conventional  EEG is used for the purpose s of confirming inclusion criterion #3 and 
EEG monitoring during IP administration . In situations when  a conventional EEG is not immediately 
available, the rapid  EEG may be used to confirm inclusion criterion #3. Since the rapid EEG has a 
limited batter y life, it should be switched to  a conventional EEG within several hours but not earlier  than 
90 minutes  after IP initiation  to allow uninterrupted collection  of EEG for the 30- minute  SE cessation  
co-primary endpoint . It will be at the investigator’s discretion if the use of the rapid EEG will benefit 
their site . The device should be used according to institution standard practices .  
12. Blood sampling (veno us or arterial) for pharmacokinetic (PK)  analysis  of ganaxolone  and Captisol® will 
be collected at the following times:  
Required  collections:  
a. Aft
er the start of the IP infusion: 60 minutes (+/ - 5 min), then 2, 6 (+/- 5 min), 10, 24  and 
36 hours (+/- 2 hour) following  IP initiation,  
b. At the time of IP discontinuation (+/ - 1 hour), either at the end of the taper or if the IP 
administration is stopped without a taper  (e.g., when the participant progresses to IV anesthesia 
for seizure/SE treatment) , and  
c. 24 hours (+/- 1 hour) following  IP discontinuation.  
Variable PK collection times based on participant response: 
Between IP initiation and at the end of the first 24 hours of  the follow -up period , where possible, collect 
a PK sample:  
d. At the time of an SAE  (related or not related)  
 
Confidential  Page 21 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
Pharmacokinetic samples should  be collected from the contralateral peripheral access or the arteria l line  
and avoid collecting samples downstream of the IP infusion.  The location of IP access and location of 
PK sample collection should be documented in the participant’s source. If the PK sample cannot be 
collected due to poor venous or arterial access and the I P infusion site is the only viable option, the 
sample should not  be collected and the reason for non -collection documented in the participant’s source. 
Pharmaco kinetic  samples will be stored frozen as per the Biospecimen Manual .  
13. Blood gas  samp l es, arterial or venous, if collected  to manage the participant’s care  from the time of SE 
diagnosis through the end of the  first 24 hours of the follow -up period , the electronic  case report form 
(eCRF) should be completed. If samples are not collected, a sample is not required.  
If a decision is made to intubate the participant between IP initiation through  the e nd of the first  24 hours 
of the follow -up period , a blood gas sample should be collected. The sample should be collected 
immediately prior to or as close as possible to the time of intubation.  
14. Clinical Global Impression of Severity and Improvement (CGI -S an d CGI -I, respectively)  
CGI-S should be collected:  
a. Predose (screening)  
CGI-I should be collected:  
a. 10 and 24 hours (+/- 1 hour) following  IP initiation,  
b. The time of IP discontinuation (+/- 1 hour), either at the end of the taper or if the IP 
administration is stopped without a taper,  
c. 24 (+/- 1 hour) , 48, 72, 96, and 120 hours (+/- 2 hours) following  IP discontinuation, and  
d. At the time of hospital discharge.  
e. Week 1, 2, 3, and 4 follow- up visits (in person or via telephone contact).  
f. For participants who terminate early  from the study, collect at the time of early termination 
(whenever possible) .  
15. EuroQoL (EQ -5D-5L) q uestionnaire should be collected:  
a. 120 hours (+/- 2 hour) following  IP discontinuation and  
b. At the time of hospital discharge.  
c. Week  2, 3, and 4 follow -up visits (in person or via telephone contact).  
d. For participants who terminate early  from the study, collect at the time of early termination 
(whenever possible).  
16. Modified Rankin Scale ( mRS) s hould be collected:  
a. 24 (+/- 1 hour) , 48, 72, 96, and 120 hours (+/- 2 hours) following  IP discontinuation, and  
b. At the time of hospital discharge.  
c. Week 2, 3 and 4 follow -up visits (in person or via telephone contact).  
d. For participants who terminate from the study, collect at the time of early termination (whenever 
possible) . 
17. Etiology of Status Epilepticus Questionnair e sho uld be collected predose (screening).  
18. Seizure Description Questionnaire  should be collected predose (screening) and as close as possible to IP 
initiation.  
19. Status Epilepticus Cessation Questionnaire  shoul d be collected as close as possible to  24 and  72 hours 
following IP  initiation .  
20. Super Refractory Status Epilepticus Questionnaire  shoul d  be collected  as close as possible to the 
diagnosis of SRSE and no later than  the final  study  follow -up visit/contact.  
21. Adverse events (AE s) an d Concomitant medications: AEs will be collected from the time of  IP initiation  
until the final study follow -up visit/contact via non- direct questioning.  Concomitant medications will be 
collected during the same time period.  
a. All adverse events and associated concomitant medications will be collected through the final study  
fol
low-up visit/contact.  
 
Confidential  Page 22 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
b. For participants who terminate early  from the study, prior to discontinuation , as much information 
as is available should be recorded for A Es/SAEs and their associated concomitant medications, 
especially those that may have led to the early termination.  
c. AEDs administered within 14 days of IP initiation  will be recorded along with the reason for 
administration.  
Instructions for collecting benzodiazepines , AEDs , anesthesia, and vasopressor medications prior to and 
post IP initiation  is referenced in Section s 5.1 and 5.2. Some concomitant medications only require 
eCRF entries to support the highest dose administered, please reference the eCRF Completion 
Guidelines for details.  
22. Healthcare Utilization Questionnaires include the Hospitalization Questionnaire and the Positive Pressure 
Ventilation (PPV) and Intubation Questionnaire. The Hospitalization Questionnaire should be collected 
at hospital discharge or at final study visit/contact.  
The need for non -invasive or invasive ventilatory support within 24 hours prior to IP initiation and 
following IP initiation and within 48 hours following IP discontinuation should be collected as close as possible to the event.  
Study follow -up and
  discontinuation: 
Participants who terminate early  from the study, e.g., due to withdrawal of consent, should have early termination 
procedures completed when early termination is being considered, wherever possible . 
Participants who discontinue IP with or without a taper  (e.g., were administered IP for less than  2 hours , progress  
to anesthesia for seizure suppression or discontinue IP due to safety or any other reason except due to withdrawal 
of consent ) will continue in the study . The follow -up period assessments/procedures will be collected every 
24 hours through 120 hours  (or until hospital discharge)  and at the time of hospital discharge , followed by weekly 
follow -up visits/contacts at Week 1, 2, 3 , and 4 . 
All participants  who discontinue IP, except those who are terminated early from the study, will have the follow -
up period assessments/procedures, and the follow -up visits/contacts at Week 1, 2, 3, and 4.  Week s 1, 2, 3 and 4 
visits can be conducted as an inpatient visit, if the participant is still in the hospital or as a telephone contact, if 
the participant has been discharged. Attempts should be made to have discharged participants return for one of 
these visits to be in person.  
During these visits/contacts, the site will follow -up on all S AEs and AEs, and medications administered . Each 
participant will be followed for approximately 4 weeks.  
During the study, it is expected that the total blood volume drawn from pediatric participants for all safety and 
pharmacokinetic sampling will be approximately 36 mL and will not exceed 40 mL of blood. The total blood 
drawn from adult participants will be approximately  140.3  mL and will not exceed 190.4  mL. 
Inclusion and Exclusion Criteria:   
Inclusion Criteria:   
1. Participant, participant’s  parent, guardian,  or LAR must provide  signed informed consent/assent, 
and once  capable (per institution al guidelines), there  must be documentation of  consent/assent by 
the participant demonstrating they are  willing and aware  of the investigational nature  of the study 
and related procedures . Where allowed by law, if the patient lacks the capacity  to make informed 
decisions regarding his/her me dical treatment options, the treating clinician may follow their 
deferred consenting pr actices . The clinician will make the final decision based on the best 
interests of the pat ient. 
2. Male  or females 12 years  of age and older at the  time of the first dose  of IP. 
3. SE meeting the following criteria:  
a. A diagnosis of SE with or without prominent motor features based on clinical and EEG findings  
according to the investigator’s judgment , based on the following: 
i. For SE with prominent motor features: Clinical and EEG  seizure activity indicative of 
convulsive, myoclonic or focal motor SE  
ii. For SE without prominent motor features (nonconvulsive SE): Appropriate clinical features and an EEG indicative of NCSE (see modified Salzburg criteria
19 in Appendix 3). 
iii. For any type of SE: 
 
Confidential  Page 23 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
• Approximately 6 minutes of cumulative seizure activity over a 30 -minute period within the 
hour before IP initiation, AND  
• Seizure activity during the 30 minutes immediately prior to IP initiation . 
b. The treating clinician(s) anticipate that IV anesthesia is likely to be the next treatment for SE that 
persists following initiation of IP . 
4. Participants must have  received any two or more of the following agents for  treatment of  the 
current episode  of SE administered at an adequate  dose and for a sufficient duration, in the 
judgment of the investigator, to demonstrate  efficacy (guidelines for  adequate doses are  provided 
in Appendix 2): 
o Benzodiazepines , 
o IV Fosphenytoin/phenytoin,  
o IV Valproic  acid,  
o IV Levetiracetam,  
o IV Lacosamide , 
o IV Brivaracetam, or  
o IV Phenobarbital  
5 BMI  <40 or, if  BMI  is not able  to be  calculated at  screening, participant is  assessed by investigator  as 
not morbidly obese . 
Exclusion Criteria:  
1. Life expectancy of less than 24 hours.  
2. Anoxic brain injury or an uncorrected , rapidly reversable metabolic condition as the primary cause of SE 
(e.g., hypoglycemia <50 mg/dL or hyperglycemia >400 mg/dL).  
3. Participants who have received high -dose IV anesthe tics (e.g., midazolam, propofol, thiopental, or 
pentobarbital) during the current episode of SE for more than 18 hours, or who continue to have clinical 
or electrographic evidence of persistent seizures while receiving high -dose IV anesthetics .  
4. Clinical condition or advance directive that would NOT permit use of IV anesthesia. 
5. Participants known or  suspected to be  pregnant. 
6. Participants with  known allergy or  sensitivity to progesterone  or allopregnanolone 
medications/supplements . 
7. Receiving a  concomitant IV  product containing Captisol® (marketed products listed in Appendix 4).  
8. Known or  suspected hepatic insufficiency or hepatic  failure leading to impaired synthetic liver function.  
9. Known or  suspected stage  3B (moderate  to severe; eGFR 44 -30 mL/min/1.73m2), stage  4 (severe; 
eGFR 29-15 mL/min/1.73m2), or stage  5 (kidney failure;  eGFR  <15 mL/min/1.73m2 or dialysis)  
kidney disease . 
10. Use of an investigational product for which less than 30 days or  5 half -lives  have  elapsed  from the  final 
product administration. Participation in a  non-interventional  clinical study does not exclude  eligibility.  
11. Known or  suspected history or  evidence  of a medical  condition that, in the  investigator’s judgment, 
would expose  participant to an undue  risk of  a significant adverse  event or  would interfere  with 
assessments of  safety or  efficacy during the  study . 
Maximum Duration of Participant Involvement in the Study : 
• The screening period is from the time consent/assent is obtained (or deferred, if allowed by law) to 
immediately prior to IP initiation (excluding pre -consent).  However , assessments collected prior to this 
timeframe that the investigator judges to be clinically relevant to the participant ’s current state can be 
utilized in the study and do not need to be repeated. For medically unstable participants , screening 
activities (e.g., labs or vital signs) should be collected as close to IP initiation as possible . 
• The planned duration of treatment is 2 days which includes a 12 -hour taper.  
 
Confidential  Page 24 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
• The planned duration for the follow- up period  following  IP discontinuation with or without a taper is 
approximately 4 weeks. The follow -up period s tudy assessments/procedures will be collected every 24 
hours through 120 hours  (or until hospital discharge)  and at hospital discharge with weekly 
visits/contacts  at Week 1, 2, 3 , and 4. Week s 1,2, 3, and 4 visits can be conducted as inpatient visit s, if 
the participant is still in the hospital, or as telephone visit s, if the participant has been discharged. 
Attempts should be made to have discharged participants return for one of these visits in person.  
Endpoints : 
Primary Endpoints :  
• Proportion of participants with SE cessation within 30 minutes of IP initiation without medications for 
the acute treatment of SE * 
• Proportion of participants with n o progression to IV anesthesia for 36 hours following  IP initiation  
SE cessation will be assessed by the investigator based on clinical and EEG features. Training will be provided to 
guide and help standardize decisions across clinical sites. In additio n, a central reader blinded to treatment 
assignment will review EEG  recordings  retrospectively and corroborate  the accuracy of interpretation.  
*Medications for the acute treatment of SE are defined as AEDs administered to abort ongoing SE or prevent 
imminent recurrence of SE based on clinical or EEG evidence. This definition e xcludes maintenance doses of 
AEDs or medications with anticonvulsant properties used for other reasons, such as procedural sedation.  
Key Secondary Endpoints : 
• Time to  SE cessation following IP initiation  
• Proportion of participants with n o pro gression to IV anesthesia for 72 hours  following IP initiation  
Other Secondary  End points : 
• Proportion of participants with any escalation of treatment in the first 24 hours  following IP initiation , 
i.e., any medication other than IP administered for the acute treatment of SE in the first 24 hours  
• Time to treatment escalation following IP initiation (any other medi cation used for acute treatment of 
SE) 
• Time to initiation of anesthesia for SE treatment through the final study follow -up visit/contact 
• Proportion of participants who develop SRSE through the final study follow -up visit/contact 
• Seizure burden through 72 hours following  IP initiation  
• Level of responsiveness as assessed by the FOUR Score Scale 
• Level of sedation /agitation  as assessed by the RASS  
• Clinician Global Impression -Improvement (CGI -I)  
• Level of functioning as assessed by the mRS  
• Level of functioning as assessed by the EuroQoL (EQ- 5D-5L) 
• Proportion of participants with mRS >3 a t the time of hospital discharge  
• Proportion of participants whose treatment does not progress  to IV anesthesia during the follow -up 
period  
 
Healthcare Util ization Endpoints : 
• Time on positive pressure  ventilation  after IP initiation  
• Proportion of participants requiring positive pressure ventilation  initiated during IP infusion  
• Length of stay in the intensive care unit and in -hospital after IP initiation  
• Discharge destination (location where the participant resides  at the last follow -up visit  assessment ) 
• Proportion of participants requiring artificial ventilation  
 
Open -Label Phase Endpoints  
If the study  transitions  to an open- label  phase , all endpoint  assessments as described for the double -blind phase  
will be summarized using d escriptive statistics and no formal hypothesis testing will be performed .  
 
Safety  Endpoints:  
Safety and tolerability will be assessed by physical examinations, clinical laboratory tests, ECGs, vital signs, use 
of concomitant medications, and occurrence of A Es 
 
Confidential  Page 25 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
Statistical Methods: 
The statistical analysis plan (SAP) will provide the complete details for the analysis and reporting of the dat a 
from the study.   
 Analysis of Primary Endpoint  (Doub
 le-Blind  Phase) 
The primary efficacy objective of this study is to assess the efficacy  of ganaxolone plus standard of care  versus 
placebo plus standard of care  in producing rapid  and durable SE cessation without the need for treatment 
escalation to IV anesthesia for at least 36 hours following  IP initiation.  
Since the primary objective is a composite objective, in order to establish effectiveness of ganaxolone, the 
superiority of ganaxolone versus placebo added to standard of care  would need to be established for the following 
co-primary endpoints:  
1. Proportion of participants with SE cessation as determined by the investigator within 30 minutes of IP 
initiation without medications for the  acute treatment of SE  
2. Proportion of participants with n o progression to IV anesthesia for 36 hours following  IP initiation  
Analysis of the response rates observed for each co- primary  efficacy  endpoint will be conducted using logistic 
regression methods. The model will include terms for treatment group and baseline STESS as a covariate. The 
analysis will be based on the intent  to treat (ITT) population . Model- based point estimates (i.e., odds ratio), 95% 
confidence intervals and p- values will be reported.  In addition, the point estimate of difference of the proportions 
of participants achieving either and both co -primary endpoints between two treatment arms will be provided. The 
95% confidence interval will be provided using Clopper -Pearson method.  
 
Analysis of Key Secon d ary Endpoints  (Double -Blind  Phase ) 
The following key secondary endpoints will be analyzed:  
1. Time to SE cessation following IP initiation  
2. Proportion of participants with n o progression to IV anesthesia for 72 hours following  IP initiation  
If the primary  endpoints are statistically significant, t he analysis of key secondary efficacy endpoints will be 
performed sequentially in the order listed above.  
The time to SE cessation will be analyzed using the Kaplan -Meier method.20 The comparison of the survival 
curves between treatment groups will be conducted by a log -rank test.  The second key secondary endpoint will be 
analyzed using the same statistical model as pre -specified for the co -primary endpoints .  
Further details will be provided in the SAP.  
 
Data Monitoring Committee  
Emerging  study data will be reviewed on a regular basis by an independent Data Monitoring Committee (DMC). 
The mission of the DMC is to safeguard the interests of study participants and to ensure  the integrity and 
credibility of the trial. To enable the DMC to achieve its mission, it will have ongoing access to efficacy and 
safety data and information  regarding quality of trial conduct and will ensure that the confidentiality of these data 
is protected. A DMC char ter will provide the principles and guidelin es for the DMC process . 
 
Sample Size  
The planned sample size for the study was 124 participants  randomized in a 1:1 ratio . This sample size assume d 
at least  a 75% response rate with  ganaxolone treatment for each of the co- primary endpoints and no more than a 
45% response rate with placebo . With 62 participants randomized to each treatment arm, there would  be at least 
90% power for each co -primary endpoint to achieve statistical significance at a 2-sided 5% level of significance.  
 
Confidential  Page 26 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
Interim Analysis  
An interim analysis was  planned when two -thirds of the ITT population have completed 72 hours of efficacy 
assessments on the co -primary and key secondary endpoints (approximately 41 participants per arm). The overall 
type I error rate (i.e., alpha=0.05, 2 -sided) will be controll ed using a power family alpha spending function, with a 
2-sided nominal alpha level of 0.0293 at the interim analysis. The interim analysis will be performed by an 
independent statistician who is not involved in study operation or study conduct.  
The interim analysis was performed by an independent statistician who was not involved in study operation or 
study conduct and was based on 83 participants who had completed the primary and key secondary efficacy assessments. The DMC recommended may contin ue without modification.  
Further details will be provided in the SAP.  
 
Confidential   Page 27 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
STUDY SCHEDULE(S)  
Table 1. Schedule of Assessments  (Double -Blind and Open -Labe l Phase s) 
Periods/Day/ 
Duration Screening 
a 
Day -1 to 
Day 1 
Predose 
through 
screening  Dosing 
Day 1 
IP initiation  
0 through 24 hours 
following IP initiation Dosing  
Day 2 
24 hours 
through 36 
hours 
following IP 
initiation  Taper 
Day 2 
(12 hours)  
Starts at 36 hours 
following IP 
initiation IP 
Discontinuation IP Discontinuation 
Follow-up b Early 
Termination 
Visit  1 2 3 4 5 6 7 8 9 10 11 – 14 98 
Timepoint   Minutes (m) /Hours (h) following  IP initiation  
  With or without 
Taper  Hours following  IP 
Discontinuation 
  Hospital  
Discharge Weekly 
follow-
up 
(Week 1, 
2, 3, & 4)  ET 
-0 60 
m 2 
h 6 
h 10 
h 24 
h 36 
h 48 
h Collected prior 
to or as close to 
IP 
discontinuation 
as possible  24 48  72 96 120  6 ± 3 
14 ± 3, 
21 ± 3, 
and 28 ±  
3 days 
following 
IP discon   
Informed consent/assent                   
Inclusion/exclusion criteria                   
Demography and medical , 
including seizures or SE 
etiology and medication  
historyc                  
Physical  examd                  
STESS                   
Vital signse                   
RASSf                  
FOUR Scoref                  
Safety 12 lead ECGg                  
Cardiodynamic 12 lead 
ECG monitoring (sub study 
only)h  
                
  
Biochemistry, hematology, 
and AED si                  
 
Confidential   Page 28 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
Table 1. Schedule of Assessments  (Double -Blind and Open -Labe l Phase s) 
Periods/Day/ 
Duration Screening 
a 
Day -1 to 
Day 1 
Predose 
through 
screening  Dosing 
Day 1 
IP initiation  
0 through 24 hours 
following IP initiation Dosing  
Day 2 
24 hours 
through 36 
hours 
following IP 
initiation  Taper 
Day 2 
(12 hours)  
Starts at 36 hours 
following IP 
initiation IP 
Discontinuation IP Discontinuation 
Follow-up b Early 
Termination 
Visit  1 2 3 4 5 6 7 8 9 10 11 – 14 98 
Timepoint   Minutes (m) /Hours (h) following  IP initiation  
  With or without 
Taper  Hours following  IP 
Discontinuation 
  Hospital  
Discharge Weekly 
follow-
up 
(Week 1, 
2, 3, & 4)  ET 
-0 60 
m 2 
h 6 
h 10 
h 24 
h 36 
h 48 
h Collected prior 
to or as close to 
IP 
discontinuation 
as possible  24 48  72 96 120  6 ± 3 
14 ± 3, 
21 ± 3, 
and 28 ±  
3 days 
following 
IP discon   
Urine chemistry  (N-acetyl -
β-D-glucosaminidase 
(NAG) , β2-microglobulin, 
and Creatinine)k                  
Coagulationk                  
Routine Urinalysisi                  
Drugs of abuse, including 
alcoholl                  
Pregnancy test (FCBP only)l                  
EEGm                  
Blood Gasn                  
CGI-S                   
CGI-Io                  
Seizure Description 
Questionnaire -predosep                  
Status Epilepticus Cessation  
Questionnaireq                  
Super Refractory Status 
Epilepticus Questionnaire 
(SRSE)r                  
EuroQol (EQ -5D-5L)s                  
mRS                   
AEs/SAEsu                  
 
Confidential   Page 29 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
Table 1. Schedule of Assessments  (Double -Blind and Open -Labe l Phase s) 
Periods/Day/ 
Duration Screening 
a 
Day -1 to 
Day 1 
Predose 
through 
screening  Dosing 
Day 1 
IP initiation  
0 through 24 hours 
following IP initiation Dosing  
Day 2 
24 hours 
through 36 
hours 
following IP 
initiation  Taper 
Day 2 
(12 hours)  
Starts at 36 hours 
following IP 
initiation IP 
Discontinuation IP Discontinuation 
Follow-up b Early 
Termination 
Visit  1 2 3 4 5 6 7 8 9 10 11 – 14 98 
Timepoint   Minutes (m) /Hours (h) following  IP initiation  
  With or without 
Taper  Hours following  IP 
Discontinuation 
  Hospital  
Discharge Weekly 
follow-
up 
(Week 1, 
2, 3, & 4)  ET 
-0 60 
m 2 
h 6 
h 10 
h 24 
h 36 
h 48 
h Collected prior 
to or as close to 
IP 
discontinuation 
as possible  24 48  72 96 120  6 ± 3 
14 ± 3, 
21 ± 3, 
and 28 ±  
3 days 
following 
IP discon   
Concomitant medicationu                  
Healthcare Utilization 
Questionnairesv                  
  
 
Confidential   Page 30 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
Discon = discontinuation; ET = Early Termination; ECG = electrocardiogram; IP = investigational product;; FCBP = females of c hildbearing potential; EEG = electroencephalograms; AE = adverse event; SAE = 
serious AE; STESS = Status Epilepticus Severity Score; RASS = Richmond Agitation and Sedation Scale; FOUR Score = Full Outline of UnResponsiveness Score; AED = antiepileptic drug; CGI -S = Clinical 
Global Impression of Severity; CGI -I = Clinical Global Impression of Improvement; mRS = modified Rankin Scale  
a. The screening period is from the time participant/participant’s parent/guardian/LAR consent is obtained (or deferred, if allowed by law) to immediately prior to IP initiation  However, assessments collected 
prior to this timeframe that the investigator judges to be clinically relevant to the participant’s current state can be utilized in the study and do not need to be repeated. For medically unstable participants, 
screening activities (e.g., labs or vital signs) should be collected as close to IP initiation  as possible. 
b. The planned duration for the follow -up period after IP is discontinued is approximately 4 weeks. Study assessments/procedures will be collected every 24 hours th rough 120 hours (or until hospital discharge) 
and at the time of hospital discharge followed by weekly follow- up visits at Week 1, 2, 3 and 4.  Weeks 1, 2, 3 and 4 visits can be conducted as an inpatient visit, if the participant is still in the hospital, or as a 
telephone contact, if the participant has been discharged. Attempts should be made to have discharged participants return for one of these visits to be in person for clinical laboratory sample collection and RASS & FOUR Score assessments which can only be performed in person.  
c. Demography, medical history , including seizures or SE etiology , and medication history will be collected prior to IP initiation but can be collected whenever feasible before the end of the taper.  
d. Physical exam should be obtained from the participant’s chart or completed predose (screening) or, if not available, collect within 2 hours following IP initiation, and at 36 hours , if clinically indicated , 
following IP initiation.  Collect at the time of IP discontinuation (+/- 1 hour), either at the end of the taper or if the IP administration is stopped without a taper and 24 hours (+/ - 1 hour) following IP 
discontinuation and at the time of hospital discharge. F or participants who terminate early  from the study, collect at the time  of early termination (whenever possible) . The investigator may conduct at any 
other time based on clinical judgment.  
e. Vital signs including blood pressure, pulse, respiratory rate, temperature, and oxygen saturation should be collected predose (screening), 60 minutes (+/ - 15 min), 2 (+/ - 15 min), 6, 10, 24, and 36 hours 
(+/- 2 hour) following IP initiation. Collect at the time of IP discontinuation (+/- 1 hour), either at the end of the taper or if the IP administration is stopped without a taper and 24 hours (+/ - 2 hours) following 
IP discontinuation, and at the time of hospital discharge. For participants who terminate early from the study, collect at the time of early termination (whenever possible) . The investigator may collect at any 
other time based on clinical judgment. Weight and height should be collected predose (screening) for calculation of BMI inclusion criterion, if feasible. If not collected predose (screening), collect prior to the end of  the first 24 hours of the follow -up period.  
f. RASS and FOUR score scales should be collected predose (screening), 60 minutes  (+/- 15-min), 2, 6, 10 (+/- 30 minutes ), 24 and 36 hours (+/ - 1 hour) following IP initiation. Collect at the time of IP 
discontinuation (+/- 1 hour), either at the end of the taper or if the IP administration is stopped without a taper. Collect 24 (+/- 1 hour), 48, 72, 96, and 120 hours (+/ - 2 hours) following IP discontinuation and 
at the time of hospital discharge. Collect at the weekly follow- up visits (Week 1, 2, 3, or 4) for hospitalized participants and for participants who have been discharged  (whenever possible) . For participants 
who terminate early  from the study (whenever possible), collect at the time of early termination. 
g. ECG should be collected predose (screening)  and 2 hours  (+/- 30 min) following IP initiation. Collect at the time of IP discontinuation (+/- 1 hour), either at the end of the taper or if the IP administration is 
stopped without a taper and 24 hours (+/ - 1 hour) following IP discontinuation and at the time of hospital discharge. For participants who terminate early  from the study, collect at the time of early termination 
(whenever possible) . The investigator may collect any other time based on clinical judgm ent. 
h. Cardiodynamic 12 lead ECG monitoring. Select sites will participate in a sub study using a continuous 12 lead ECG recorder which should be started approximately 60 minutes prior to IP initiation and should continue for 36 hours following IP initiation. For more details refer to  Appendix 5.  
i. Clinical labs, hematology, serum chemistry (including creatinine, blood urea nitrogen, creatinine clearance calculation  [if available] , estimated glomerular filtration rate [eGFR] calculation [if available] ), and 
concomitant AED levels (fosphenytoin/phenytoin,  valproic acid, levetiracetam, lacosamide, phenobarbital, or brivaracetam, if collected per standard of care ) and Routine Urinalysis (including urine protein, 
and microscopic examination , if any abnormal  value is observed on the urine dipstick test) should be collected predose (screening), if unable to collect predose , collect within 2 hours following IP initiation.  
Collect at the time of IP discontinuation (+/- 1 hour), either at the end of the taper or if the IP administration is stopped without a taper and 24 hours (+/- 1 hour) following IP discontinuation and at the time of 
hospital discharge. Collect at the weekly follow- up visits (Week 1, 2, 3, or 4) for hospitalized participants and for participants who have been discharged  (whenever possible) . For participants who terminate 
early from the study, collect at the time of early termination (whenever possible) . Collect in the event of an SAE. The investigator may collect at any other time based on clinical judgment.  
j. Urine chemistry sample for N-acetyl- β-D-glucosaminidase (NAG) ,β2-microglobulin, and creatinine should be collected predose (screening ), if un
 able to collect predose , collect within 2 h ours following IP 
initiation, 24 hours (+/- 1 hour) following IP discontinuation and at the time of hospital discharge. Collect at one of the weekly follow- up visits (Week 1, 2, 3, or 4) for hospitalized participants and when 
possible, for participants who have been discharged.  For participants who terminate early from the study, collect at the time of early termination (whenever possible) . Urine samples will be stored frozen 
unless otherwise dictated or revised in the Biospecimen Manual.  
k. Clinical coagu
lation (including fibrinogen, activated partial thromboplastin time [APTT], prothrombin time [PT] and international normalize ratio [INR]) should be collected predose (screening), if unable to 
collect predose , collect within 2 hours following IP initiation, 24 hours (+/ - 1 hour ) following IP discontinuation and at the time of hospital discharge. For participants who terminate early from the study, 
collect at the time of early termination (whenever possible) . The investigator may collect at any  other time based on clinical judgment. 
l. A urine or serum sample for drugs of  abuse testing should be collected predose per the institution standard of care . A urine or serum sample for alcohol testing should be collected, if medically indicated.  A 
urine or serum sample for pregnancy testing for females who are of childbearing potential, should be collected predose (screening). If unable to collect sample (s) at predose, collect as soon as possible 
following IP in itiation . Enrollment is not contingent upon results. However, if a participant has a positive test result, it will be at the investigator’s discretion to weigh the risks versus  benefits for enrollment or 
continued participation. If the investigator decides to discontinue the IP, refer to the taper directions in the Investigational Product, Dose and Mode of Administration section.  If the institution requires the 
pregnancy test results be obtained prior to IP initiation, the institution guidelines will be followed. The investigator may collect at any other time based on clinical judgment.  
m. EEG is required for confirmation of CSE and NCSE diagnosis.  Continuous EEG recording should be utilized for all participants and should  start at least 60 minutes before IP initiation and continue through 
the end of the first 24 hours of the follow -up period.  
 
Confidential   Page 31 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
n. Blood gas , arterial or venous , if collected to manage the participant’s care from the time of SE diagnosis through the first end of the first 24 hours of the follow -up period, the eCRF should be completed. If 
samples are not collected, a sample is not required. If a decision is made to intubate the participant between IP initiation through the end of the first 24 hours of the follow- up period, a blood gas sample should 
be collected. The sample should be collected immediately prior to or as close as possible to the time of intubation.  
o. CGI- I should be collected  10 and 24 hours (+/ - 1 hour) following IP initiation. Collect at time of IP discontinuation (+/- 1 hour), either at the end of the taper or if the IP administration is stopped without a 
taper. Collect 24 (+/- 1 hour), 48, 72, 96, and 120 hours (+/ - 2 hours) following IP discontinuation and at the time of hospital discharge.  Collect at Week 1, 2, 3, and 4 follow- up visits/contacts. For 
participants who terminate early  from the study, collect at the time of early termination (whenever possible).  
p. Seizure Description Questionnaire should be collected predose (screening) as close as possible prior to IP initiation. 
q. Status Epilepticus Cessation Questionnaire should be collected as close as possible to  24 and  72 hours following IP initiation.  
r. Super Refractory Status Epilepticus ( SRSE) Questionnaire should be collected as close as possible to the diagnosis of SRSE and no later than the final study follow- up visit/contact. 
s. EuroQoL (EQ -5D-5L) should be collected at 120 hours (+/ - 2 hours) following IP discontinuation and at the time of hospital discharge. Collect at Week 2, 3, and 4 follow- up visit/contacts. For participants 
who terminate early  from the study, collect at the time of early termination (whenever possible).   
t. mRS  should be collected 24 (+/- 1 hour), 48, 72, 96, and 120 hours (+/ - 2 hours) following IP discontinuation and at the time of hospital discharge. Collect at Week 2, 3, and 4 follow- up visits/contacts. For 
participants who terminate early  from the study, collect at the time of early termination (whenever possible) . 
u. AEs will be collected  from the  time of IP initiation  until the final study follow- up visit/contact via non- direct questioning. Concomitant medications will be collected during the same time period. All AEs and 
associated concomitant medications will be collected through the final study follow- up visit/contact. For participants who terminate early  from the study, prior to discontinuation as much information as is 
available should be recorded for ongoing AEs /SAEs, new AEs /SAEs, and their associated concomitant medications, especially those that may have led to the early termination. Each AED administered within 
14 days of  IP initiation will be recorded and the reason for administration through the final study follow- up visit/contact. 
v. Healthcare Utilization Questionnaires include the Hospitalization Questionnaire and the Positive Pressure Ventilation (PPV) and Intubation Questionnaire. The Hospitalization Questio nnaire should be 
collected at hospital discharge or at  final study visit/cont act. The need for non-invasive or invasive ventilatory support within 24 hours prior to IP initiation  and f ollowing IP initiation and within 48 hours  
following IP discontinuation should be collected as close as possible to the event.  
  
 
Confidential   Page 32 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
Table 2. Investigational Product Infusion and Pharmacokinetic Sample Collection  (Double -Blind and Open -Labe l Phases)  
Periods/Day/  
Duration Screening  
Day -1 to 
Day 1 
Predose 
through 
screening  Dosing  
Day 1 
IP initiation  
0 through 24 hours following IP 
initiation Dosing  
Day 2 
24 hours through 36 hours 
following IP initiation  Taper  
Day 2 
(12 hours) 
Starts at 36 hours  
following IP initiation  IP  
Discontinuation 
With or without 
Taper IP 
Discontinuation 
Follow-up 
Visit  1 2 3 3 4 5 
IP infusiona       
Timepoint   Minutes (m) /Hours (h) following IP initiation    Hours following 
IP 
Discontinuation  
-0 60 
m 2 
h 6 
h 10 
h 
 24 
h 36 
h   24 
h 
Pharmacokinetic 
blood sample 
collectionb      
      
IP = investigational product  
a. Investigational product will be administered as a 48-hour continuous infusion, which includes an initial 3- minute bolus and ends with a 12-hour taper.  
b. Blood sample collection (venous or arterial) for pharmacokinetic analysis  (gana xolone and Captisol®) will occur at 60 minutes (± 5 min), then at 2, 6 (± 5 min), 10, 24 and 36 hours 
(± 2 hours ) following IP initiation. Collect at the time of IP discontinuation (± 1 hour), either at the end of the taper or if the IP administration is stopped without a taper (e .g., when the 
participant progresses to IV anesthesia for seizure/SE treatment),  and 24 hours (± 2 hour) following IP discontinuation. Variable PK collection time between IP initiation and the end 
of the first 24 hours in the follow -up period , where possible, collect a PK sample at the time of an SAE (related or not related); Pharmacokinetic samples should be collected from the 
contralateral peripheral access or the arterial line and avoid collecting samples downstream of the IP infusion. The location of IP access and location of PK sample collection should be 
documented in the  participant’s chart. If the PK sample cannot be collected due to poor venous or arterial access and the IP infusion site is the only viable option, the sample should not 
be collected and the reason for non-collection documented in the participant’s source. Pharmacokinetic samples will be stored frozen as per the Biospecimen Manual.  
 
  
 
 
 
Confidential  Page 33 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
1 BACKGROUND INFORMATION  
1.1 Indication and Current Treatment Options  
Status epilepticus (SE) is defined as a prolonged, self -sustaining seizure or recurrent seizures 
without intervening recovery of consciousness.1 The International League Against Epilepsy 
(ILAE) has further defined SE as a condition resulting either from the failure of mechanisms 
responsible for seizure termination or from the initiation of mechanisms which lead to prolonged seizures.
2 The minimum duration of seizures constituting SE is typically defined as 5  minutes for 
convulsive SE (CSE) and 10 minutes for non- convulsive SE (NCSE).3 The ILAE has proposed 
definitions that encompass the time at which seizures become self -sustaining (t1) and a time 
when neurologic damage results (t2). For GCSE, these are 5 and 30 minutes, respectively; for nonconvulsive SE (NCSE), they are 10 and 60 minutes.
2  
In general, SE incidence varies from 9.9 to 41/100,000 per year with a bimodal age distribution. The youngest and oldest patients suffer from SE most often, specifically those in the first decade of life (14.3/100,000) and those over 60 years of age (28.4/100,000).
21 While the etiologies tend 
to be unique to specific age groups, the basic approach to treatment is similar across all ages and etiologies .
22,23 Treatment is largely focused on rapid SE cessation, including initiation of drugs to 
terminate seizures and reversal of conditions that may lower seizure threshold. Potentiating GABAergic inhibition is a key mechanism to achieve  rapid seizure cessation in both adults and 
children.  
If not treated immediately, prolonged seizure activity can result in permanent neuronal damage and contribute to the high morbidity and mortality associated with SE.
8,24,25 Mortality due to SE 
can range from 3% to 40% depending on etiology, age, type of SE and its duration.26 Previous 
studies have shown that seizures cause neuronal death via excitotoxic mechanisms as a result of excessive neuronal activity.
1 Furthermore, CSE is associated with many complications, including 
cardiac arrhythmias, rhabdomyolysis, pulmonary edema, electrolyte and glucose imbalance, and temperature disturbances.
27 
Status epilepticus often occurs in the setting of pre -existing epilepsy, but it can also be caused by 
cerebral injury in individuals with no prior history of seizures.8 In patients with chronic epilepsy, 
low blood concentration of antiepileptic drugs (AEDs) is a common cause of SE.1 Other 
recognized causes of SE include, but are not limited to, stroke, anoxia or hypoxia, metabolic causes, and alcohol or drug withdrawal.
1,8  
Status epilepticus can be classified into 2 subtypes: Convulsive SE and NCSE.8,24 Convulsive SE 
is characterized by continuous or repetitive tonic- clonic seizures without interictal recovery of 
full consciousness. Nonconvulsive SE is defined as prolonged continuous electrographic seizure activity without convulsive clinical symptoms or a series of nonconvulsive seizures without 
complete interictal clinical recovery. If CSE is prolonged, clinical manifestations may evolve to those of NSCE, a stage sometimes referred to as “subtle convulsive status epilepticus”.
28,6 
Additionally, SE can be categorized based on its refractoriness to treatment. The first -line 
standard of care medications for SE are benzodiazepines which, depending on the agent used, may be administered intravenously, intramuscularly or via the buccal route.
13 While these agents 
 
Confidential  Page 34 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
have demonstrated efficacy in early SE, a recent study found that 25% and 36% of subjects with 
SE did not respond to intramuscular (IM) midazolam or intravenous (IV) lorazepam, respectively.
29 Early SE that is refractory to first line  treatment is termed established SE (ESE). 
Only two -thirds of subjects with SE respond to the first treatment, and evidence shows that 
prolonged seizures can result in permanent neuronal damage and contribute to the high morbidity and mortality associated with SE.
30 
Refractory SE (RSE) is defined as SE resistant to treatment with one first- line AED 
(benzodiazepines) and one second-line AED such as IV fosphenytoin/phenytoin, valproic acid or levetiracetam.
11,31 The prognosis worsens with progression to RSE, with mortality in 
approximately one-third of patients and another one- third suffering from chronic neurologic 
sequalae.14,32,33 
If second -line IV AEDs fail, IV anesthetic agents must be used to induce therapeutic coma to 
attempt control of SE.1 Midazolam, propofol, pentobarbital or other anesthetics are administered , 
and coma is maintained for 24 hours or longer, after which the dose of the anesthetic agent is reduced to determine whether seizure activity has been aborted. Repeated courses of IV anesthesia may be attempted to control SE, with longer duration of IV ane sthesia associated with 
a worse prognosis.
15 SE that fails treatme nt with a course of IV anesthesia is classified as super -
refractory SE (SRSE), which is associated with increased length of hospitalization and higher costs of care.
34 SRSE represents only 13% of hospital admissions for SE but is responsible for 
56% of costs. Mortality in SRSE is 40%, compared to 15% for RSE and 10% for non- refractory 
SE.  
A recently completed study assessed the neurosteroid, brexanolone (allopregnanolone), 
compared to placebo in the treatment of SRSE (C linical Trial.gov [STUDY_ID_REMOVED]). The study 
failed to meet its primary endpoint, the proportion of patients successfully weaned from IV anesthetics (43.9% vs. 42.4% for brexanolone and placebo, respectively, p=0.8775). The failure 
of brexanolone to treat SRSE may have been due to the severity or stage of progression of SE or 
to other factors. There has not been a controlled clinical trial of an AED for RSE.  
An important aspect of SE diagnosis and treatment is the use of electroencephalograph ic (EEG ) 
monitoring. EEG is necessary to determine the adequacy of SE therapy, particularly in NCSE, 
which often has no clinical manifestations to guide treatment. After control of CSE, subclinical electrographic seizure activity can be detected in up to 48% of pa tients.
35 If IV anesthesia is 
required, the EEG is used to assess whether depth of sedation is sufficient. The presence of a burst-suppression pattern on EEG is indicative of adequate levels of anesthesia for control of SE.  
1.2 Product Background and Clinical Information   
Nonclinical Data  
The biological effects of ganaxolone (GNX) have been assessed in numerous in vitro and in vivo models and non-clinical pharmacodynamics (PD), pharmacokinetics (PK), and toxicology studies conducted in mice, rats, rabbits, monkeys, and dogs.
36 
 
Confidential  Page 35 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
The most common effect following treatment with GNX in toxicology studies was dose- related 
sedation, an expected pharmacological effect of a positive modulator of GABA A receptors.  In 
both the oral (PO) and IV programs, there was little evidence of target organ or systemic toxicity 
associated with either single - or multiple -dose treatment with GNX . No functional or anatomic 
changes within hematopoietic tissue or any specific organ such as liver, kidney or gastrointestinal (GI) systems were seen in the repeat -dose studies.  
Ganaxolone was not teratogenic in rats or mice and did not significantly affect the development of offspring. Ganaxolone had no effects on fertility and early embryonic development in rats. No potential for genotoxicity was detected. Treatment of neonatal rats with GNX produced expected signs of sedation but did not affect development or demonstrate any postmortem changes. 
In rats continuously dosed with IV GNX for 14 days, no GNX- related changes were noted in 
clinical pathology parameters or histopathology examination. There was no evidence of local 
irritation when GNX was given IV or peri-venously in preclinical studies. Furthermore, IV GNX did not cause hemolysis and was compatible with human plasma. 
The anticonvulsant activity of GNX was established in multiple in vivo models of seizure 
activity in rats and mice. The results from these studies show that GNX blocks seizure propagation, elevates seizure threshold , and can reverse seizures with delayed administration.  
Ganaxolone, administered IV, was also evaluated and shown to be effective in models of SE.
37 
These evaluations were conducted in rats and SE was induced by lithium pilocarpine administration. Seizure response was measured by EEG activity, behavioral convulsions, and seizure related mortality. In these studies, the administration of GNX was delayed up to 60 minutes after SE onset. Seizures at this time point after SE onset are resistant to benzodiazepine treatment and are considered to represent a treatment resistant version of SE. Ganaxolone, administered IV, produced a long-lasting reduction in EEG seizure response, behavioral convulsions, and also decreased seizure related mortality. In a study in which a 
subtherapeutic dose of GNX was co -administered with a subtherapeutic dose of diazepam, a 
synergistic effect on reduction of EEG seizure was observed. In comparison to IV administered 
allopregnanolone, GNX produced a longer lasting reduction in seizure activity. These preclinical data provide the support for the clinical evaluation of GNX in SE subjects.  
Ganaxolone administered IV was also evaluated for effects on EEG patterns in otherwise normal (non- epil
eptic) rats. In one study, GNX was administered at a dose of 3 mg/kg every 30 minutes 
for 5  doses (total: 15 mg/kg). Under this dosing paradigm, GNX produced a complex EEG 
profile. Shortly after dosing, brief (~1 
sec) periods of intense EEG activity with a peak frequency 
of around 
10 Hz were observed. EEG power was increased in the GNX compared to the vehicle 
group from 0–50 Hz and reduced from 50–96 Hz. This EEG is consistent with a sedation EEG pattern. Rats still responded to painful stimuli. Thus, GNX did not produce an anesthetic response. In the second study, G NX was administered IV at 3  mg/kg every 3 minutes. Under this 
dosing paradigm, GNX produced a burst suppression- like EEG pattern after 4  doses (12  mg/kg). 
Rats were sedated, but still responded to tail pinch stimuli indicating that GNX did not cause a full anesthetic response.  
The tox
icity of Captisol® was evaluated in juvenile male and female Sprague Dawley rats dosed 
via twice daily (BID) subcutaneous injection (1000, 2500, and 5000 mg/kg/day) from Postnatal 
 
Confidential  Page 36 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
Day (PND) 14 through PND 35 (Study 00398517). Endpoints included mortality, clinical signs, 
body weights, body weight gains, food consumption, organ weights, and macroscopic and microscopic examinations. All males and females survived to the scheduled necropsies. No remarkable clinical observations were noted during the detailed clinical observations or 1–2 
hours following the first daily dose at any dose level. Nonadverse lower mean weight gain and corresponding food consumption was noted in the 5000 mg/kg/day group males and nonadverse microscopic findings in the kidneys, adrenal glands, axillary lymph node, and injection sites were observed in the 1000, 2500, and 5000 mg/kg/day group males and females. The epithelial cell vacuolation in the kidneys was not considered severe and histiocytic vacuolation in the 
adrenal gland, axillary lymph node, and injection sites were due to a biologic response to the presence of foreign material at the injection sites.  At the recovery necropsy, microscopic findings 
persisted in the kidneys, adrenal glands, axillary lymph node, and injection sites, but with a general decrease in severity, suggesting partial recovery. 
Based on the lack of adverse effects in males and females at all dose levels tested, a dose level of 
5000 mg/kg/day (2500 mg/kg/dose BID) was considered to be the no-observed- adverse- effect 
level (NOAEL) for juvenile toxicity of Captisol® in rats.  
Clinical Data  
In 20 completed Phase 1 studies, 319 healthy volunteers received GNX doses of 50 to 2,000 mg/day for periods of up to 2 weeks. 
In the 20 completed Phase 2/3 clinical studies, 1,238 study participants have received GNX, 
including adults with epilepsy, migraine and post- traumatic stress disorder, and children with 
epilepsy and Fragile X syndrome. There are 109 pediatric study participants currently enrolled in 
2 ongoing epilepsy trials (CDKL5-deficiency disorder and PCDH19- related epilepsy).  
The overall frequency of treatment -emergent adverse events (TEAE) in company -sponsored 
placebo -controlled studies was 61.7% (613/993) in study participants who received GNX 
and 51.8% (330/637) in those who received placebo. The most frequently reported TEA Es in GNX- treated participants were somnolence, dizziness, fatigue, and headache. All of 
these events, except for headache, which occurred more frequently in GNX - than placebo- treated 
study participants. CNS -related adverse events were dose -related, with the majority occurring at 
doses ≥500 mg/day. The majority of TEAEs were not unexpected based on the mechanism of action of GNX and were non-serious, mild to moderate in severity and did not lead to discontinuation of treatment.  
No clinically significant trends in electrocardiogram (ECG) intervals, vital signs, or physical or 
neurologic examinations have been noted, and no mean changes from baseline in clinical laboratory results have been identified. Overall, there have been only a few clinically significant individual changes from baseline in laboratory measurements in GNX trials. In the completed, placebo -controlled Phase 1, 2, and 3 studies, 0.3% of subjects treated with GNX and 0.5% of 
subjects treated with placebo exhibited e levated liver function tests during the study (aspartate 
transaminase or alanine transaminase >3 times the upper limit of normal [ULN]). There have been no cases attributed to GNX fulfilling criteria for Hy’s law.  
 
Confidential  Page 37 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
In controlled clinical trials of GNX, 1.1% of subjects receiving placebo and 1.7% of subjects 
receiving GNX  reported an AE of rash. However, rash led to discontinuation in GNX- treated 
subjects in 6 cases (0.6%) compared to no cases (0%) in placebo -treated subjects. Two subjects 
participating in a Phase  2 study investigating GNX in treatment of epilepsy developed an SAE of 
rash. Both events resolved after discontinuation of the IP. 
Ganaxolone is rapidly absorbed into plasma and readily moved into breast milk . The effects of 
GNX on milk production and the breastfed infant are unknown. After cessation of the infusion, 
plasma GNX levels are expected to drop rapidly, but it is possible that low, subtherapeutic levels persist for several days as GNX is slowly released from tissues. Therefore, a washout period of 45 days is required following cessation of GNX treatment before breastfeeding. Previous toxicology studies in animals focusing on prenatal and neonatal development have not demonstrated toxicities associated with GNX. Ganaxolone has been administered to infants with severe forms of epilepsy as early as 4 months of age.  
In clinical trials involving administration of GNX over several weeks, the IP  has been tapered off 
over a 1- to 2- week period. There have been no reports of withdrawal symptoms emerging after 
cessation of GNX.  
Always refer to the latest version of the  GNX I nvestigator’s Brochure (IB) for the overall 
risk/benefit assessment and the most accurate and current information regarding metabolism, 
pharmacokinetics, efficacy , and safety of GNX.  
2 STUDY OBJECTIVES AND PURPOSE  
2.1 Rationale  for the study  
Few drugs are approved for the treatment of SE and an urgent need for evidence-based, efficacious therapies remains, particularly for patients with RSE who have failed treatment with benzodiazepines and one or more second- line AEDs.
13 There is no evidence from randomized, 
controlled trials to support the use of one AED over another in any but the earliest stage of SE, in which benzodiazepines such as IV lorazepam or IM midazolam have been demonstrated to be effective.
29 The Established Status Epilepticus Treatment Trial ( ESETT) demonstrated that three 
commonly used AEDs were ineffective in over half of patients with  established status epilepticus 
(ESE), and none were superior to the others in stopping seizures.9 There is limited evidence from 
retrospective case series suggesting potential utility for IV levetiracetam or lacosamide in RSE
38,39 though interpretability is limited by the retrospective nature  of the data, lack of control 
groups and potential confounding by use of concomitant treatments. 
Ganaxolone is the 3β -methylated synthetic analogue of the neuroactive steroid allopregnanolone. 
It differs
 from other GABAergic agents in that it binds to both synaptic and extrasynaptic 
GABA A receptors at a binding site distinct from benzodiazepines or barbiturates.17 Resistance to 
treatment in SE has been attributed to the internalization of postsynaptic GABA A receptors and 
increase in synaptic density of glutamate receptors.12 This alteration of receptor trafficking may 
underlie a shift in the balance of  excitation and inhibition resulting in the perpetuation of SE.  
 
Confidential  Page 38 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
Because prolonged seizures result in a reduction of GABA A-mediated synaptic inhibition, 
antiepileptic treatments that rely on enhancing intrasynaptic GABA A neurotransmission become 
less effective the longer SE continues. Because of its action at extrasynaptic GABA A receptors, 
which are not downregulated with progression of SE, ganaxolone has the potential for 
therapeutic benefit when benzodiazepines and barbiturates are likely to be ineffective. Because of its mode of action, as well as its extensive safety  record, ganaxolone represents a promising 
alternative to current treatments for SE.  
The potential utility of ganaxolone for treatment of SE is also supported by the results of a phase 2, open-label study in 17 patients with RSE (Study 1042- SE-2001). Ganaxolone was 
administered IV via a bolus dose and concurrent initiation of a 48 to 96- hour infusion according 
to one of three dosing regimens as outlined in Table  3. 
Table  3. Enrollment in Study 1042 -SE-2001 Dose Level Cohorts  
Cohort  Dose of GNX/day  Duration at target level 
≥500 ng/mL (hours)  Number of patients per 
cohort  
Low 500 mg/day  4 5 
Medium  650 mg/day  0 4 
High  713 mg/day  8 8 
GNX  = ganaxolone.  
The median age of enrolled patients was 56.9 years (range 23 to 88 years) and 53% were female. Causes of SE included vascular disease (str oke or intracranial hemorrhage,  N = 7), brain tumors 
(N = 4), alcohol withdrawal or drug overdose (N = 2), metabolic disturbances (N  = 2) or 
autoimmune causes (N  = 2). In two patients, the etiology of SE was unknown.  
The majority of patients (N  = 12) had NCSE, one of whom had converted from convulsive to 
non-convulsive SE. Study participants had failed a mean of 2.9 IV AEDs, including first- line 
treatment with benzodiazepines. The mean number of second- line IV AEDs was 2.1, including 
phenytoin, fosphenytoin, valproate, lacosamide and levetiracetam. All of the patients had received either lacosamide or levetiracetam , or both.  
None of the 17 enrolled patients required treatment with IV anesthetics through 24 hours following initiation of ganaxolone, the primary efficacy endpoint of the study. The median time to SE cessation was 5  minutes from initiation of ganaxolone ( N = 15 evaluable patients); 14/15 
achieved SE cessation within 30  minutes and one achieved SE cessation at approximately 
4 hours. Post hoc analysis of EEG monitoring data indicated that maintenance of an infusion rate producing a blood ganaxolone concentration of 500 ng/mL for 8 hours, and not 4 hours, resulted in sustained suppression of epileptiform activity. The dosing regimen in the present study is 
designed to maintain a ganaxolone concentration ≥ 500 ng/mL for the first 12 hours of IP 
infusion. It will also achieve plasma concentrations that replicate those associated with anticonvulsant effects in preclinical SE models and that are therefore expected to demonstrate anticonvulsant properties in humans.  
The ganaxolone IV to be used in this study is a proprietary formulation that is solubilized with 
Captisol
® (betadex sulfobutyl ether sodium), with the dose of Captisol® not exceeding 50 grams 
per day.  
 
Confidential  Page 39 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
Among the 17 enrolled subjects who received GNX, the most common TEAE were somnolence 
(5 subjects, 29.4%), hypotension (4 subjects, 23.5%), and hypokalemia (3 subjects, 17.6%). 
Severe TEAEs were reported in 6 subjects (35.3%). The most frequently (reported  in 2 or more 
subjects [i .e., ≥10%]) reported severe TEAEs by system organ class were Nervous System 
Disorders, reported in 4 subjects (23.5%). Refer to the GNX IB for detailed safety information.  
2.2 Study Objectives  
2.2.1 Primary Objective  
• To evaluate the efficacy and safety  of ganaxolone IV for the treatment of SE after failure of 
two or more antiseizure  medications .  
2.2.2 Secondary Objectives  
• To assess the time to SE cessation following ganaxolone administration.  
• To evaluate the sustained efficacy of ganaxolone IV beyond the 48-hour treatment period as 
assessed by prevention of progression to IV anesthesia for the treatment of SE.  
2.2.3 Exploratory Objectives 
• To determine  the effect of ganaxolone on healthcare utilization .  
• To assess the effect of ganaxolone on doses of other antiseizure treatments and changes in 
seizure burden . 
• To evaluate the effect of ganaxolone on quality of life, functional status, and level of 
responsiveness. 
3 STUDY DESIGN  
3.1 Study Design and Flow Chart  
This is a double- blind, randomized, placebo -controlled study to evaluate the efficacy and safety 
of ganaxolone IV solution in SE, with an option to transition to  open- label  treatment to obtain 
additional safety data following a demonstration of efficacy at the interim  analysis, data 
monitoring committee ( DMC) recommendation , and Sponsor agreement . The term “participant” 
will be used in place of “subject” in accordance with the FDA glossary which states these terms 
may be used interchangeably. 
3.1.1 Double -blind  Phase  
Approximately 160 participants w ere planned to be screened to randomize approximately 124 
study participants at least 12 years of age with SE. Randomization stopped at 100 patients for 
business reasons. Randomized participants will  receive ganaxolone IV solution or placebo, 
referred to as investigational product (IP), in a 1:1 ratio added to SE standard of care.  
Potential participants may be identified in the emergency department, ICU or other units in the 
hospital and will be consented/assented or deferred, where allowed by law and then screened for inclusion/exclusion criteria prior to being randomized to start IP treatment.  
 
Confidential  Page 41 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
Approximately 60 to 100 study participants will receive ganaxolone IV in  the double-blind and 
open- label phases combined.  
 
3.2 Interim Analysis  
As described in Section 10.7, an interim analysis will be conducted when two- thirds of the  ITT 
population have completed 72 hours of  efficacy assessments (approximately 41 participants per 
arm). Based upon the interim analysis results, recommendation from the DMC , and agreement 
from the Sponsor, the study will either continue without modification or will transition  to 
enrollment in an open- label  phase. A ll participants enrolled in the open- label phase will receive 
open- label ganaxolone IV  solution added to SE standard of care. The screening, duration of the 
treatment, and follow-up periods, as well as the study schedule, would remain the same for 
participan ts enrolled under either the double -blind or open- label phases as described above and 
in Figure 1. Approximately 60 to 100 study participants are planned to  receive ganaxolone IV in  
the double-blind and open- label phases combined.   
3.3 Duration and Study Completion Definition  
The maximum duration of study participation is expected to be approximately 4 weeks.  
The study completion date is defined as the date the final participant, across all sites, completes 
their final study assessment /procedure ; this includes the follow -up visit/contact, whichever is 
later. The study completion date is used to ascertain timing for posting and reporting of study results.  
3.4 Sites and Regions  
This multicenter study is to be conducted in the United States, Canada, and Australia, with approximately 100 sites planned to participate.  
4 STUDY POPULATION  
Each participan t/participant’s parent/guardian/ legally authorized representative ( LAR) must 
participate in the informed consent process and provide written informed consent/assent, unless allowed by law, e.g. , deferred consent,  before any procedures specified in the 
protocol are performed . Consent/assent will be administered per institution IRB/EC policy 
and may vary across sites, i.e., some sites may be able to consent/assent over the phone or other communication methods. Informed c onsent/assent for participants who are known to 
be at risk for SE may be obtained prior to a SE event. The period the pre -consent/assent is 
valid will be determined by institution  IRB/EC. However, reconsenting will be needed 
should the consent/assent be updated at any point during the study.  
4.1 Inclusion Criteria  
The participant  will not be considered eligible for the study without meeting all  the criteria 
below. 
 
Confidential  Page 42 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
1. Participant, participant’s  parent, guardian, or LAR must provide  signed  informed 
consent/assent, and once capable  (per institution guidelines), there  must be 
documentation of consent/assent by the  participant demonstrating they are willing 
and aware of the investigational nature of the study and related procedures . Where 
allowed by law, where the patient lacks the capacity to make informed decisions 
regarding his/her medical treatment options, the treating clinician may follow their deferred consenting practices. The clinician will make the final decision based on the best interests of the patient.  
2. Male or females 12 years of age and older  at the  time of the first dose  of IP. 
3. SE meeting the following criteria:  
a. A diagnosis of SE with or without prominent motor features based on clinical and EEG findings according to the investigator’s judgement, based on the 
following : 
i. For SE with prominent motor features: Clinical and EEG seizure activity indicative of convulsive, myoclonic or focal motor SE  
ii. For SE without prominent motor features (nonconvulsive SE): Appropriate clinical features and an EEG indicative of NCSE (see modified Salzburg criteria
19 in Appendix 3). 
iii. For any type of SE: 
• Approximately 6 minutes of cumulative seizure activity over a 
30-minute period within the hour before IP initiation, AND  
• Seizure activity during the 30 minutes immediately prior to IP 
initiation . 
b. The treating clinician(s) anticipate that IV anesthesia is likely to be the next treatment for SE that persists following initiation of IP . 
4. Participants must have received any two or more of the following agents for treatment of 
the current episode of SE administered at an adequate dose and for a sufficient duration, 
in the judgment of the investigator, to demonstrate efficacy (guidelines for adequate doses are provided in Appendix 2): 
o Benzodiazepines, 
o IV Fosphenytoin/phenytoin, 
o IV Valproic acid,  
o IV Levetiracetam,  
o IV Lacosamide, 
o IV Brivaracetam, or  
o IV Phenobarbital 
5. BMI  <40 or, if BMI  is not able  to be calculated at  screening, participant is assessed by 
investigator as not morbidly obese.  
4.2 Exclusion Criteria  
Participant s are excluded from the study if any of the following exclusion criteria are met.  
 
Confidential  Page 43 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
1. Life expectancy of less than 24 hours.  
2. Anoxic brain injury or an uncorrected rapidly reversable metabolic condition as the primary 
cause of SE (e.g., hypoglycemia <50 mg/dL or hyperglycemia >400 mg/dL). 
3. Participants who have received high -dose IV anesthetics (e.g., midazolam, propofol, 
thiopental, or pentobarbital) during the current episode of SE for more than 18 hours, or who continue to have clinical or electrographic evidence of persistent seizures while receiving high- dose IV anesthetics.  
4. Clinical condition or advance directive that would NOT permit use of IV anesthesia . 
5. Participants known or suspected to be pregnant. 
6. Participants with  known allergy or sensitivity to progesterone  or allopregnanolone 
medications/supplements.
 
7. Receiving a concomitant IV product containing Captisol ® (marketed products listed in 
Appendix 4). 
8. Known or suspected hepatic insufficiency or hepatic failure leading to impaired synthetic 
liver function.  
9. Known or suspected stage 3B (moderate  to severe; eGFR 44 -30 mL/min/1.73m2), stage  4 
(severe; eGFR 29 -15 mL/min/1.73m2), or stage  5 (kidney failure; eGFR <15 mL/min/1.73m2 
or dialysis) kidney disease.  
10. Use of an investigational product for which less than 30 days or 5 half- lives have elapsed 
from the final product administration. Participation in a non -interventional clinical study does 
not exclude eligibility.  
11. Known or suspected history or evidence of a medical  condition that, in the investigator’s 
judgment, would expose participant to an undue risk of a significant adverse event or would interfere  with assessments of  safety or  efficacy during the  study. 
4.3 Restrictions  
Participant s must abstain from the use of alcohol until the end of the 24-hour IP discontinuation  
follow -up period . 
Females are prohibited from  breastfeed ing for 45 days after the last dose of IP . 
4.4 Reproductive Potential  
4.4.1 Female Contraception  
Sexually active females of child bearing potential should be using an acceptable form of 
contraception and must be advised to use acceptable contraceptives throughout the study period 
and for 30 days after the last dose of IP. If hormonal contraceptives are used, they should be 
administered according to the  package insert.  
Females of child bearing potential who are not currently sexually active must agree to use 
acceptable contraception, as defined below, if they become sexually active during the period of the study and 30 days after the last dose of IP .  
Female participan ts should be: 
 
Confidential  Page 44 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
• Postmenopausal (12 consecutive months of spontaneous amenorrhea and ≥ age 51 years), 
or 
• Surgically sterile (having undergone one of the following surgical acts: hysterectomy, 
bilateral tubal ligation, bilateral oophorectomy , or bilateral salpingectomy)  and at least 
6 weeks post- sterilization, or  
• Should have a urine or serum sample collected for pregnancy testing prior to IP  initiation . 
If not possible, collect as soon as possible following IP  initiation. Enrollment is not 
contingent upon results. However, if a participant  has a positive test result, it will be at the 
investigators ’ discretion to weigh the risks versus benefit for continued participation. If 
the institution requires the pregnancy test results be obtained prior to IP initiation , the 
institution  guidelines will be followed.  
Acceptable methods of contraception are:  
• Intrauterine device plus condoms  
• Double barrier methods (e.g., condoms and diaphragm with spermicidal gel or foam) 
• Hormonal contraceptives (oral, patch, injectable, or vaginal ring), stabilized for at least 30 days prior to the study participation , plus condoms. Note : If participant becomes sexually 
active during the study, they should use one of the other acceptable methods noted above in addition to the hormonal contraceptive until it has been stabilized for 30 days. 
Contraceptive measures such as Plan B
TM, sold for emergency use after unprotected sex, are not 
acceptable methods for routine use.  
4.4.2 Male Contraception 
Male participants must agree to take all necessary measures to avoid causing pregnancy in their sexual partners during the study and for 30 days after the last dose of IP . Medically acceptable 
contraceptives include surgical sterilization (such as a vasectomy) and a condom used with a spermicidal  gel or foam. 
Male participants should not donate sperm during the study and for 30 days  after the last dose of 
IP. 
4.5 Discontinuation of Participants  
A participant may withdraw, or their parent , guardian, or LAR may withdraw the participant 
from the IP administration  and/ or the study at any time for any reason without prejudice to their 
future medical care by the physician or the institution . The investigator or Sponsor may 
withdraw the participant  at any time ( e.g., in the interest of participant safety) . The investigator is 
encouraged to discuss withdrawal of a participant  from IP  with the Medical Monitor , when 
possible, unless due to progression to an IV anesthetic for  seizure suppression. 
4.5.1 Investigational product  discontinuation  
Participants who discontinue IP without a taper (e.g., were administered IP for less than 2 hours, 
progress to anesthesia for seizure suppression or discontinue IP due to safety or any other reason, 
except due to withdrawal of consent) will have the follow -up assessments/procedures collected 
 
Confidential  Page 45 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
every 24 hours through 120 hours (or until hospital discharge) and at the time of hospital 
discharge, followed by weekly follow -up visits/contacts at Week 1, 2, 3 and 4.  
4.5.1.1 Reasons for IP  discontinuation  include , but are not  limited to , the following: 
• Adverse event or imminent safety concern  
• Medical procedure  
• Lack of efficacy with progression to high dose IV anesthesia for seizure/SE control 
• Lack of efficacy without progression to high dose IV anesthesia for seizure/SE control 
• Progression to high dose IV anesthesia for reason not related to seizure/SE  
• Death  
• Consent withdrawal 
• Physician decision  (must be specified in the participant’s source documents and 
electronic case report form [ eCRF ]) 
• Other  (must be specified in the participant’s source document s and eCRF) . 
4.5.1.2 Study Withdrawal  
All participants reserve the right to withdraw from the clinical study at any time, as stated in the informed consent/assent form.  
Participant s who terminate early  from the study (e.g., due to consent withdrawn), any 
outstanding procedures and the evaluations listed for the Early Termination Visit in Table 1  
should be completed when early termination is being considered. 4.5.2 Participant Withdrawal Criteria  
The Sponsor is not providing formal thresholds to discontinue a participant from the study. The 
Sponsor encourages the i nvestigator to continuously assess any potential risks and benefits of 
participation during the entire study. The investigator should not hesitate to discontinue a participant from the clinical study if, according to the  investigator’s  clinical judgment, the risks 
exceed any potential benefits. Reference examples below.  
1. If the participant experiences worsening and persistent ventilatory depression despite routine clinical interventions (e.g., jaw thrust, chin lift or o xygen supplementation) that, in the 
judgment of the investigator, can be improved upon by discontinuation of the IP, t he 
investigator may choose to discontinue such participant from the study. If positive ventilatory support is initiated and the participant is stable as per the investigator’s clinical judgment, IP may be continued. 
2. ECG evidence of QT prolongation (QTcF >500 msec, or an increase of QTcF >60 msec above baseline to a value >480 msec on the 12 lead ECG, confirmed on a repeat 12- lead 
ECG taken after resting at least 5 minutes in a supine or semi recumbent  position after the 
original finding of prolonged QTcF). 
3. Kidney function impairment such that eGFR ≤ 44 mL/min /1.73m
2 and participant is not 
starting dialysi s. 
 
Confidential  Page 46 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
4. Any other adverse event or safety issue (e.g., severe persistent hypotension/hypertension or 
tachycardia/bradycardia) that suggests it is not in the participant’s best interest to continue to receive IP . 
5. Rash that is clinically significant and considered to be related to the IP (e.g., morbilliform, 
urticarial, papular). 
6. Participant experiences an SAE considered to be related to the IP . 
Decisions to discontinue from the study will be made by the i nvestigator. If feasible, the reason 
for discontinuation should be discussed with the Medical Monitor prior to the participant’s 
discontinuation unless due to the progressi on to anesthesia for  seizure suppression .  
4.5.3 Reasons for Study  Discontinuation  
The reason for study discontinuation must be determined by the investigator and recorded in the 
participant’s  medical record and i n the eCRF . If a participant  is withdrawn for more than 
one reason, each reason should be documented in the source document and the most clinically relevant reason should be entered in the eCRF .  
Reasons for discontinuation include, but are not limited to, the following : 
• Adverse event 
• Protocol deviation  
• Consent withdrawal 
• Lost to follow -up 
• Lack of efficacy  
• Death  
• Physician d ecision  (must be specified in the participant’s source documents and eCRF)  
• Other (must be specified in the participant’s s ource documents and eCRF)  
4.5.4 Participan ts Lost to Follow -up Prior to Last Scheduled Visit  
A minimum of three  documented attempts must be made to contact any participan t lost to 
follow -up at any timepoint prior to the last scheduled contact (office visit or telephone contact). 
At least one of these documented attempts must include a written communication sent to the 
participan t’s last known address via courier or mail (with an acknowledgment of receipt request) 
asking that they return to the site for final safety evaluations . If a contact is not made, the 
participant should be classified as Lost to Follow-up in the eCRF . However, if contact is made 
but the participant refuses or is unable to come to the final safety evaluation , they should be 
classified as Other and the reason  documented in the eCRF.  
5 PRIOR AND CONCOMITANT TREATMENT  
5.1 Prior Treatment  
Prior treatment includes all non- study  treatment (including AEDs) administered  within 14 days 
of IP  initiation (or pharmacokinetic equivalent of five half -lives , whichever is longer) . 
 
Confidential  Page 47 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
Treatments including but not limited to herbal treatments, vitamins, sur gical implants (such as 
Vagus nerve stimulator), and prescribed medications, if available, must be recorded on the 
appropriate eCRF  page. 
Benzodiazepines, AEDs and Anesthesia Medications  
• Prior to IP initiation (not experiencing a seizure event) 
o Medications administered during this timeframe will be collected per the medication 
order 
• Prior to IP initiation (for the current SE eve nt) 
o Medications administered during this timeframe will be collected  separately (i.e., 
each dose administered will be collected separately)  
Vasopressors 
• The administration of a continuous IV vasopressor infusion in the 24- hours prior to IP 
initiation  will be collected in the Prior and Concomitant Medication e CRF 
5.2 Concomitant Treatment  
Concomitant treatment refers to all treatment taken between the date of the first dose of IP  and 
the final study  follow -up visit/contact.  
Concomitant treatment information must be recorded on the appropriate eCRF page . 
Benzodiazepines, AEDs and Anesthesia Medications  
• During IP administration and for 120 hours of the follow-up period  
o Medications administered during this timeframe will be collected  separately (i.e., 
each dose administered will be collected separately)  
• Follow-up period (starts 120 hours following IP discontinuation) 
o Medications administered during this timeframe will be collected per the medication order 
Vasopressors 
• Administration of a continuous IV vasopressor  infusion during IP administration or within 24 
hours following IP discontinuation will be collected in the Prior and Concomitant Medication eCRF.  
For some of the concomitant medications only the highest dose administered will be required in the eCRF. Reference the eCRF Completion G uidelines for guidance . 
 
Confidential  Page 48 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
5.2.1 Permitted Treatment  
To qualify for inclusion ( Section  4.1), the pa rticipant  must have received an acute treatment with 
any two or more of the following agents for treatment of the current episode of SE: 
benzodiazepines, IV fosphenytoin/phenytoin, IV valproic acid, IV levetiracetam, IV lacosamide, 
IV phenobarbital, IV brivaracetam , or IV phenobarbital. Taking any of these drugs alone or in 
combination is acceptable. Fosphenytoin/phenytoin will be counted as one (1) IV AED. 
Levetiracetam and brivaracetam will be counted as two (2) IV AEDs.  
If the participant is receiving an oral AED to manage a chronic medical condition, (e.g., epilepsy, migraine, or neuropathic pain), the AED is acceptable and may continue unchanged. This maintenance treatment does not count towards the SE treatment failures required to qualify for this study. 
The site will record the reason for each AED dose during IP administration in the appropriate 
CRF page.  
5.2.2 Prohibited Treatment  
If a participant progresses at any time during the study to an IV anesthetic (e.g., midazolam, propofol, thiopental, or pentobarbital) given with the primary intent specifically to treat seizures 
or achieve burst suppression  IP administration will be discontinued without taper but the 
participant will continue in the study. Additional details  can be found in Sectio n 4.5.  
Concomitant u se of IV products containing Captisol
® during IP administration is prohibited (see 
exclusion criterion #7 and  Appendix 4). 
6 INVESTIGATIONAL  PRODUCT  
6.1 Identity of I nvestigational P roduct  
The IP  is ganaxolone IV solution, 1 mg/mL,  or placebo  which will be provided in 500 mL glass 
bottles with a grey stopper, purple flip-off cap and aluminum overseal. Each 500 mL bottle 
contains 425 mL of a sterile solution . The  IP is provided as a unit dose bottle. Placebo will only 
be used for the double- blind  phase of the study. Should the study transition to open- label , the 
ganaxolone IV solution administered as IP will be identical to the ganaxolone IV solution administered during the double- blind  phase.  
The active formulation consists of a sterile solution of ganaxolone drug substance that has been solubilized by complexation with Captisol
® (Betadex Sulfobutyl Ether Sodium). The drug 
product is terminally heat- sterilized.  
On 01 June 2022 the Drug Enforcement Administration (DEA) issued its interim final rule placing ganaxolone, including its salts, in schedule V of the Controlled Substances Act. The DEA drug code for Ganaxolone (commercial name, Ztalmy) is 2401. 
For more details on t he composition of the ganaxolone IV solution, 1 mg/mL refer to the 
Pharmacy Manual . 
 
Confidential  Page 49 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
6.1.1 Blinding the Treatment Assignment 
6.1.2 Double -Blind Phase  
During the double- blind  phase of the study, all participating staff involved in the evaluation and 
execution of the study will remain blinded to the participant ’s treatment assignment .  
6.1.3 Open-L abel Phase  
If the study transition s to an open- label phase (refer to Section  10.7), blinding will not be 
applicable for new participants enrolled in the open- label phase of the study .  
6.2 Administration of Investigational Product (s) 
6.2.1 Interactive Response Technology for Investigational Product Management 
Interactive Response Technology ( IRT) will be utilized for the following tasks:  
• IP allocation  (double- blind  phase only) 
• Randomization (double-blind phase only) 
• Supply management  
• Inventory management and supply ordering 
• Expiration date tracking  
• Returns 
• Emergency unblinding (double- blind  phase only) 
Details of the system and a system user manual will be provided for the i nvestigator files at each 
site. 
6.2.2 Allocation of Participant s to Treatment  
6.2.2.1 Double -Blind Phase  
The actual treatment given to individual participants is determined by a randomization schedule. 
Participant  identification numbers are assigned prior to dosing . Within each site (numbered 
uniquely within a protocol), participant number s are assigned in  the sequence of participant 
presentation for study participation . To allow for timely  delivery of IP to the hospital unit, the IP 
bottles may be allocated for use in the IRT prior to the participant meeting all eligibility  criteria 
to avoid impact to standard of care. Investigational product will not be administered until 
eligibility has been determined. Enrollment is defined as the initiation of IP infusion.   
6.2.2.2 Open-L abel Phase  
All eligible participants enrolled under the  open -label  phase of the study will receive ganaxolone 
IV solution  added to SE standard of care. No randomization will occur.  
As per the double- blind  phase, w ithin each site, participant numbers will be  assigned in the 
sequence of participant presentation for study participation. Investigational product will not be 
 
Confidential  Page 50 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
administered until eligibility has been determined. Enrollment is defined as the initiation of IP 
infusion. 
6.2.3 Dosing  
Once consent/assent has been obtained or deferre d, where all owed by law and if the participant 
meets protocol entry criteria, IP will be added to standard of care.  
Participants must have received any two or more of the following agents for the treatment of the 
current episode of SE (benzodiazepine and one IV AED or two IV AEDs) , administered  at an 
adequate dose and for a sufficient duration , in the judgment of the investigator, to demonstrate 
efficacy  (guidelines for adequate doses are provided in Appendix 2):  
• Benzodiazepines, 
• IV Fosphenytoin/phenytoin, 
• IV Valproic acid,  
• IV Levetiracetam,  
• IV Lacosamide, 
• IV Brivaracetam, or  
• IV Phenobarbital 
Administering fosphenytoin/phenytoin will be counted as one (1) AED. Administering levetiracetam and brivaracetam will be counted as two (2) AEDs.  
Investigational product will be administered  as a 48 -hour continuous infusion, which includes an 
initial 3 -minute bolus and ends with a 12-hour taper. 
The investigator will confirm that the pa rticipant meets clinical and EEG criteria for SE during 
the 60-minute period prior to IP initiation and  will reconfirm that ongoing ictal activity is present 
within 30 minutes immediately prior to IP  initiation .  
Investigational product should be administered through a dedicated peripheral or central IV line  
or a dedicated lumen of a multi- lumen catheter. Infusion lines should be changed according to 
institution standard practices. The maximum time an IP bottle can be hung at the participant’s bedside for administration is 24 hours.  
Note : At any time , the infusion rate of IP may be temporarily decreased or permanently stopped 
for safety reasons.  
Status epilepticus cessation will be assessed  by the investigator based on clinical and EEG 
features. Training will be provided to guide and help standardize decisions across clinical sites. In addition, during the double- blind  phase , a central reader  blinded to treatment assignment will 
review EEG recordings retrospectively  and corroborate  accuracy of interpretation . If the study 
transition s to open- label  treatment after a demonstration of efficacy at the  interim analysis , a 
central reader will still revie w the EEG recordings retrospectively and corroborate accuracy of 
interpretation  but will not be blinded to treatment assignment given that all participants will be 
receiv ing open -label ganaxolone IV solution. 
 
Confidential  Page 51 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
6.2.3.1 Participant s weighing at least 40 kg:  
• A 30 mg bolus dose (over ~3 minutes) will be administered with a continuous infusion of 
80 mg/hour for 2 hours followed by a continuous infusion rate of 40 mg/hour for 10 hours, and then 20 mg/hour for the remaining 12 hours of Day 1.  
• On Day 2, from 24 to 36 hours following IP initiation, the continuous infusion rate of 20 mg/hour can be increased up to a maximum rate of 45 mg/hour until the start of the taper at 36 hours. The infusion rate will be determined by the investigator  to best manage seizure 
relapse and cannot exceed the rate of 45 mg/hour between 24- and 36- hours following IP initiation.  
• To taper IP, beginning 36 hours following  IP initiation, the infusion rate will be reduced by 
33.3% every 4 hours until the infusion is stopped or until the infusion rate becomes too low to sustain the IV line.  
• Note: If, according to the investigator’s clinical judgment, IP taper needs to start sooner than 36 hours after initiation, the infusion rate will be decreased by 33.3% of the rate at the beginning of the IP taper every 4 hours. 
• At the time the IP infusion is discontinued, the participant will progress to the follow -up 
period assessments/procedures.  
 
Confidential  Page 52 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
 
6.2.3.2 Participant s weighing <40 kg will be dosed on a per  kilogram basis:  
• A 0.75 mg/kg bolus dose (over ~3 minutes) will be administered with a continuous infusion 
at a dose of 2.0 mg/kg/hour for 2 hours followed by a continuous infusion dose of 
1.0 mg/kg/hour for 10 hours, and 0.5 mg/kg/hour for the remaining 12 hours of Day 1. 
• On Day 2, 24 to 36 hours following  IP initiation, the continuous infusion rate of 
0.5 mg/kg/hour can be increased up to a maximum of 1.125 mg/kg/hour until the start of IP 
taper at 36 hours. The infusion rate will be determined by the investigator to best manage 
seizure relapse and cannot exceed the rate of 1.125 mg/kg/hour during hours 24 to 36 of Day 2 at any time.  
• To taper IP, beginning 36 hours following  IP initiation, the infusion rate will be reduced by 
33.3% every 4 hours until the infusion is stopped or until the infusion rate becomes too low to sustain the IV line.  
Note: If, according to the investigator’s clinical judgment, IP taper needs to start sooner than 36 hours after initiation, the infusion rate will be decreased by 33.3% of the rate at the beginning of the IP taper every 4 hours.  Table 4. Dosing for Participants  ≥40 kg (on a  mg/hour basis)  
Days  Start Time from IP Initiation  IP Dose  
 IP Infusion Rate  
(mL/hour)  Duration  
Day 1  0 hours: bolus dose via syringe or 
infusion pump  30 mga N/A 3 minutes  
(0.05 hours)  
Day 1  0 hours through 2 hours following  IP 
initiation: continuous infusion, started 
with bolus  80 mg/hr  80  2 hours  
Day 1  2 hours through 12 hours following  
IP initiation  40 mg/hr  40 10 hours  
Day 1  12 hours through 24 hours following  
IP initiation   20 mg/hr  20 12 hours  
Day 2b 24 hours through 36 hours following  
IP initiation  20 - 45 mg/hr  20 - 45 12 hours  
 Taper  
Day 2c 36 through 48 hours following  IP 
initiation (12 -hour taper) 13 - 30 mg/hr  13 - 30 4 hours  
9 - 20 mg/hr  9 - 20 4 hours  
6 - 13 mg/hr  6 - 13 4 hours  
IP = investigational product . 
a. The 30 mg bolus is administered over ~3 minutes.  
b. On Day 2 (24 through 36 hours), the continuous infusion rate can be increased from 20 mg/hour to a maximum rate of 45 mg/hour at any time, if needed, to manage seizure relapse or other medical reason.  
c. To taper the IP, the infusion rate at the 36 -hour following IP initiation timepoint will be reduced by 33.3% 
every 4 hours until the infusion rate is stopped or if the infusion rate becomes too low to sustain the infusion 
line, at which point it will be stopped. The first taper will be 33.3% from the  current infusion rate (e.g., if the 
current infusion rate is 20 mg/hr, the first taper will be 13 mg/hr) the second taper will be 33.3% from the first 
tapered infusion rate (e.g., if the current infusion rate i s 20 mg/hr, the second taper will be 9 mg/hr), and the 
final taper will be 33.3% from the previous tapered infusion rate (e.g., if the current infusion rate is 20 mg/hr, the final taper will be 6 mg/hr). If, in the investigator’s judgment, the taper needs to start at an earlier timepoint 
during the treatment period, the infusion rate at the start of the first taper will be decreased by 33.3% every 
4 hours as described.  
 
Confidential  Page 53 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
• At the time the IP infusion is discontinued the participant will progress to the follow-up 
period assessments/procedures.  
Table 5. Dosing for Participant s <40 kg (on a mg/kg/hour basis)  
Days  Start Time from IP Initiation  IP Dose  IP Infusion Rate  
(mL/ kg/hour)a Duration  
Day 1  0 hours: bolus dose via syringe or 
infusion pump  0.75 mg/kgb N/A 3 minutes  
Day 1  0 hours through 2 hours following  IP 
initiation continuous infusion, started 
with bolus  2.0 mg/kg/hr  2.0 2 hours  
Day 1  2 hours through 12 hours following  IP 
initiation  1.0 mg/kg/hr  1.0 10 hours  
Day 1  12 hours through 24 hours following  
IP initiation  0.50 mg/kg/hr  0.50 12 hours  
Day 2c 24 hours through 36 hours following  
IP initiation  0.50 – 1.125  
mg/kg/hr   0.50 - 1.125  12 hours  
 Taper  
Day 2d  36 through 48 hours following  IP 
initiation (12 -hour taper) 0.34 – 0.75mg/kg/hr  0.34 - 0.75 4 hours  
0.22 – 0.51mg/kg/hr  0.22 - 0.51 4 hours  
0.15 – 0.34mg/kg/hr  0.15 - 0.34 4 hours  
IP = investigational product . 
a. Reference the Pharmacy Manual for IP infusion rates based on mg/kg/hour dosing.  
b. The 0. 75 mg/kg bolus is administered over ~ 3 minutes.  
c. On Day 2 (24 through 36 hours), the continuous infusion dose can be increased from 0. 5 mg/kg/hour to a 
maximum dose of 1.125 mg/kg/hour at any time, if needed, to manage seizure relapse or other medical 
reason.  
d. To taper the IP, the infusion rate at the 36 -hour following IP initiation timepoint will be reduced by 33.3% 
every 4 hours until the infusion rate becomes too low to sustain the infusion line, at which point it will be stopped. The first taper will be 33.3% from the current infusion rate (e.g., if the current infusion rate is 0. 50 
mg/kg/hr, the first taper will be 0. 34 mg/kg/hr), the second taper will be 33.3% from the first tapered infusion 
rate (e.g., if the current infusion rate is 0. 50 mg/kg/hr, the second taper will be 0. 22 mg/kg/hr), and the final 
taper will be 3 3.3% from the previous tapered infusion rate (e.g., if the current infusion rate is 0. 5 mg/kg/hr, 
the final taper will be 0. 15 mg/kg/hr). If, in the investigator’s judgment, the taper needs to start at an earlier 
timepoint during the treatment period, the infusion rate at the start of the first taper will be decreased by 
33.3% every 4 hours as described.  
 
6.2.4 Investigational Product Infusion Precautions  
Throughout the study, heart rate and rhythm, blood pressure, and oxygen saturation are monitored.  Investigational product may be temporarily or permanently discontinued, if clinically 
indicated, for treatment of persistent hypotension (sustained systolic blood pressure <90 mmHg), cardiac arrhythmia or oxygen desaturation. 
Due to Captisol
® presence in the IV formulation of the IP, renal function will be monitored 
throughout the study. In addition to standard and accepted biomarkers of renal function (i.e., 
creatin
ine clearance and estimated glomerular filtration ratio [eGFR]), urinary exploratory 
biomarkers of renal function (N -acetyl -β-D-glucosaminidase [NAG], β 2-microglobulin, and 
creatinine ) will be monitored throughout the study and reviewed by the DMC.  
 
Confidential  Page 54 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
6.2.5 Medical Oversight  
Participants will require close medical monitoring as defined by local institutional practice 
guidelines for the treatment of patients with the diagnosis of seizures or status epilepticus.  
Telemedicine  
Telemedicine is an acceptable practice for conducting protocol- driven assessments/procedures as 
defined by local institutional practice guidelines.  
6.2.6 Investigational P roduct T apering ( One or M ore May A pply)  
Scenarios for stopping IP without a taper may include: 
o Participants who receive IP for less than 2 hours  
o Investigational product infusion is discontinued or interrupted (e.g., for safety concerns related or not related to IP or due to planned medical procedures), and a decision is made not to restart the infusion  
o If at any time during IP administration the participant progresses to an anesthetic with the 
primary intent specifically to treat seizures or achieve burst suppression   
o For other safety reasons based on the investigator’s clinical judgment 
6.2.7 Do
se Adjustment s and Interruptions 
Investigational product dose (infusion rate) decreases, and interruptions are discouraged during treatment. However, if there is an urgent medical need (e.g., severe hypotension, severe sedation) or standard of care  requires a procedure for which the infusion rate would need to be temporarily 
decreased or interrupted (e.g., MRI) it should be kept as short as possible and should not exceed 2 hours. If the interruption is >2 hours, the Medical Monitor should be consulted before restarting the infusion.  
Note:  
• After a dose (infusion rate) decrease or interruption, the investigator’s clinical judgment of risk/benefit will determine IP administration or discontinuation.  
• Investigational product discontinuation does not affect participation in the study. All participants should be followed until they reach the final study follow- up visit/contact or 
consent is withdrawn. 
• In cases when IP discontinuation is considered (e.g., severe sedation), when possible, the Medical Monitor should be contacted prior to IP discontinuation.  
• If the decision is made to restart IP, the infusion should be restarted at the rate matching 
the rate at the corresponding nominal time, counted from the start of the IP infusion on 
Day 1  (Time 0). Investigational product bolus or “catch -up” dose to deliver the IP that 
was missed during the interruption should not be administered.  
• Infusion rate  increases above those specified in the protocol are not allowed at any time 
during infusion. This is to ensure daily Captisol
® and ganaxolone limits are maintained at 
≤50 g/day or 1.25 g/kg/day  (in participants weighing <40 kg) and ≤833 mg/day or 
20.825 mg/kg/day (in participants weighing <40 kg) , respectively.  
 
Confidential  Page 55 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
6.2.8 Unblinding the Treatment Assignment  
6.2.8.1 Double -Blind Phase  
During the study, the treatment assignment must not be broken except in emergency situations in 
which the identification of the IP  is required for further treatment of the participan t. If possible, 
the investigator should contact the Medical Monitor before unblinding. However, this should not 
delay unblinding in case of an emergency. The investigator should contact the Medical Monitor as soon as possible after the investigator has unblinded  the participant.  
If the treatment assignment is broken, the date, the signature of the person who broke the code, and the reason for breaking the code are recorded in the source documents. Upon breaking the blind, the participant will have the follow -up period assessments/procedures, and the follow-up 
visits/contacts at Weeks 1, 2, 3, and 4. The IRT will record all unblinding events. 
6.3 Labeling, Packaging, Storage, and Handling  
6.3.1 Labeling  
Labels containing study information and bottle identification are applied to the IP container s.  
Each 500 mL  bottle contains no less than ( NLT ) 425 mL of IP  at a ganaxolone concentration of 
1 mg/mL  or placebo . (Note: placebo is only applicable for the double- blind phase). A label is 
applied to each bottle with information on strength, manufacturing batch numbers or job number, 
storage conditions, and name of the manufacturer, as well as a warning that the drug is intended 
for research only.  
The IP  will be dispensed to qualified staff members who will administer the IP  to the  participant.  
All IP  is labeled with a minimum of the following: protocol number, unique bottle number, 
dosage form (including product name and quantity in pack), directions for use, storage conditions, batch number and/or packaging reference, the statements “Caution: New Drug—Limited by Federal (or US) Law for Investigational Use” and “Keep out of reach of children,” 
and the Sponsor’s name and address. No information should be visible, which could potentially 
unblind the IP  (only applicable for the double- blind  phase). The l abel may be updated per local 
requirements.  
Additional labels (e.g., those used when dispensing marketed product) may be applied to the IP 
bottle to satisfy local or institution  requirements, but must not:  
• Contradict the clinical study label. 
• Obscure the clinical study label . 
Sponsor approval is not required to make this change. 
 
Confidential  Page 56 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
6.3.2 Packaging  
IP solution for administration will be provided to the site as individual bottles containing 
ganaxolone IV solution 1 mg/mL , or placebo . (Note: placebo is only applicable to the 
double- blind phase ). 
Changes to Sponsor-supplied packaging prior to dosing may not occur without full agreement in 
advance by the Sponsor. 
6.3.3 Storage 
The investigator has overall responsibility for ensuring that IP  is stored in a secure, limited  
access location  in accordance with applicable requirements under the Controlled Substance Act 
(CSA) and Drug Enforcement Administration (DEA) regulations. Limited responsibility may be 
delegated to the pharmacy or member of the study team, but this delegation must be documented. Investigational products are distributed by the pharmacy or by a nominated member of the study team . Details on how to store the IP  can be found in the Pharmacy Manual . Prior to 
administration inspect the IP  for particulate matter, cloudiness, and discoloration . If any of these 
is present, do not use and notify the Sponsor. 
Investigational product must be stored in accordance with labeled storage conditions . 
Temperature monitoring of the IP  is required at the storage location to ensure that the IP is 
maintained within an established temperature range . The investigator is responsible for ensuring 
that the temperature is monitored throughout the duration of the study and that records are 
maintained . The temperature should be monitored continuously by an in-house system, by a 
mechanical recording device such as a calibrated chart  recorder, or by manual means, such that 
both minimum and maximum thermometric values over a specific time period can be recorded and retrieved as required . Such a device ( i.e., certified min/max thermometer) would require 
manual resetting upon each recording. The Sponsor must be notified immediately upon discovery of any excursion from the established range. Temperature excursions will require site 
investigation as to cause and remediation . The Sponsor will determine the ultimate impact of 
excursions on the IP  and will provide supportive documentation, as necessary . Under no 
circumstances should the product be dispensed to participants until the impact has been 
determined and the product is deemed appropriate for use by the Sponsor. 
The Sponsor should be notified immediately if there are any changes to the storage area of the IP 
that could affect the integrity of the product(s), such as fumigation of a storage room. 
6.4 Investigational Product Accountability  
Investigators will be provided ample  amounts of the IP to carry out this protocol for the agreed 
number of participan ts. The investigator or designee will acknowledge receipt of the IP, 
documenting shipment content and condition. Accurate records of all IP  dispensed, used, 
returned, and/or destroyed must be maintained as detailed further in this section.  
The investigator has the overall responsibility for dispensing/administering IP . Where 
permissible, tasks may be delegated to a qualified designee ( e.g., pharmacist) who is adequately 
 
Confidential  Page 57 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
trained in the protocol and who works under the supervision of the investigator. This delegation 
must be documented in the applicable study delegation of authority form. 
The investigator or their designee (as documented by the investigator in the applicable study 
delegation of authority form) will place the IP administration orders and confirm that the IP is 
only administered to participants included in this study following the procedures set out in the 
study protocol. Each participant  will be given only the IP  carrying their treatment assignment . 
All dispensed medication  will be documented i n the eCRF s and/or other IP record .  
No IP  stock or returned inventory from a Marinus-sponsored study may be removed from the site 
where originally shipped without prior knowledge and consent by the Sponsor. If such transfer is authorized by the Sponsor, all applicable local, state, and national laws must be adhered to for the transfer.  
The Sponsor or its representatives must be permitted access to review the supplies storage and distribution procedures and records. 
At the end of the study, or as instructed by the Sponsor, all unused stock will be sent to a 
nominated contractor on behalf of the Sponsor for destruction or  will be  destroyed by the site. 
Investigational product being returned to the Sponsor’s designated contractor must be counted 
and verified by clinical site personnel and the Sponsor (or designated CRO). For unused supplies for which the original tamper evident feature is verified as intact, the tamper evident feature must not be broken, and the labeled amount is to be documented in lieu of counting. Shipment return forms, when used, must be signed prior to shipment from the site . Returned IP  must be packed in 
a tamper  evident manner to ensure product integrity. Contact the Sponsor for authorization to 
return any IP prior to shipment. Shipment of all returned IP  must comply with local, state, and 
national laws.  
Investigational product administered to the participant will be destroyed upon completion of the 
individual bottle administration according to institution standard procedures. 
With the written agreement of the Sponsor, unused stock may be destroyed at the site or a local 
facility . In this case, destruction records identifying what was destroyed, when, and how must be 
obtained with copies provided to the Sponsor. Destruction of IP  must be in accordance with 
local, state, and national laws.  
Based on entries in the IP accountability forms , it must be possible to reconcile IP delivered with 
those used and returned. All IP  must be accounted for, and all discrepancies investigated and 
documented to the Sponsor’s satisfaction.  
6.5 Participant Compliance  
The IP  will only be administered by appropriately trained site staff . Investigational product 
accountability must be assessed at the container/packaging level for unused IP  that is contained 
within the original tamper evident sealed container ( e.g., bottles ) or at the individual count level 
for opened containers/packaging. The pharmacist/nominated person will record details on the IP 
accountability form. 
 
Confidential  Page 58 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
7 STUDY PROCEDURES  
7.1 Study Schedule  
The study schedule will remain the same under both the double-blind and open- label phases. See 
Table 1  and Table 2  for details regarding scheduled assessments and procedures in this study.   
The following “priority order” will be in effect when more than one procedure or assessment is 
required at a timepoint: 
1. Spontaneous or solicited AE reporting 
2. Vital signs  
3. Pharmacokinetic sample collection  
4. Clinical laboratory tests  
5. Physical examination  
NOTE: Blood sampling for pharmacokinetic evaluation should be performed at the precise protocol scheduled time. Actual sampling time(s) must be accurately recorded in the source document and appropriate eCRF. 
7.1.1 Screening Period  
7.1.1.1 Screening  
Potential participants may be identified in the emergency department, ICU, or other units  in the 
hospital, and will be consented/assented and then screened for inclusion/exclusion criteria prior 
to being enrolled to start  IP treatment.   
Procedures specific to this protocol and not otherwise considered standard of care, will not be performed until written informed consent/assent  from the participant /participant’s 
parent/guardian/LAR has been appropriately obtained or deferred, where allowed by law. Consent for participants  who are at risk for SE may be obtained prior to occurrence of SE, this is 
also referred to as pre -consenting. Additional details on consent /assent  can be found in Section 
11.3.1. 
7.1.1.2 Screen Failures 
Individuals who do not meet the criteria for participation in this study (screen failure) may not be 
rescreened once they have been designated as a screen failure during the same episode of SE. Participants  who have failed  screening in a prior episode of SE may be rescreened if they 
experience a new SE event.   
 
Confidential  Page 59 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
7.1.2 Treatment Period  
7.1.2.1 Investigational Product  Initiation Through Taper  (Day  1 to Day  2) 
Eligible SE participant s will be enrolled to receive either ganaxolone IV solution or placebo 
(double- blind phase ) or ganaxolone IV solution (open- label phase) added to SE standard of care. 
Investigational product will be administered  as a 48 -hour continuous infusion, which  includes an 
initial 3 -minute bolus and ends with a 12-hour taper. 
The investigator will confirm that the participant meets clinical and EEG criteria for SE during 
the 60- minute period prior to IP initiation and will reconfirm that ongoing ictal activity is present 
within 30 minutes immediately prior to IP  initiation . Following  IP initiation, the standard 
duration of treatment is 2 days (48 hours) which includes a 12-hour taper as described in Section  6.
 
7.1.3 Follow- up Period ( starting at IP discontinuation through Week 4) 
Participant s will have the  follow-up period assessments/procedures collected following  IP 
discontinuation (with or without taper ) as noted in Section 3. Assessments/procedures will be 
collected every 24 hours through 120 hours (or until hospital discharge) and at the time of hospital discharge, followed by weekly follow- up visits/contacts at Week 1, 2, 3 and 4. 
Participants who discontinue IP without a taper, e.g., were administered IP for less than 2 hours, progress to anesthesia for seizure suppression or discontinue IP due to safety or any other reason, except due to withdrawal of consent, will have the follow -up assessments/procedures collected 
every 24 hours through 120 hours (or until hospital discharge) and at the time of hospital discharge, followed by weekly follow -up visits/contacts at Week 1, 2, 3 and 4.  
The follow- up period for this protocol is approximately 4 weeks. Week 1, 2, 3, and 4 visits may 
be conducted as an inpatient visit, if the participant is still in the hospital, or as a telephone contact, if the participant has been discharged . Attempts should be made to have discharged 
participants return for one of these visits to be in person. The participant/participant’s 
parent/guardian/LAR, as appropriate, will receive a follow -up contact weekly approximately 7 ± 
3, 14 ± 3, 21 ± 3, and 28 ± 3 days following the IP discontinuation date. If the hospital discharge 
visit corresponds to the Week 1, 2, 3, or 4 ( ± 3 days ) visits, it can take the place of the weekly 
visit.  
During these follow-up period visits/contacts , the site will follow -up on all SAEs and non-
serious AEs, AE resolution that occurs, and concomitant medications. Adverse e vents and SAEs 
that are not resolved at the time of contact will be followed to closure (see Section 8.1 ). Table 1  
lists the assessments that should be collected during the follow-up visits/contacts. 
7.1.4 Additional Care of Participant s After the Study  
No after care is planned for this study. Participants should follow their physician’s care plan and 
referral guidance.  
 
Confidential  Page 60 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
7.2 Study Evaluations and Procedures  
7.2.1 Demographic and Other Baseline Characteristics  
The following demographic data will be recorded: 
• Date of birth  
• Sex 
• Ethnic origin (Hispanic or Latino or not Hispanic or Latino) 
• Race (American Indian or Alaska Native, Asian, Black or African American, Native 
Hawaiian or Other , Pacific Islander, White , or Other)  
7.2.2 Efficacy   
Efficacy will be  evaluated by collecting the following assessments as noted in Table 1 .  
The name and address of each third -party vendor (e.g., central EEG reader) used in this study 
will be maintained in the investigator’s and Sponsor’s files.  
7.2.2.1 Electroencephalogram (EEG)  
An EEG is required for confirmation of CSE and NCSE diagnosis. Continuous EEG monitoring 
should be used for all study participants and should start before IP  initiation to obtain a baseline 
assessment and should continue through the end of the  first 24 hours of the follow -up period 
(i.e., 24 hours following IP discontinuation).  
Sites will  be offered the use of a rapid  EEG device to assist with screening and enrollment of 
participant s with NCSE . It is preferred  that a conventional EEG is used for the purpose of 
confirmin g inclusion criterion #3 and EEG monitoring during IP administration.  
In situations when a conventional EEG is not immediately available , the rapid EEG may be used  
to confirm inclusion criterion #3 and enroll the participant . Since the rapid EEG has a limited 
battery life, it should be switched to a conventional EEG  within several hours but not earlier than 
90 minutes after IP initiation to allow uninterrupted collection of EEG for the 30- minute SE 
cessation co -primary endpoint. It will be at the investigator’s discretion if the use of the rapid 
EEG will benefit their site. The devic e should be used according to institution standard practices.  
All devices utilize d in the study will have received FDA 510(k) clearance . It will be at the 
investigator’s discretion if they feel the device will benefit their site and if any institutional 
approvals are needed to utilize the device. A copy of the device user manual and system specifications will be on file at any site utilizin g the device.  
7.2.2.2 Status Epilepticus Severity Score (STESS)  
The STESS is a prognostic score relying on 4 outcome predictors (age, history of seizures, 
seizure type and extent of consciousness impairment).  
 
Confidential  Page 61 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
7.2.2.3 Clinical Global Impression of Severity and Improvement (CGI -S and CGI -I, 
respectively)  
The CGI -S and CGI -I assess overall health and functional status of a participant. Participant and 
clinician rater versions indicate general worsening or improvement on a seven -point Likert -like 
scale.  For specific collection timepoints reference Table 1 . 
7.2.2.4 Richmond Agitation and Sedation Scale (RASS)  
The RASS  is a medical scale used to measure the agitation or sedation  level. For specific 
collection timepoints reference  Table 1 . 
7.2.2.5 The Full Outline of Un Responsiveness (FOUR) Score  
The FOUR Score is a tool designed to assess patients with impaired level of consciousness. 
There are four parameters evaluated in order to cover domains of neurological function: eye response, motor response, brainstem reflex and respiration. For specific coll ection timepoints 
reference Table 1 . 
7.2.2.6 Seizure Description  Question naire   
The Seizure Description Questionnaire is a descriptive questionnaire that captures the clinical 
features of SE prior to IP initiation using ILAE 2015 classification.  This questionnaire should be 
collected  as close as possible to IP initiation . Reference Table 1 . 
7.2.2.7 Status Epilepticus Cessation  Questionnaire  
For this study, SE Cessation is defined as the beginning of the first 30- minute epoch following IP 
initiation in which SE burden is no longer fulfilled (<20% ictal burden and is at least 50% less during the 30 minutes prior to IP initiation). This questionnaire should be collected as close as possible to 24 and
 72 hours following IP initiation . Reference Table 1 . 
7.2.2.8 Super Ref ractory Status Epilepticus Questionnaire  
The definition of SRSE is SE that is continuous or recurs during or after the SE treatment with IV anesthesia for 24 hours or longer. This questionnaire should be collected  as close as possible 
to the diagnosis of SRSE and no later than the final study follow-up visit/contact. Reference Table 1 . 
7.2.2.9 Modified Rankin Scale (mRS)  
The mRS is a commonly used 6 -point scale for measuring the degree of disability or dependence 
in the daily activities of people who have suffered a stroke or other causes of neurology disability. The m RS should be assessed at the timepoints noted in  Table 1 .  
 
Confidential  Page 62 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
7.2.2.10 EuroQol (EQ-5D-5L) 
The EQ -5D-5L is a descriptive system of health -related quality of life states consisting of 5 
dimensions: mobility, self -care, usual activities, pain/discomfort , and anxiety/depression. For 
specific collection timepoints reference Table 1 .  
7.2.3 Safety  
Safety will be evaluated by collecting the following assessments as noted in Table 1 .  
If a third -party vendor is used for any safety analysis,  then t he name and address of each third - 
party vendor will be maintained in the investigator’s and Sponsor’s files.  
7.2.3.1 Medical, Seizure or SE , and Medication History  
Medical history will include the following: 
• Previous and concomitant illnesses, surgeries, and medications  
• Family history  
• History of drug and alcohol abuse 
• Seizure or SE etiology   
7.2.3.2 Physical Examination  
A physical examination will be performed at the timepoints described in Table 1  by a qualified 
licensed physician, physician’s assistant, or nurse practitioner .  
The physical examination will include a review of the following body systems:  
• General appearance  
• Skin 
• Head, eyes, ears, nose, and throat  
• Spine, neck , and thyroid 
• Musculoskeletal  
• Respiratory  
• Cardiovascular  
• Neurologic 
• Abdomen (including liver and kidneys) 
• Other systems as appropriate  
Abnormalities identified at the first PE thought to be present prior to IP  initiation will be 
documented in the participant ’s source documents and in the medical history eCRF. Conversely, 
abnormalities identified at the first PE that are t hought to develop following  IP initiation should 
be recorded as AEs on the AE eCRF page, as deemed by the investigator.  
 
Confidential  Page 63 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
Changes after the first PE will be recorded as AEs on the AE eCRF page, as deemed by the 
investigator.  
7.2.3.3 Adverse Event Collection  
Participant s and their parent/guardian/ LAR will be questioned in a general way to ascertain if 
AEs have occurred ( e.g., “Have you had any health problems since your last visit?”). Adverse 
events will be  collected from the time of IP  initiation through the final study follow-up 
visit/contact .  
Refer  to Section 8, Adverse and Serious Adverse Events Assessment . 
7.2.3.4 Vital Signs  
Vital signs include blood pressure, pulse, respiration rate, oxygen saturation, and temperature. Ideally , noninvasive automated monitoring of vitals should be started at screening and continue 
through the end of the first 24 hours of the follow -up period. If not continuously monitored, 
vitals should be assessed as stated in  Table 1  including collection for participants who stop IP  
without a taper or terminate early  from  the study. 
Noninvasive blood pressure (systolic and diastolic) and pulse rate will be measured by an automated blood pressure device after the participant has been in a supine position for at least 5 
minutes. Ideally, t he same arm should be used for all measurements.  
Any deviations from the predose ( screening ) vital signs that are deemed clinically significant  
based on investigator judgment should be recorded as AE s. 
Weight and height should be collected predose ( screening ) for calculation of the BMI inclusion 
criterion , if feasible.  If not collected at screening , they will need to be collected prior to the end 
of the f irst 24 hours of the follow -up period. 
7.2.3.5 Electrocardiogra phy (ECG) 
A 12  lead ECG should be collected after the participant has been in a supine position for at least 
5 minutes. 
If abnormal results are observed, the investigator will assess clinical significance and determine 
whether the results should be recorded as an AE.  
The timepoints for ECG collection is noted in Table 1 . 
7.2.3.6 Cardiodynamic 12-L ead Electrocardiography (ECG) M onitoring  
Select sites will participate in a sub study using a continuous 12 lead ECG recorder. For more 
details refer to Appendix 5.  
 
Confidential  Page 64 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
7.2.3.7 Clinical Laboratory Evaluations 
All clinical laboratory assays will be performed according to the institution’s laboratory normal 
procedures. If there are laboratory collections that are not done by the institution’s laboratory, the 
institution should follow their standard procedures for sending samples to their reference laboratories for analysis (e.g., AEDs). The collection timepoints are detailed in Table 1 . 
Reference ranges are to be supplied by the laboratory and will be used to assess the clinical laboratory data for clinical significance and out of range pathologic changes. The investigator should assess out of range clinical laboratory values, indicating if the values are clinically significant or not clinically significant. Abnormal clinical laboratory values that are unexpected or not explained by the participant’s clinical condition may, at the discretion of the investigator or Sponsor , be repeated as soon as possible until confirmed, explained, or resolved. 
Urine Chemistry  
Urine samples for N- acetyl -β-D-glucosaminidase (NAG), β 2-microglobulin, and creatinine will 
be col
lected at the times specified in  Table 1. Urine samples will be stored frozen. Details 
regarding sample collection, processing, storage, and shipment to the bioanalytical vendor are described in the Biospecimen Manual.  
Drugs of Abuse Testing 
A urine or serum sample for drugs of abuse testing should be collected per the institution 
standard of care and prior to IP initiation. A urine or serum sample for alcohol testing should be collected if medically indicated.  If medically indicated, the investigator may expand testing for 
additional drugs of abuse above the institution’s standard of care. If unable to collect predose, 
collect as soon as possible following  IP initia tion. However, if a participant tests positive, it will 
be at the investigator’ s discretion to weigh the risks versus benefits for enrollment or continued 
participation. If the investigator decides to discontinue the IP, refer to Section 4.5. 
Pregnancy Test   
As described in Table 1  and Section 4.4, a urine or serum pregnancy test should be collected for 
all females of childbearing potential prior to IP initiation, and if pregnancy is suspected. If 
unable to collect predose, collect as soon as possible following  IP initiation. Enrollment is not 
contingent upon results. However, if a participant has a positive test result, it will be at the 
investigator’s discretion to weigh the risks versus benefits for continued participation. If the 
investigator decides to discontinue the IP, please refer to Section 4.5. If the institution requires the pregnancy test results be obtained prior to IP initiation , the institution  guidelines will be 
followed.  
Blood Gas 
All blood gas samples arterial or venous, if collected, will be at  the investigator’s discretion to 
manage care. If collected from the time of SE diagnosis through the end of the first 24 hours of 
the follow -up period, the eCRF should be completed. If samples are not collected, a sample will 
not be required.  
 
Confidential  Page 65 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
If a decision is made to intubate the participant between IP initiation through the end of the first 
24 hours of the follow-up period, a blood sample should be collected. The sample should be 
collected immediately prior to or as close as possible to the time of intubation.  
The clinical laboratory tests performed as part of the protocol are listed in Table 6. 
Table 6. Clinical Laboratory Tests  
Hematology  Coagulation  Biochemistry  Urinalysis  
Hemoglobin  
(Hb)  
Hematocrit  
(Hct)  
Red blood cell count  
(RBC)  
White blood cell count; 
total and differential  
(WBC)  
Mean corpuscular 
hemoglobin (MCH)  
Mean corpuscular 
hemoglobin 
concentration (MCHC)  
Mean corpuscular 
volume  
(MCV)  
Platelet count  
WBC Differential  
% Basophils  
% Eosinophils  
% Lymphocytes  
% Monocytes  
% Neutrophils  
Basophil count 
Eosinophil count  
Lymphocyte count  
Monocyte count 
Neutrophil count Fibrinogen  
Activated partial 
thromboplastin time 
(aPTT)  
Prothrombin time 
(PT) 
International 
normalized ratio 
(INR)  Sodium  
Potassium  
Calcium  
Glucose  
Total protein  
Albumin  
Creatinine  
Blood urea nitrogen  
(BUN)  
Total Bilirubin  
Alkaline phosphatase  
(ALP)  
Aspartate transaminase (AST)  
Alanine transaminase  
(ALT)  
Total cholesterol1 
Estimated Glomerular 
Filtration Rate (eGFR) , if 
available  
Creatinine Clearance  
calculation , if available  
 
Urine Chemistry  
N-acetyl -β-D- glucosaminidase 
[NAG]  
Β2-microglobulin  
Creatinine   
 
Antiepileptic drug levels  
(AEDs ; per institution 
standard of care) 
fosphenytoin/ phenytoin,   
valp
roic acid,  
levetiracetam,  
 lacosamide, phenobarbital or 
brivaracetam  pH 
Protein  
Blood  
Ketones  
Glucose  
Bilirubin  
Specific gravity  
 
If any abn
ormal value  is 
observed on the urine 
dipstick test, the sample 
should be further analyzed 
with urine microscopy:  
WBC 
RBC 
Cellu
lar casts  
Granular casts  
Hyaline casts  
 
Urine or Serum Drug s of 
Abuse  Testing  
(per institution standard of 
care) 
Phencyclidine  
Opioids2  
Cannabinoids3  
Methamphetamine /Ampheta
mine  
Cocaine  
Barbiturates  
Benzodiazepines  
Alcohol , if medically  
indicated  
 
Urine or Serum Pregnancy  
1. Total cholesterol level , if collected per standard of care , should be collected predose (screening).  
2. May be limited to drug class or list specific drug such as oxycodone, methadone, heroi n. 
3. May be limited to drug class or list specific substance such as THC.  
 
Confidential  Page 66 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
7.2.4 Others  
7.2.4.1 Clinical Pharmacology Blood Sample Collection and Handling Procedures 
Blood samples for pharmacokinetic analysis (PK) will be collected at the times specified in  
Table 2. The Sponsor’s expectation is that the i nvestigator will ensure that every effort is made 
to collect all PK  blood samples at the precise protocol scheduled time. Pharmacokinetic blood 
collection must not deviate from the nominal collection time set forth in the protocol by more 
than ± 5 minutes f or samples drawn within 6 hours following IP initiation  or by more than ±  
2 hours for samples drawn beyond 36 hours following  IP initiation . Samples drawn outside these 
parameters will be considered a protocol deviation.   
Venous blood samples (2 mL) will be drawn from indwelling catheters or by direct venipuncture 
into K 2EDTA Vacutainer® tubes (lavender top), capped, mixed by inversion (×10), and chilled 
immediately on crushed ice . If using indwelling catheters, they should be kept patent with 
isotonic saline and the saline should be withdrawn (1  mL) and discarded before the blood sample 
is taken.  Use of topical anesthesia to reduce the pain of an indwelling catheter is permitted and , if 
used, should be documented as a concomitant medication . If venous blood sample collection is 
not possible an arterial  sample may be collected . The type of sample will be recorded in the 
source documents and eC RF.  
Pharmacokinetic samples should b e collected from the contralateral peripheral access or the 
arterial line and avoid collecting samples downstream of the IP infusion . The location of IP  
access and location of PK sample collection should be documented in the participant ’s source. If 
the PK sample cannot be collected due to poor venous access and the IP  infusion site is the only 
viable option, the sample  should not be collected and the reason for non-collection documented 
in the participant ’s source.  
Details regarding sample collection, processing, storage, and shipment to the bioan alytical 
vendor are described in the Biospecimen Manual . The freezer temperature where these samples 
are stored must be controlled, monitored, and recorded during the storage period until the 
samples are shipped on dry ice to the bioanalytical vendor  for analysis . The Sponsor must be 
notified of any temperature excursions. 
7.2.4.2 Shipment of Plasma Pharmacokinetic Samples  
Unless agreed upon by the Sponsor , within approximately 1 week after participant s complet e the 
first 24 hours of the follow-up period, the site will ship the primary plasma samples to  the 
bioanalytical vendor. Upon notification of receipt of the primary samples by the bioanalytical 
vendor, the backup samples will be shipped to the bioanalytical laboratory. Refer to the Biospecimen Manual for details regarding sample  shipping.  
7.2.4.3 Plasma Drug Assay Methodology 
Plasma concentrations will be measured using the most current validated liquid chromatography 
with tandem mass spectrometry (LC/MS/MS) method. Other metabolites may be monitored or quantitated as appropriate. Raw data will be stored in the archive of the designated bioanalytical laboratory.  
 
Confidential  Page 67 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
Table  7. Volume of Blood to Be Drawn from Each Participant  
Assessment  Sample 
Volume 
(mL) a Number of 
Required 
Collection 
Timepoint  
Samples  Number of 
Variable 
Collection 
Timepoint 
Samples  Total Volume (mL)  
Safety b Biochemistry 
(with indwelling 
catheter)  8.5 5 3 42.5 to 68  
 Hematology  4.0 5 3 20 to 32  
 Coagulation  5.1 3 1 15.3 to 20.4 
Pharmacokinetic samples 
(with indwelling catheter) c 3.0 8 0 24  
Blood gas (for intubation 
only) b 1.0 0 1 1 
Total mL  140.3 to 190.4 
a. If a catheter is used, the first milliliter (mL) collected is to be discarded, then the required volume is collected 
into the appropriate tube for the assessment. This additional 1 mL has been added the biochemistry and 
pharmacokinetic collections noted in the table. This assumes the hematology, coagulation, and AED samples 
will be collected at the same times as the biochemistry samples. The collection volume for coagulation testing at sites ranged from 2.7mL to 7.5.0mL,  as such the median volume of 5.1mL was used for the table 
calculation.  
b. See Table 1 for sample collection timepoints. There are required collection timepoints for all participants and 
variable collection timepoints that only apply in specific situations. The two different types have been separated in the table to show the maximum and min imum number of sample collections for a participant.  
c. Blood samples for pharmacokinetic analysis will be collected as noted in  Table 2 . 
d. Venous or arterial samples are acceptable.  
 
Table  8. Volume of Blood to Be Drawn from Each Participant (Pediatric Institution 
Sample Volumes)  
Assessment  Sample 
Volume 
(mL) a Number of Required 
Collection Timepoint  
Samples  Number of Variable 
Collection 
Timepoint Samples  Total 
Volume 
(mL)  
Safety b Biochemistry 
(with indwelling 
catheter)  2.0 5 3 10 to 16 
 Hematology  1.0 5 3 5 to 8 
 Coagulation  1.0 3 1 3 to 4 
Pharmacokinetic samples 
(with indwelling catheter) c 3.0 8 0 24  
Blood gas (for intubation 
only) b 1.0 0 1 1 
Total mL  36 to 40 
a. If a catheter is used, the first milliliter (mL) collected is to be discarded, then the required volume is collected 
into the appropriate tube for the assessment. This additional 1 mL has been added to the biochemistry  and 
pharmacokinetic collections noted in the table. This assumes the hematology, coagulation, and AED samples will be collected at the same times as the biochemistry samples.  
b. See Table 1 for sample collection timepoints. There are required collection timepoints for all participants and 
variable collection timepoints that only apply in specific situations. The two different types have been 
separated in the table to show the maximum and min imum number of sample collections for a participant.  
 
Confidential  Page 68 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
c. Blood samples for pharmacokinetic analysis will be collected as noted in  Table 2 . Venous or arterial samples 
are acceptable.  
  
During the study, it is expected that some sites (e.g ., pediatric  institutions ) will collect smaller 
volumes of blood from participant s per local laboratory standards. The ranges in Table  7 and 
Table  8 reflect the possible range for adult and child versus a pediatric only institution . The total 
blood volume drawn from pediatric participants for all safety and pharmacokinetic sampling will 
be approximately 36 mL and will not exceed 40 mL . The total blood drawn from adult 
participants will be approximately 14 0.3 mL and will not exceed 190.4 mL. 
As noted in Table 1 , several of the collection points are considered optional; however, to provide 
the most conservative estimate of the blood volume drawn, these option al collections have been 
included in Table  7 and Table  8.  
Note: The amount of blood to be drawn for each assessment is an estimate. The amount of blood to be drawn may vary according to the instructions provided by the manufacturer or laboratory for an individual assessment. When more than one blood assessment is to be done at a single 
timepoint/period, if they require the same type of collection tube, the assessments may be 
combined. 
7.3 Healthcare Utilization Questionnaires  
The Healthcare Utili zation Questionnaires include the Hospitalization Questionnaire and the 
Positive Pressure Ventilation (PPV) and Intubation Questionnaire. The Hospitalization 
Questionnaire should be collected at hospital discharge or at final study visit/contact. The need for non-invasive or invasive ventilatory support within 24 hours prior to IP initiation and following IP initiation and within 48 hours following IP discontinuation should be collected as close as possible to the event.   
 
Confidential  Page 69 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
8 ADVERSE AND SERIOUS ADVERSE EVENTS ASSESSMENT  
8.1 Definition of Adverse Events, Period of Observation, Recording of Adverse 
Events  
An AE is any untoward medical occurrence in a clinical investigation participant who has been 
administered a pharmaceutical product; it does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of an IP  
product, whether or not related to the IP .
40  
As this study allows for pre -consenting of participants, a ll AEs will be collected from the time of 
IP initiation until the final study follow -up visit/contact stated in Section 7.1 . Where possible, a 
diagnosis rather than a list of symptoms should be recorded. If a diagnosis has not been made, then each symptom should be listed individually. All AEs should be recorded on the AE eCRF 
page and in source documents. In addition to untoward AEs, unexpected benefits outside the IP 
indication should also be recorded on the AE eCRF  page. 
All AEs must be followed  for the durations described below. For AEs followed to closure , this  
indicates that an outcome is reached, stabilization is achieved (the investigator does not expect any further improvement or worsening of the event), or the event is otherwise explained . When 
appropriate, medical tests and examinations are performed so that resolution of event(s) can be documented. 
For participant s who  terminate early  from the study, prior to discontinuation as much 
information as possible as is available should be recorded for AEs/SAEs and their associated 
concomitant medication, especially those that may have led to the early termination. 
8.1.1 Severity Categorization 
The severity of AEs must be recorded during the course of the event, including the start and stop 
dates for each change in severity . An event that changes in severity should be recorded as a new 
event. Worsening of pretreatment events, after initiation of the IP , must be recorded as new AEs 
on the appropriate eCRF  page. 
The medical assessment of severity is determined by using the following definitions: 
Mild:  A type of AE that is usually transient and may require only minimal treatment or 
therapeutic intervention . The event does not generally interfere with usual activities 
of daily living. 
Moderate:  A type of AE that is usually alleviated with specific therapeutic intervention . The 
event interferes with usual activities of daily living, causing discomfort, but poses no significant or permanent risk of harm to the research participant. 
Severe:  A type of AE that interrupts usual activities of daily living, that significantly affects 
clinical status, or that may require intensive therapeutic intervention.  
 
Confidential  Page 70 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
8.1.2 Relationship Categorization 
A physician/investigator must make the assessment of the relationship between the IP  and each 
AE. The investigator should decide whether, in their medical judgment, there is a reasonable 
possibility that the event may have been caused by the IP . If there is no valid reason for 
suggesting a relationship, the AE should be classified as “not related .” Otherwise, if there is any 
valid reason, even if undetermined or untested, for suspecting a possible cause and effect 
relationship between the IP  and the occurrence of the AE, the AE should be considered “related .” 
The causality assessment must be documented in the source document.  
The following additional guidance may be helpful: 
Term  Relationship definition  
Related  The temporal relationship between the event and the administration of the investigational product is compelling and/or follows a known or 
suspected response pattern to that product, and the event cannot be 
explained by the participant ’s medical condition, other therapies, or 
accident.  
Not r elated  The event can be readily explained by other factors , such as the 
participant ’s underlying medical condition, concomitant therapy, or 
accident , and no plausible temporal or biologic relationship exists 
between the investigational product and the event. 
  8.1.3 Outcome Categorization  
The outcome of AEs must be recorded during the study in the eCRF . Outcomes are as follows:  
• Fatal  
• Not recovered/not r esolved  
• Recovered/ resolved  
• Recovered/ resolved w ith sequelae  
• Recovering/resolving 
• Unknown 
8.1.4 Symptoms of the Disease Under Study  
Symptoms of the disease under study should not be class ified as AEs as long as they are within 
the normal day to  day fluctuation or expected progression of the disease and are part of the 
efficacy data to be collected in the study; however, significant worsening of the symptoms should be recorded as an AE. Specifically, SE signs and symptoms that were present at study entry and that varied  in intensity over the duration of study treatment are not considered AEs 
unless in the investigator’ s opinion there is an unexpected  worsening of the events. However, if 
all seizure activity resolved and the participant  returned to base line status, but SE recurred, the 
event would then be recorded as an SAE. 
 
Confidential  Page 71 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
8.1.5 Clinical Laboratory and Other Safety Evaluations 
A change in the value of a clinical laboratory, vital sign, or ECG assessment can represent an AE 
if the change is clinically significant  or if, during treatment with the IP , a shift of a parameter is 
observed from a normal value to an abnormal value, or there is a further worsening of an already abnormal value. When evaluating such changes, the extent of deviation from the reference range, the duration until return to the reference range  (either while continuing treatment or following  IP 
discontinuation), and the range of variation of the respective parameter within its reference range must be taken into consideration. 
At the end of the treatment phase, for participant s who complete the study and do not progress to 
an IV anesthetic for  seizure suppression, i f there are abnormal clinical laboratory, vital sign, or 
ECG values that were not present in the pretreatment assessments closest to the start of IP  
initiation, further investigations should be performed until the values return to within the 
reference range or until a plausible explanation (e.g., concomitant disease) is found for the abnormal values. 
The investigator should decide, based on the above criteria and the clinical condition of a 
participant , whether a change in a clinical laboratory, vital sign, or ECG parameter is clinically 
significant and therefore represents an AE.  
8.1.6 Pregnancy  
As this study allows for pre -consenting of participants, all pregnancies are to be reported from 
the time of IP  initiation until the defined follow-up period stated in Section  7.1. 
Any report of pregnancy for any female study participant or the partn er of a male study 
participant  must be reported within 24 hours to the Marinus Drug Safety vendor using the 
Pregnancy Report Form . If a participant  has a positive  test result , it will be at the investigator ’s 
discretion to weigh the risks versus benefits for continued participation. 
Every effort should be made to gather information regarding the pregnancy outcome and 
condition of the infant. It is the responsibility of the investigator to obtain this information within 
30 calendar days after the initial notification and approximately 30 calendar days after delivery .  
Pregnancy complications such as spontaneous abortion/miscarriage or congenital abnormality 
are considered SAEs and must be reported as outlined in Section 8.2 of the protocol using the Marinus SAE Fax Cover Letter. Non -serious AEs are to be reported as per clinical eCRF 
Completion Guidelines. Note : An elective abortion is not considered an SAE. 
In addition to the above, if the investigator determines that the pregnancy meets serious criteria, it must be reported as an SAE to the Marinus Drug Safety vendor as outlined in Section  8.2 of 
the protocol using the Marinus SAE  Fax Cover Letter. T he test date of the first positive 
serum/urine β-human chorionic gonadotropin test or ultrasound result will determine the 
pregnancy onset date. 
 
Confidential  Page 72 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
8.1.7 Medication Errors and Other Reportable Information  
Medication errors  made in prescribing, dispensing, administering, or use of an IP must be 
reported as protocol deviations. An overdose is a medication error and is defined as 
administration of IP exceeding the prespecified total daily dose of the IP which for this study is 
set by a 50 g/day (1.25 g/kg/day in participants weighing < 40 kg) Captisol® limit which 
corresponds to a maximum of 833 mg/day (20.825 mg/kg/day in participants weighing <40 kg) 
ganaxolone.  
If a medication error results in a Capti sol®/ganaxolone overdose, this is a protocol deviation that 
may have the potential to affect the safety of the affected participant.  The administration of lower 
doses of the IP as a result of an IP rate decrease or as part of IP discontinuation are not 
considered medication errors and are permitted by protocol. In addition to medication errors the followin
 g events are considered  other r eportable information 
and are reportable to the Marinus Drug Safety  vendor within 15 days of awareness of the event  
using the Medication Errors and Other Reportable Information Report F orm. A copy of the 
Report Form (and any applicable follow- up reports) must also be sent to the Medical Monitor 
using the details specified in the emergency contact information section at the beginning of the 
protocol: 
• Accidental exposure 
• Lactation exposure 
• Product Misuse 
All IP  provided in this study will be administered by appropriate s ite staff.  
8.2 Serious Adverse Event Procedures  
8.2.1 Reference Safety Information  
The R eference S afety I nformation for this study is the Ganaxolone IB , which the Sponsor has 
provided under separate cover to all investigators.   
8.2.2 Reporting Procedures  
All initial and follow -up SAE reports must be reported by the investigator to the Marinus  Drug 
Safety vendor within 24 hours of the first awareness of the event . Note: The 24-hour reporting 
requirement for SAEs does not apply to reports of medication errors and other r eportable 
information (see Section 8.1.7) unless the event  results in an SAE.  
The investigator must complete, sign, and date the Marinus SAE Fax Cover Letter  and verify the 
accuracy of the information recorded on the form with the corresponding source documents (Note: Source documents are not to be sent unless requested) and fax or email  the form to the 
Marinus Drug Safety  vendor. A copy of the Marinus SAE Fax Cover Letter  (and any applicable 
 
Confidential  Page 73 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
follow -up reports) must also be sent to the Medical Monitor using the details  specified in the 
emergency contact information section of the protocol. 
8.2.3 Serious Adverse Event Definition  
An SAE is any untoward medical occurrence (whether considered to be related to IP  or not) that 
at any dose: 
• Results in death  
• Is life -threatening. Note: The term “life -threatening” in the definition of “serious” refers 
to an event in which the participant  was at risk of death at the time of the event; it does 
not refer to an event that hypothetically might have caused death if it w ere more severe.  
• Requires inpatient hospitalization or prolongation of existing hospitalization. Note: 
Hospitalizations, which are the result of elective or previously scheduled surgery for 
preexisting conditions  that have not worsened after initiation of treatment, should not be 
classified as SAEs. For example, an admission for a previously scheduled ventral hernia repair would not be classified as an SAE; however, a complication resulting from a hospitalization for an elective or previously scheduled surgery that meets serious criteria must be reported as an SAE.  
• Results in persistent or significant disability  or incapacity  
• Is a congenital abnormality or birth defect  
• Is an important medical event . Note: Important medical events that may not result in 
death, be life  threatening, or require hospitalization may be considered an SAE when, 
based on appropriate medical judgment, they jeopardize the patient  and may require 
medical or surgical intervention to prevent one of the outcomes listed in this definition . 
Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home; blood dyscrasias that do not result in inpatient  hospitalization , or the development of drug dependency or drug abuse.  
8.2.4 Serious Adverse Event Collection Time F rame  
As this study allows for pre -consenting of participants, a ll SAEs (regardless of relationship to 
study) are collected from the time of IP  initiation until the final study follow -up visit/contact 
stated in Section  7.1 and must be reported to the Marinus Drug Safety vendor within 24 hours of 
the first awareness of the event.  
In addition, any SAE considered “related” to the IP  and discovered by the investigator at any 
interval after the study has completed must be reported to the Marinus Drug Safety vendor within 24 hours of the first awareness of the event.  
8.2.5 Serious Adverse Event Onset and Resolution Dates 
The onset date of the SAE is defined as the date the event meets serious criteria. The resolution date is the date the event no longer meets serious criteria, the date the symptoms resolve, or the date the event is considered chronic. In the case of hospitalizations, the hospital admission and discharge dates are considered the onset and resolution dates, respectively.  
 
Confidential  Page 74 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
In addition, any signs or symptoms experienced by the participant following  IP initiation  or 
leading up to the onset date of the SAE, or following the resolution date of the SAE, must be 
recorded as an AE, if appropriate.  
8.2.6 Fatal Outcome  
Any SAE that results in the participant’s death (i.e., the SAE was noted as the primary cause of death) must have fatal checked as an outcome, with the date of death recorded as the resolution date. For all other events ongoing at the time of death that did not contribute to the participa nt’s 
death, the outcome should be considered not resolved, without a resolution date recorded. 
For any SAE that results in the participant ’s death or any ongoing events at the time of death, 
unless another IP  action was previously taken (e.g., the IP was  interrupted , reduced, or 
withdrawn ), the action taken with the IP  should be recorded as “dose not changed” or “not 
applicable” (if the participant never received the IP ). The IP  action of “ withdrawn ” should not be 
selected solely as a result of the participant’s death.  8.2.7 Regulatory Agency, Institutional Review Board, Ethics Committee, and Site 
Reporting  
The Sponsor or its delegate is responsible for notifying the relevant regulatory authorities  in the 
US of related, unexpected SAEs. For ex -US countries, the Sponsor will comply with local laws 
and requirements with  regard to SAE reporting. 
In addition, the Sponsor or its delegate is responsible for notifying active sites and central IRBs 
of all related, unexpected SAEs occurring during all interventional studies across the ganaxolone 
program.  
The investigator is responsible for notifying the local IRBs , local EC , or the relevant local 
regulatory authority of all SAEs that occur at their  site as required.  
  
 
Confidential  Page 75 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
9 DATA MANAGEMENT  
9.1 Data Collection  
The investigator’s authorized site personnel must enter the information required by the protocol 
in the eCRF . A study monitor will visit each site in accordance with the monitoring plan and 
review the eCRF  data against the source data for completeness and accuracy . Discrepancies 
between source data and data entered in the eCRF  will be addressed by qualified site personnel. 
When a data discrepancy warrants correction, the correction will be made by authorized site personnel. Data collection procedures will be discussed with the site prior to enrollment (e.g., site initiation or other type of visit, investigator meet ing, or other planned training). Once a 
participant is enrolled, the site should initiate data entry  within 5 days of enrollment with the 
goal of having all protocol required data entered within 5 days of the participant’s last follow -up 
visit/contact.   
9.2 Clinical Data Management  
Data are to be entered into a clinical database as specified in the eCRF Completion Guidelines. Quality control and data validation procedures are applied to ensure the validity and accuracy of the clinical database.  
Data are to be reviewed and checked for omissions, errors, and values requiring further clarification using computerized and manual procedures. Data queries requiring clarification are to be communicated to the site for resolution. O nly authorized personnel will make corrections to 
the clinical database, and all corrections are documented in an auditable manner.  
9.3 Data Monitoring Committee (DMC) 
The emerging study data will be reviewed on a regular basis by an independent DMC. The mission of the DMC will be to safeguard  the interests of study participants and to enhance the 
integrity of the trial. To enable the DMC to achieve its mission, it will have ongoing access to efficacy and safety data and information  regarding quality of trial conduct and will ensure that  
the confidentiality of these data are protected. A DMC charter will provide the principles and 
guidelines for the DMC process.  
10 STATISTICAL CONSIDERATIONS  
10.1 Statistical Analysis Process  
The statistical analysis plan (SAP) will provide the complete details for the analysis and reporting of the data from the study.  
To preserve the integrity of the statistical analysis and study conclusions, the SAP will be 
finalized and approved prior to database lock for the interim analysis and  prior to  the Sponsor 
being unblinded to treatment assignments. All deviations from or changes to the SAP following database lock will be described in detail and summarized in the final clinical study report. 
 
Confidential  Page 76 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
10.2 Sample Size Determination  
Approximately 124 participants will be randomized and qualified for the study. The sample size 
is based on the assumption of at least 75% response rate to ganaxolone treatment for each of the co-primary endpoints and no more than 45% response rate to placebo treatment and 1:1 
randomization ratio.  
With 62 participants randomized to each treatment arm, there  would be at least 90% power for 
each co -primary endpoint to achieve statistical significance at 2 -sided 5% level of significance.  
10.3 Analysis Population s 
The following population are defined: 
Population  Description    
Safety  All participants who received IP. 
Intent to Treat  (ITT)  All randomized  participants in the double -blind phase  of the study  who 
received  IP and had at least one non -missing efficacy assessment . 
Per Protocol (PP)  All participants in the ITT population  without  major protocol deviations  
related to co-primary endpoint efficacy  assessment s. 
Open -Label  (if applicable)  All enrolled participants who received open -label IP (should the study 
transition to open -label ). 
 
10.4 Statistical Analyses  
The SAP will be finalized prior to database lock (DBL) and it will include a more technical and 
detailed description of the statistical analyses described in this section. This section is a summary of the planned statistical analyses of the most important endpoints including primary and key secondary endpoints . 
10.4.1 Primary Endpoints  (Double -Blind Phase ) 
The primary efficacy objective of this study is to assess the efficacy  of ganaxolone plus standard 
of care versus placebo plus standard of care in producing rapid  and durable SE cessation without 
the need for treatment escalation to IV anesthesia for at least 36 hours following IP initiation . 
Since the primary efficacy objective is a composite objective, in order to establish effectiveness of ganaxolone and support approval, the superiority of ganaxolone vs placebo added to standard of care would need to be established for the following co-primary endpoints: 
1. Proportion of participant s with SE cessation within 30 minutes of IP initiation without 
medications for the acute treatment of SE  
2. Proportion of participants with n o progression to IV anesthesia for 36 hours following IP 
initiation  
SE cessation will be determined by the investigator based on clinical and EEG features (see Appendix 1 for SE cessation guide). Training will be provided to guide and help standardize decisions across clinical sites. In addition, a retrospective, confirmatory analysis of time of SE cessation will be performed by a central EEG reader blinded to treatment assignment .  
 
Confidential  Page 77 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
Medications for the acute treatment of SE are defined as AEDs administered to abort ongoing SE 
or prevent imminent recurrence of SE based on clinical or EEG evidence. This definition excludes maintenance doses of AEDs or medications with anticonvulsant properties used for other reasons, such as procedural sedation.  
Both co- primary efficacy endpoints must be statistically significant to  claim the study being 
positive.  No ordering is involved in the hypothesis testing of the two co-primary endpoints. 
The efficacy analysis of the response rates observed for each co -primary endpoint will be 
conducted by using logistic regression methods. The model will include terms for treatment group and baseline STESS as a covariate.  The a nalysis will be based on  the ITT population. 
Model- based point estimates (i.e. , odds ratio), 95% confidence intervals and p- values will be 
reported. In addition, the point estimate of difference of the proportions of participants achieving either and both co-primary endpoints between two treatment arms will be provided. The 95% confidence interval will be provided using Clopper- Pearson method.
41 
Due to the nature of the disease and short observational period, occurrence of intercurrent events is expected to be low, and thus a treatment policy approach is planned for the co- primary 
analyses.  
10.4.2 Key Secondary Endpoints  (Double -Blind Phase ) 
The following key secondary endpoints will be analyzed: 
1. Time to SE cessation following IP initiation  
2. Proportion of participants with n o progression to IV anesthesia for 72 hours following IP 
initiation  
If the primary endpoints are statistically significant, the key secondary endpoints will be compared between ganaxolone and placebo treatment groups based on the ITT population with a hierarchical testing progress at the same alpha level of the primary endpoints. Each key 
secondary endpoint will only be tested if the prior endpoint is statistically significant.  
The time to SE cessation endpoint will be analyzed using the Kaplan- Meier method .
20 The 
comparison of the survival curves between treatment groups will be conducted by a log- rank test.  
The second key secondary endpoint will be analyzed using the same statistical model as pre-specified  for the co -primary endpoints. 
10.4.3 Other Secondary E ndpoints   
The following secondary endpoints will be analyzed: 
• Proportion of participants with any escalation of treatment in the first 24 hours following IP initiation , i.e., any medication other than IP for the acute treatment of SE in the first 24 hours  
• Time to treatment escalation following IP initiation (any other mediation used for acute treatment of SE) 
 
Confidential  Page 78 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
• Time to initiation of anesthesia for SE treatment through the final study follow -up 
visit/contact  
• Proportion of participants who develop SRSE through the final study follow -up visit/contact 
• Seizure burden through 72 hours following IP initiation 
• Level of responsiveness as assessed by the FOUR Score Scale  
• Level of sedation /agitation  as assessed by the RASS  
• Clinician Global Impression -Improvement (CGI- I)  
• Level of functioning as assessed by the mRS  
• Level of functioning as assessed by the EuroQoL (EQ-5D-5L) 
• Proportion of participants with mRS  ≥3 at the time of hospital discharge  
• Proportion of participants whose treatment does not progress to IV anesthesia for  4 weeks 
following IP initiation  
10.4.4 Healthcare Utilization  Endpoints  
If the key secondary endpoints are statistically significant, analysis of the first healthcare 
utilization endpoint, time on positive pressure ventilation, will be performed. The time on positive pressure  ventilation endpoint will be analyzed using the Kaplan- Meier method.
 The 
comparison of the survival curves between treatment groups will be conducted by a log- rank test.  
• Time on positive pressure ventilation after IP initiation . 
• Proportion of participants requiring positive pressure  ventilation initiated during IP  infusion. 
• Length of stay in the intensive care unit and in hospital after IP initiation . 
• Discharge destination (location where the participant is living at the last follow -up 
assessment) . 
The other healthcare utilization endpoints will be summarized descriptively.  
Further details are provided in the SAP.  
10.4.5 Open-L abel Endpoints  
If the study transitions to the open- label  phase , all endpoint assessments as described for the 
double-blind phase will be summarized using descriptive statistics and no formal hypothesis 
testing will be performed. Efficacy analyses performed for the open -label phase of this study will 
be based on the Open-Label (OL) population. 
10.5 Safety Analyses  
Adverse Events will be coded using the Medical Dictionary for Regulatory Activities. The number of events, incidence, and percentage of treatment- emergent AEs will be calculated 
overall, by system organ class, by preferred term, and by treatment group in the double-blind phase, and summarized overall if the study transitions to open -label . Treatment emergent AEs 
will be further summarized by severity and relationship to IP. Adverse events related to IP, AEs leading to withdrawal, SAEs, and deaths will be similarly summarized and listed.  
 
Confidential  Page 79 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
Physical examinations, c linical laboratory tests, vital signs, ECG findings , use of concomitant 
medications  will be summarized by treatment group  in the double- blind  phase, and summarized 
overall if the study transitions to open- label .  
10.6 Pharmacokinetic Analyses  
The PK population will include all participants who have received at least 1 dose of IP and who 
have had at least 1 sample collected and a valid bioanalytical result obtained. The following plasma pharmacokinetic parameters for ganaxolone and Captisol will be calculated as data allows and as appropriate using noncompartmental approaches:  
• Maximum plasma concentration (C max)  
• Time of maximum concentration (T max)  
• Area under the concentration versus time curve from time 0 to t hours (AUC 0-t)  
• Area under the concentration versus time curve from time 0 to infinity (AUC inf)  
• Clearance (CL). Calculated as dose/AUC inf. 
Pharmacokinetic variables will be computed using WinNonlin Professional, version 5.2 or similar software. Actual elapsed sampling times relative to IP administration will be used for the estimation of pharmacokinetic metrics. Additional parameters may be c alculated on discretion of 
the pharmacokineticist, pending review of the data.  
10.7 Interim Analyses  
An interim analysis was  planned when two -thirds of the ITT population have completed 72 hours 
of efficacy  assessments on the co-primary and key secondary endpoints (approximately 41 
participants per arm). The overall type I error rate (i.e., alpha=0.05, 2- sided) will be  controlled 
using a power family alpha spending function, with a 2-sided nominal alpha level of 0.0293 at the interim analysis. The interim analysis will be performed by an independent statistician who is not involved in study operation or study conduct. 
The interim analysis was performed by an independent statistician who was not involved in study 
operation or study conduct and was based on 83 participants who had completed the primary and key secondary efficacy assessments. The DMC recommended that the study may continue 
without modification.  
To control the overall type I error rate (i.e., a two -sided alpha level of 0.05), the alpha value for 
the final analysis will be adjusted by the final sample size.  For example, if the final analysis sample size is 100, the two -sided alpha level for the final analysis is 0.0410. 
Further details will be provided in the SAP.  
11 SPONSOR’S AND INVESTIGATOR’S RESPONSIBILITIES  
This study is conducted in accordance with current applicable regulations, International Council for Harmonisation (ICH), European Union ( EU) Directive s and its updates, and local ethical and 
legal requirements .  
 
Confidential  Page 80 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
The name and address of each third -party vendor (e.g., CRO) used in this study will be 
maintained in the investigator ’s and Sponsor’s files, as appropriate.  
11.1 Sponsor’s Responsibilities  
11.1.1 Good Clinical Practice (GCP) Compliance  
The study Sponsor and any third party to whom aspects of the study management or monitoring 
have been delegated will undertake their assigned roles for this study in compliance with all current, applicable industry regulations, ICH GCP Guidelines, and EU Directive s, as well as all 
applicable national and local laws and regulations. 
Visits to sites are conducted by representatives of the study Sponsor and/or the company 
organizing/managing the research on behalf of the Sponsor to inspect study data, participants ’ 
medical records, and eCRF s in accordance with current GCP and the respective local and 
(inter)national government regulations and guidelines . Records and data may additionally be 
reviewed by auditors or by regulatory authorities. 
The S ponsor ensures that local regulatory authority requirements are met before the start of the 
study. The Sponsor (or a nominated designee) is responsible for the preparation, submission, and 
confirmation of receipt of any regulatory authority approvals required prior to release of IP  for 
shipment to the site.  
11.1.2 Public Posting of Study Information 
The Sponsor, or their designee, is responsible for posting appropriate study information on applicable websites such as ClinicalTrials.gov  and Europe’s website - Eudract.ema.europa.eu . 
Information included in clinical study registries may include participating investigator’s  names 
and contact information. 
11.1.3 Submission of Summary of Clinical Study Report to Competent Authorities of 
Member States Concerned and Ethics Committees  
The Sponsor will provide a summary of the clinical study report to the competent authority of the 
member state(s) concerned as required by regulatory requirement(s) and to comply with the Community guideline on GCP. This requirement will be fulfilled within 6 months of the study completion date for pediatric studies and within 1 year for non -pediatric studies as per guidance.  
11.1.4 Study Suspension, Termination, and Completion 
The Sponsor may suspend or terminate the study, or part of the study, at any time for any reason. If the study is suspended or terminated, the Sponsor will ensure that applicable sites, regulatory agencies, and IRBs/ECs are notified as appropriate. A dditionally, the discontinuation of a 
registered clinical study that has been posted to a designated public website will be updated accordingly. 
 
Confidential  Page 81 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
11.2 Investigator’s Responsibilities  
11.2.1 Good Clinical Practice Compliance  
The investigator must undertake to perform the study in accordance with  current ICH GCP 
Guidelines , EU Directive s, and applicable regulatory requirements and guidelines. 
It is the investigator’s responsibility to ensure that adequate time and appropriately trained 
personnel are available at the site prior to commitment to participate in this study . The 
investigator should also be able to estimate or demonstrate the potential for recruiting the 
required number of suitable participants within the agreed recruitment period.  
The investigator will maintain a list of appropriately qualified persons to whom the investigator has delegated significant study  related tasks, and shall, upon request of the Sponsor, provide 
documented evidence of any licenses and certifications necessary to demonstrate such qualification . Curriculum vitae for investigators and sub investigators are provided to the study 
Sponsor (or designee) before starting the study. 
If a potential research participant has a primary care physician, the investigator should, with the 
participant ’s consent, inform them of the participant’s participation in the study. 
A coordinating principal investigator is appointed to review the final clinical study report for multicenter studies . Agreement with the final clinical study report is documented by the signed 
and dated signature of the principal investigator (single site study) or coordinating principal investigator (multicenter study), in compliance with Directive 2001/83/EC as amended by 
Directive 2003/63/EC and ICH Guidance E3 (1995).  
11.2.2 Protocol Adherence and Investigator Agreement  
The investigator and any sub investigators must adhere to the protocol as detailed in this 
document. The investigator is responsible for enrolling only those participants who have met 
protocol eligibility criteria . Investigators are required to sign an investigator agreement to 
confirm acceptance and willingness to comply with the study protocol. 
If the investigator suspends or terminates the study at their site, the investigator will promptly 
inform the Sponsor and the IRB/EC and provide them with a detailed written explanation. The investigator will also return or destroy all IP , containers, and other study materials in accordance 
with the Sponsor instructions. Upon study completion, the investigator will provide the Sponsor, IRB/EC, and regulatory agency with final reports and summaries as required by (inter)national regulations. 
Communication with local IRBs/ECs, to ensure accurate and timely information is provided at 
all phases during the study, may be done by the Sponsor, applicable CRO, investigator, or, for multicenter studies, the coordinating principal investigator according to national provisions and will be documented in the investigator agreement.  
 
Confidential  Page 82 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
11.2.3 Documentation and Retention of Records  
11.2.3.1 Case Report Forms  
Electronic CRFs  are supplied by the Data Management vendor detailed in the investigator’s and 
Sponsor’s files, as applicable, and should be handled in accordance with the instructions from the 
Sponsor. 
The investigator is responsible for maintaining adequate and accurate medical records from 
which accurate information is recorded onto eCRF s, which have been designed to record all 
observations and other data pertinent to the clinical investigation . Electronic CRFs  must be 
completed by the investigator or designee as stated in the site delegation log. 
All data will have separate source documentation; no data will be recorded directly into the 
eCRF . 
All data sent to the Sponsor must be endorsed by the investigator. 
The clinical research associate ( CRA)/study monitor will verify the contents against the source 
data according to the monitoring plan. If the data are unclear or contradictory, queries are sent 
for corrections or verification of data.  
Incorrect paper source entries must be crossed with a single line as to not obscure the original entry . Corrections must be made adjacent to the item to be altered, initialed, and dated by an 
authorized investigator or designee as stated in the site delegation log . Overwriting of this 
information or use of liquid correction fluid is not allowed. 
11.2.3.2 Recording, Access, and Retention of Source Data and Study Documents  
Original source data to be reviewed during this study will include, but are not limited to, the 
participant ’s medical file  and original clinical laboratory reports .  
All key data must be recorded in the participant ’s medical records.  
The investigator must permit authorized representatives of the Sponsor; the respective national, local, or foreign regulatory authorities; the IRB/EC; and auditors to inspect facilities and to have direct access to original source records relevant to this study, regardless of media.  
The CRA/study monitor (and auditors, IRB/EC, or regulatory inspectors) may check the eCRF  
entries against the source documents. The consent form includes a statement by which the participant  agrees to allow the monitor/auditor from the S ponsor or its representatives, national 
or local regulatory authorities, or the IRB/EC to have access to source data ( e.g., participant ’s 
medical file, appointment books, original laboratory reports, X-rays, etc .).  
These records must be made available within reasonable times for inspection and duplication, if required, by a properly authorized representative of any applicable regulatory authority or an auditor.  
 
Confidential  Page 83 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
Essential documents must be maintained according to ICH GCP requirements and may not be 
destroyed without written permission from the Sponsor. 
11.2.3.3 Audit/Inspection  
To ensure compliance with relevant regulations, data generated by this study must be available 
for inspection upon request by representatives of, for example, the FDA, other regulatory authorities, the S ponsor or its representatives, and the IRB/EC for each site.  
11.2.3.4 Financial Disclosure  
The investigator is required to disclose any financial arrangement during the study and for 1 year after, whereby the outcome of the study could be influenced by the value of the compensation for conducting the study, or other payments the investigator rec eived from the Sponsor. The 
following information is collected: any significant payments from the Sponsor or subsidiaries, such as a grant to fund ongoing research, compensation in the form of equipment, or retainer for ongoing consultation or honoraria; any proprietary interest in IP; and any significant equity interest in the Sponsor or subsidiaries as defined in 21 Code of Federal Regulations 54 2(b) 
(1998). 
11.3 Ethical Considerations  
11.3.1 Informed Consent  
It is the responsibility of the investigator to obtain written informed consent and assent, where applicable, from all study participant s prior to any study related procedures, including screening 
assessments. As the disease under consideration is a life-threatening condition for which participant s presenting may not be capable of providing consent or assent for themselves, a 
parent/guardian/LAR will be required to sign upon identification of the participant for study participation. Consent/assent will be administered according to institution  IRB/EC policy and 
may vary across sites , i.e., some sites may be able to consent/assent over the phone or other 
communication methods. At the first opportunity , consent and assent should be obtained from 
the participant directly . Alternatively , consent and assent for participant s who  are at risk for SE 
may be obtained prior to an SE event through a pre-consenting process. The period of time  the 
pre-consent/assent is valid will be determined by each institutions IRB/EC. However, reconsenting will be required should the consent/assent be updated at any point during the study. 
All consent  and assent  documentation must be in accordance with applicable regulations and 
GCP . Each participant , participant ’s parent, guardian, or the LAR, as applicable, is requested to 
sign and date the participant ’s informed consent form /assent  or a certified translation , if 
applicable, after the participant, participant’s parent, guardian, or LAR has received and read (or 
been read) the written participant  information and received an explanation of what the study 
involves, including but not limited to the objectives, potential benefits and risk, inconveniences, 
and the participant ’s rights and responsibilities . A copy of the informed consent and assent  
documentation (i.e., a complete set of participant information sheets and fully executed signature pages) must be given to the participant, participant ’s parent, guardian, or the LAR, as applicable. 
 
Confidential  Page 84 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
This document may require translation into the local language. Signed consent forms must 
remain in each participant’s study file and must be available for verification at any time. 
The investigator provides the Sponsor with a copy of the consent form and assent  that was 
reviewed by the IRB/EC and received their favorable opinion/approval. A copy of the IRB/EC’s 
written favorable opinion/approval of these documents must be provided to the Sponsor prior to 
the start of the study unless it is agreed to and documented (abiding by regulatory guidelines and national provisions) prior to study start that another party ( i.e., S ponsor or coordinating 
investigator) is responsible for this actio n. Additionally, if the IRB/EC requires modification of 
the sample participant  information and consent document provided by the Sponsor, the 
documentation supporting this requirement must be provided to the Sponsor. 
11.3.2 Institutional Review Board or Ethics Committee  
For sites outside the EU, it is the responsibility of the investigator to submit this protocol, the 
informed consent and assent  documents (approved by the Sponsor or their designee), relevant 
supporting information, and all types of participant recruitment information to the IRB/EC for review, and all must be approved prior to site initiation. 
Responsibility for coordinating with IRBs/ECs is defined in the investigator agreement.  
Prior to implementing changes in the study, the Sponsor and the IRB/EC must approve any 
revisions of all informed consent /assent  documents and amendments to the protocol unless there 
is a participant safety issue.  
Investigational product supplies will not be released until the S ponsor or designee  has received 
written IRB/EC approval of and copies of revised documents. 
For sites outside the EU, the investigator is responsible for keeping the IRB/EC apprised of the 
progress of the study and of any changes made to the protocol, but in any case, at least once a year. This can be done by the Sponsor or investigator for sites within the EU, or for multicenter 
studies, it can be done by the coordinating principal investigator, according to national 
provisions. The investigator must also keep the local IRB/EC informed of any SAEs and 
significant AEs.  
11.4 Privacy and Confidentiality  
All US -based sites and laboratories or entities providing support for this study, must, where 
applicable, comply with the Health Insurance Portability and Accountability Act (HIPAA) . A 
site that is not a covered entity as defined by HIPAA must provide documentation of this fact to the CRO/Sponsor. All sites, laboratories , or entities providing support for this study, must, where 
applicable, comply with General Data Protection Regulation (GDPR) for purposes of data protection and privacy. 
The confidentiality of records that may be able to identify participants will be protected in 
accordance with applicable laws, regulations, and guidelines.  
 
Confidential  Page 85 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
After participant, participant’s parent, guardian, or the LAR have consented to take part in the 
study, the S ponsor and/or its representatives review the medical records and data collected 
during the study. These records and data may, in addition, be reviewed by others, including the following: independent auditors who validate the data on behalf of the Sponsor; third parties with whom the Sponsor may develop, register, or market ganaxolone ; national or local regulatory 
authorities; and the IRB/EC that gave  approval for the study to proceed. The S ponsor and/or its 
representatives accessing the records and data will take all reasonable precautions in accordance with applicable laws, regulations, and guidelines to maintain the confidentiality of participant s’ 
identities.  
Participant s are each assigned a unique identifying number; however, their initials and date of 
birth may also be collected and used to assist the Sponsor in verify ing the accuracy of the data 
(e.g., to confirm that laboratory results have been assigned to the correct participant ).  
The results of studies containing participant s’ unique identifying numbers , relevant medical 
records, and possibly initials and dates of birth  will be recorded . They may be transferred to, and 
used in, other countries that may not afford the same level of protection that applies within the 
countries where this study is conducted. The purposes of any such transfer would include to support regulatory submissions, to conduct new data analyses to publish or present the study results, and to answer questions asked by regulatory or health authorities. 
11.5 Study Results/Publication Policy  
Marinus will endeavor to publish the results of all qualifying, applicable, and covered studies according to external guidelines in a timely manner regardless of whether the outcomes are perceived as positive, neutral, or negative. Additionally, Marinus adheres to external guidelines (e.g., Good Publication Practices 2) when forming a publication steering committee, which may be done for large, multicenter Phase 2 to 4 and certain other studies as determined by Marinus. The purpose of the publication steering committee is to act as a noncommercial body that advises or decides on dissemination of scientific study data in accordance with the scope of this policy. 
All publications relating to Marinus products or projects must undergo appropriate technical and 
intellectual property review, with Marinus’ agreement to publish prior to release of information . 
The review is aimed at protecting the S ponsor’s proprietary information existing either at the 
commencement of the study or generated during the study. To the extent permitted by the publisher and copyright law, the principal investigator will own (or share with other authors) the copyright on his/her publications. To the extent that the principal investigator has such sole, joint, or shared rights, the principal investigator grants the Sponsor a perpetual, irrevocable, royalty free  license to make and distribute copies of such publications. 
The term “publication” refers to any public disclosure, including original research articles, review articles, oral presentations, abstracts and posters at medical congresses, journal supplements, letters to the editor, invited lectures, opinion pieces, book chapters, electronic postings on medical/scientific websites, or other disclosure of the study results, in printed, 
electronic, oral , or other form.  
 
Confidential  Page 86 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
Subject to the terms of the paragraph below, the investigator shall have the right to publish the 
study results, and any background information provided by the S ponsor that is necessary to 
include in any publication of study results or necessary for other scholars to verify such study 
results. Notwithstanding the foregoing, no publication that incorporates the Sponsor’s confidential information shall be submitted for publication without the S ponsor’s prior written 
agreement to publish and shall be given to the Sponsor for review at least 60 days prior to 
submission for publication. If requested in writing by Marinus , the institution and principal 
investigator shall withhold submission of such publication for up to an additional 60 days to allow for filing of a patent application. 
If the study is part of a multicenter study, the first publication of the study results shall be made 
by the Sponsor in conjunction with the S ponsor’s presentation of a joint, multicenter publication 
of the compiled and analyzed study results. If such a multicenter publication is not submitted to a 
journal for publication by the S ponsor within an 18-month period after conclusion, abandonment, 
or termination of the study at all sites, or after the S ponsor confirms there shall be no multicenter 
study publicat ion of the study results, an investigator may individually publish the study results 
from the specific site in accordance with this section . The investigator must, however, 
acknowledge in the publication the limitations of the single site data being presented. 
Unless otherwise required by the journal in which the publication appears, or the forum in which 
it is made, authorship will comply with the International Committee of Medical Journal Editors current standards. Participation as an investigator does not confer any rights to authorship of publications.  
 
Confidential  Page 87 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
12 REFERENCES  
1. Lowenstein, D. and Alldredge, B. (1998). Status epilepticus. New England Journal of 
Medicine , 338: 970-76. 
2. Trinka, E., Cock, H., Hesdorffer, D., Rossetti, A., Scheffer, I., Shinnar, S., Shorvon, S. 
and Lowenstein, D. (2015). A definition and classification of status epilepticus-Report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia, 56: 1515-23. 
3. Falco -Walter, J. and Bleck, T. (2016). Treatment of established status epilepticus. 
Journal of Clinical Medicine , 5 (5): 49. 
4. Bhattacharjee, A. and Hirsch, N. (2015). Management of status epilepticus. Anaesthesia & Intensive Care Medicine, 16: 159-60. 
5. Treiman, D. (2014). Status epilepticus. Daroff, R. and Aminoff, M. (editors). Encyclopedia of the Neurological Sciences  (Academic Press: Oxford, UK).  
6. Treiman, D. (2007). Treatment of convulsive status epilepticus. International Review of Neurobiology , 81: 273- 85. 
7. Koubeissi M, Alshekhlee A. (2007). In- hospital mortality of generalized convulsive 
status epilepticus: a large scale US sample. Neurology, 69: 886 -893. 
8. Glauser, T., Shinnar, S., Gloss, D., Alldredge, B., Arya, R., Bainbridge, J., Bare, M., Bleck, T., Dodson, W.E., and Garrity, L. (2016). Evidence- based guideline: treatment of 
convulsive status epilepticus in children and adults: report of the Guideline Committee of the American Epilepsy Society. Epilepsy Currents, 16: 48-61. 
9. Kapur, J., Elm, J., Chamberlain, J., Barsan, W., Cloyd, J., Lowenstein, D., Shinnar, S., Conwit, R., Meinzer, C., Cock, H., Fountain, N., Connor, J., Silbergleit, R., Nett and Pecarn Investigators. (2019). Randomized trial of three anticonvulsant medicatio ns for 
status epilepticus. New England of Journal Medicine , 381: 2103-13. 
10. Kapur, J. and Macdonald, R. (1997). Rapid seizure-induced reduction of benzodiazepine and Zn2+ sensitivity of hippocampal dentate granule cell GABAA receptors. Journal of Neuroscience, 17: 7532-40. 
11. Mayer, S., Claassen, J., Lokin, J., Mendelsohn, F., Dennis, L. and Fitzsimmons, B.F. (2002). Refractory status epilepticus: frequency, risk factors, and impact on outcome. Archives of Neurology, 59: 205-10. 
12. Niquet, J., Baldwin, R., Suchomelova, L., Lumley, L., Naylor, D., Eavey, R. and Wasterlain, C. (2016). Benzodiazepine-refractory status epilepticus: pathophysiology and principles of treatment. Annals of the New York Academy of Sciences, 1378: 166-73. 
13. Trinka, E., Höfler, J., Leitinger, M. and Brigo, F. (2015). Pharmacotherapy for status epilepticus. Drugs , 75: 1499-521. 
 
Confidential  Page 88 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
14. Hocker, S., Britton, J., Mandrekar, J., Wijdicks, E. and Rabinstein, A. (2013). Predictors 
of outcome in refractory status epilepticus. JAMA Neurology , 70: 72-77. 
15. Shorvon, S. and Ferlisi, M. (2012). The outcome of therapies in refractory and super-refractory convulsive status epilepticus and recommendations for therapy. Brain , 135: 
2314-28. 
16. Sutter, R., Marsch, S., Fuhr, P., Kaplan, P. and Rüegg, S. (2014). Anesthetic drugs in status epilepticus: risk or rescue?: a 6 -year cohort study. Neurology , 82: 656-64. 
17. Nohria, V. and Giller, E. (2007). Ganaxolone. Neurotherapeutics , 4: 102-05. 
18. Rogawski, M., Loya, C., Reddy, K., Zolkowska, D. and Lossin, C. (2013). Neuroactive steroids for the treatment of status epilepticus. Epilepsia, 54(suppl 6): 93- 98. 
19. Leitinger, M., Trinka, E., Gardella, E., Rohracher, A., Kalss, G., Qerema, E., Höfler, J., Hess, A., Zimmermann, G., Kuchukhidze, G., Dobesberger, J., Langthaler, P., Beniczky, S. (2016). Diagnostic accuracy of the Salzburg EEG criteria for non-convulsive status epilepticus: a restrospective study. The  Lancet Neurology , 15:1054-62. 
20. Kaplan, E. and Meier, P. (1958). Nonparametric estimation from incomplete observations. Journal of the American Statistical Association; 53: 457-481.  
21. Jędrzejczak J, Mazurkiewicz- Bełdzińska M, Szmuda M, et al. Convulsive status 
epilepticus management in adults and children: Report of the Working Group of the Polish Society of Epileptology. Neurol Neurochir Pol. 2018;52(4):419-426. 
22. Chiarello D, Duranti F, Lividini A, et al. Clinical characterization of status epilepticus in childhood: a retrospective study in 124 patients. Seizure. 2020;78:127-133. 
23. Marawar R, Basha M, Mahulikar A, et al. Updates in Refractory Status Epilepticus. Crit Care Res Pract. 2018;2018:9768949. 
24. Brophy, G., Bell, R., Claassen, J., Alldredge, B., Bleck, T., Glauser, T., Laroche, S., Riviello, Jr., J., Shutter, L., Sperling, M., Treiman, D., Vespa, P. and Committee 
Neurocritical Care Society Status Epilepticus Guideline Writing. (2012). Guidelines for 
the evaluation and management of status epilepticus. Neurocrit Care, 17: 3-23. 
25. Treiman, D. (2008). Importance of early recognition and treatment of generalized convulsive status epilepticus. The Lancet Neurology , 7: 667-68. 
26. Knake, S., Hamer, H. and Rosenow, F. (2009). Status epilepticus: a critical review. Epilepsy and Behavior , 15: 10-4. 
27. Rossetti, A. and Lowenstein, D. (2011). Management of refractory status epilepticus in adults: still more questions than answers. The Lancet Neurology , 10: 922-30. 
 
Confidential  Page 89 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
28. DeLorenzo, R., Waterhouse, E., Towne, A., Boggs, J., Ko, D., DeLorenzo, G., Brown, A. 
and Garnett, L. (1998). Persistent nonconvulsive status epilepticus after the control of convulsive status epilepticus. Epilepsia, 39: 833-40. 
29. Silbergleit, R., Durkalski, V., Lowenstein, D., Conwit, R., Pancioli, A., Palesch, Y. and Barsan, W. (2012). Intramuscular versus intravenous therapy for prehospital status epilepticus. New England Journal of Medicine , 366: 591-600. 
30. Treiman, D. (2001). GABAergic mechanisms in epilepsy. Epilepsia , 42(Suppl. 3): 8- 12. 
31. Rossetti, A., Logroscino, G. and Bromfield, E. (2005). Refractory status epilepticus: effect of treatment aggressiveness on prognosis. Archives of  Neurology , 62: 1698-702. 
32. Neligan, A. and Shorvon, S. (2010). Frequency and prognosis of convulsive status epilepticus of different causes: a systematic review. Archives of Neurology, 67: 931- 40. 
33. Sutter, R., Kaplan, P. and Rüegg, S. (2013). Outcome predictors for status epilepticus-what really counts. Nature Reviews Neurology, 9: 525-34. 
34. Strzelczyk, A., Ansorge, S., Hapfelmeier, J., Bonthapally, V., Erder, M. and Rosenow, F. (2017). Costs, length of stay, and mortality of super- refractory status epilepticus: A 
population-based study from Germany. Epilepsia , 58: 1533- 41. 
35. Claassen, J., Hirsch, L., Emerson, R. and Mayer, S. (2002). Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: a systematic review.  Epilepsia , 
43: 146-53. 
36. Ganaxolone Investigator’s Brochure. (December 2021). Radnor, PA: Marinus Pharmaceuticals, Inc.  
37. Saporito, M., Gruner, J., DiCamillo, A., Hinchliffe, R., Barker-Haliski, M., White, H. (2019). Intravenously administered ganaxolone diazepam- resistant lithium -pilocarpine -
induced status epilepticus in rats: comparison with allopregnanolone. Journal of Pharmacology  and Experimental Therapeutics , 368: 326-337. 
38. Albers, J., Moddel, G., Dittrich, R., Steidl, C., Suntrup, S., Ringelstein, E. and Dziewas, R. (2011). Intravenous lacosamide- an effective add -on treatment of refractory status 
epilepticus. Seizure, 20: 428-30. 
39. Moddel, G., Bunten, S., Dobis, C., Kovac, S., Dogan, M., Fischera, M., Dziewas, R., Schabitz, W., Evers, S. and Happe, S. (2009). Intravenous levetiracetam: a new treatment alternative for refractory status epilepticus. Journal of Neurology, Neurosurgery and 
Psychiatry, 80: 689-92. 
40. International Conference on Harmonisation (ICH) Guidance E2A March 1995. Clinical Safety Data Management: Definitions and Standards for Expedited Reporting. 
 
Confidential  Page 90 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
41. Clopper, C., Pearson, E.S. (1934). The use of confidence or fiducial limits illustrated in 
the case of the binomial. Biometrika, 26 (4): 404-413. 
  
 
Confidential  Page 91 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
13 APPENDICES  
  
 
Confidential  Page 92 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
APPENDIX 1  STATUS EPILEPTICUS CESSATION GUIDE 
Status epilepticus cessation will be based on investigator judgment, guided by the following 
clinical and electrographic features: 
1. The first 30-minute SE free period after IP initiation denotes the onset of SE cessation  
2. Electrographically SE cessation should coincide with the beginning of the first 30-minute epoch of EEG which demonstrates seizure burden <20% and at least 50% less than during the 30 minutes prior to IP initiation
 
3. For the first co -primary endpoint  only , SE cessation observed w ithout administration 
of medications for the acute treatment of SE * from the time of IP initiation through 
30 minutes following the onset of SE cessation  
*Medications for the acute treatment of SE are defined as AEDs administered to abort ongoing SE or prevent imminent recurrence of SE based on clinical or EEG evidence. This definition excludes maintenance doses of AEDs or medications with anticonvulsant properties used for other reasons, such as procedural sedation.  
  
 
Confidential  Page 93 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
APPENDIX 2  THERAPEUTIC DOSES OF BENZODIAZEPINES AND 2ND 
LINE IV AEDS  
Benzodiazepines  
Drug Name  Dose  
Diazepam  • 0.15-0.2 mg/kg IV up to 10 mg per dose  
• may repeat in 5 minutes  
Diazepam (rectal)  • 0.2-0.5 mg/kg, maximum 20 mg/dose  
Lorazepam  • 0.1 mg/kg IV up to 4 mg/dose  
• may repeat in 5 -10 minutes  
Midazolam  • 0.2 mg/kg IM, maximum 10 mg/dose  
  
2nd line IV AEDs  
Drug Name  Dose  
Phenytoin (PHT)/  
fos-phenytoin (fPHT)  • PHT l oading dose : 15-20 mg/kg IV given once, which can be 
followed by additional 10 mg/kg IV after 20 minutes if there 
is no response to the initial dose  
• PHT maintenance dose: 100 mg IV q6-8 hours (adjusted based on treatment response or blood levels)  
• fPHT loading dose : 18-20 mg PE/kg with a maximum 
infusion rate of 150 mg PE/min IV  
• Maintenance dose should begin 12 hours after loading dose  
• fPHT, maintenance dose: 5 mg PE/kg/day IM/IV divided daily 
TID 
Valproic acid (VPA)  • Loading dose : 20-40 mg/kg IV at an infusion rate of 
6 mg/kg/min  
• Maintenance dose: 10-20 mg/kg/day divided in BID -TID 
dosing  
Levetiracetam (LEV)  • Loading dose : 20-60 mg/kg  
• Maintenance dose: 1000-3000 mg/day or  
20 mg/kg/day  
Brivaracetam (BRI)  • Loading dose : 2-4 mg/kg  
Lacosamide (LAC)  • Loading dose : 400-600 mg IV  
• Maintenance dose : 20-300 mg BID  
Phenobarbital  (PHEN)  • Loading dose: 15 -20 mg/kg IV  
• Maintenance dose: 1 -4 mg/kg/day  
The doses cited above are based on the published literature and should serve as guidance only.  
 References:  
Aicua -Rapun, I., Andre, P., Rossetti, A.O., Decosterd, L.A., Buclin, T. & Novy, J. (2019) Intravenous brivaracetam in status 
epilepticus: Correlation between loading dose, plasma levels and clinical response. Epilepsy Res, 149 , 88-91.  
 
Brophy, G.M., Bell, R., Claassen, J., Alldredge, B., Bleck, T.P., Glauser, T., Laroche, S.M., Riviello, J.J., Jr., Shutter, L.,  
Sperling, M.R., Treiman, D.M., Vespa, P.M. & Neurocritical Care Society Status Epilepticus Guidelines Writing, C. (2012) . 
Guidelines for the evaluation and management of status epilepticus. Neurocrit Care, 17 , 2-23. 
 Glauser, T., Shinnar, S, Glo ss, D., Alldredge, B., Arya, R., Bainbridge, J., Bare, M., Bleck, T., Dodson, W.E., Garrity, L., Jagoda, 
A., Lowenstein, D., Pellock, J., Riviello, J., Sload, E. & Treiman, D.M. (2016) Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults: Report of the Guideline Committee of the American Epilepsy Society.  
Epilepsy Curr, 16 , 48-61.  
 
Confidential  Page 94 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
 
Wasim, M. & Husain, A.M. (2015 Nonconvulsive seizure control in the intensive care unit. Curr Treat Options Neurol, 17, 340.   
 
Confidential  Page 95 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
APPENDIX 3  SALZBURG EEG CRITERIA FOR NCSE  
Patients with known epileptic encephalopathy should have an i ncrease in prominence or 
frequency of the features above when compared to baseline and observable change in clinical 
state.   
Participants in RED box are eligible for enrollment.  
 
Beniczky S et al. Epilepsia 2013;54 (suppl 6): 28-29; Leitinger M et al. Lancet Neurol 2016;15:1054-62. Image reproduced with 
permission from publisher.  
  

 
Confidential  Page 96 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
APPENDIX 4  GLOBAL -MARKETED PRODUCTS CONTAINING 
CAPTISOL®  
The following table lists the  commonly found but not exhaustive list of products containing 
Captisol® 
Product  Active/Dosage Form  
 
VFEND IV  voriconazole for injection  
 
GEODON/ZELDOX IM  ziprasidone mesylate for injection  
 
ABILIFY IM  aripiprazole injection  
 
NEXTERONE  amiodarone injection  
 
KYPROLIS  carfilzomib for injection  
 
NOXAFIL injection  posaconazole injection  
 
EVOMELA  melphalan for injection  
 
CARNEXIV  carbamazepine injection  
 
BAXDELA intravenous  delafloxacin meglumine for injection  
 
ZULRESSO CIV  brexanolone injection  
 
Generic ‘VFEND IV’ voriconazole for injection  
 
REMIVIR, VEKLURY  Remdesivir  
 
 
Confidential  Page 99 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
IP initiation from 15 minutes to 6 minutes; and revised Convulsive SE 
criteria to include EEG seizure activity . 
Exclusion criteria #4: revised wording to ‘Seizure burden or clinical state 
would NOT warrant IV anesthesia for seizure control over the next 24 hours’  Synopsis, Section 4.2 
Defined medications for the acute treatment of SE  Synopsis, Section 104.1 
Primary Endpoint : Revised the  seizure burden to <20% and that the 
seizure burden is at least 50% less than during the 30 minutes prior to IP initiation  Synopsis, Section 10.4.1  
Other Secondary Endpoints added clarifying text for Proportion of 
participants with any escalation of treatment in the first 24 hours 
following IP initiation  Section 10.4.3  
Deleted all references of the Intent to Treat (ITT) population as per FDA 
comment to use mITT instead. Revised the description of the mITT 
population. Removed all references to Full Analysis Set (FAS)  Synopsis, Sections 10.3, 10.4.1  
Added sentence that the reason for each AED dose during IP 
administration will be recorded in the appropriate CRF  Section 5.2.1  
Appendix 3: Remdesivir added to the list of US -marketed products 
containing Captisol® Section 13, Appendix 3  
Additional grammatical, typographical errors and formatting revisions have been made in the document but are not identified here   
 
 
 
Confidential  Page 101 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
Added “ if available ” for estimated glomerular filtration rate (eGRF) 
and calculated creatinine clearance and removed albumin as this 
analyte is not tested in a routine urinalysis; added phenobarbital to the list of AED level collection  Synopsis (Methodology); Table 1 footnote i; Table 6  
Added “ if available ” for estimated glomerular filtration rate (eGRF) 
and calculated creatinine clearance and removed albumin as this 
analyte is not tested in a routine urinalysis; added phenobarbital to the list of AED level collection  Synopsis (Methodology); Table 1 
footnote i; Table 6  
Revised Drugs of Abuse testing and clarified that alcohol testing 
should be collected, if medically indicated to align with the 
institution SOC; T. Chol footnote 1 revised and footnote 2 and 3 added
 Synopsis (Methodology); Table 1 footnote l; Table 6  
Clarified that institution guidelines will be followed for pregnancy 
test results prior to IP initiation   Synopsis (Methodology); Table 1 
footnote l; Sections 4.4.1; 7.2.3.7  
Clarified that Electroencephalogram (EEG) is required for confirmation of CSE  diagnosis; removed “If continuous EEG is not 
possible or needed to diagnose (for convulsive SE) it should be 
instituted at the earliest possible time following IP initiation (if a 
predose EEG was not performed for the diagnosis of convulsive SE) as this statement no longer applies  
Added “Sites will be offered the use of a rapid EEG device to 
assist with screening of participants  with NCSE. It is preferred 
that a conventional EEG is used for the purpose of confirming inclusion criterion #3 and EEG monitoring during IP 
administration. In situations when a conventional EEG is not 
immediately available, the rapid EEG may be used to c onfirm 
inclusion criterion #3. Since the rapid EEG has a limited battery 
life, it should be switched to a conventional EEG within several 
hours but not earli er than 90 minutes after IP initiation to allow 
uninterrupted collection of EEG for the 30 -minute SE cessation 
co-primary endpoint. It will be at the investigator’s discretion if 
the use of the rapid EEG will benefit their site. The device should 
be used a ccording to institution standard practices .” This change 
will allow screening and enrollment based on a portable EEG device, 
Ceribell, (approved by the FDA), in situations when conventional EEG is not immediately available ( e.g., during night hours).  Synopsis (Methodology), Table 1 footnote m; Section 7.2.2.1  
Clarified where pharmacokinetic samples should be collected in relation to IP infusion site.  Synopsis (Methodology); Table 2 footnote b, Section 7.2.4.1  
Seizure Description Questionnaire should be collected predose only and as close as possible to IP initiation; all timepoints following IP initiation have been removed to reduce the burden of assessments 
throughout the study and to decrease the amount of re dundant 
information collected.  Synopsis (Methodology); Table 1 
footnote p; Section 7.2.2.6  
Status Cessation and Super Refractory Status Epilepticus Questionnaires and Sections 7.2.2.7 and 7.2.2.8, respectively added  Synopsis (Methodology); Table 1; footnote q & r, respectively  
Health Utilization Questionnaires and Section 7.2.2.8 added to align with statistical endpoints  Synopsis (Methodology); Table 1; footnote v 
The following inclusion criteria revised:  
#3. Removed “…without a pattern of improvement and at least 6 minutes of continuous or cumulative, intermittent seizure activity in the 30- minute period immediately prior to IP initiation, and either” 
replaced  with “…with seizure burden warranting imminent Synopsis (Inclusion/Exclusion Criteria); Section 4.1  
 
 
 
Confidential  Page 102 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
progression to IV anesthesia for seizure control. Ictal patterns 
and burden defined below.” Added “Ictal burden of 
approximately 6 minutes or more within 30 -minutes immediately 
prior to IP initiation is targeted”  
These changes in inclusion criterion #3 were made to better align 
with practical aspects of assessment of seizure burden at the bedside 
and with the second co -primary efficacy endpoint (progression to IV 
anesthesia within 36 hours).  
#4. Added phenobarbital to the list of acceptable second- line IV 
AEDs to align with SOC in the pediatric population  
#5. Revised BMI from <35 to <40  
The BMI cut -off was increased to allow enrollment of patients who 
are severely obese but not yet considered morbidly obese. BMI >40 is 
generally considered for the designation of “morbidly obese”.   
 
   
The following exclusion criteria revised:  
#2. Replaced “uncontrolled” with “ rapidly reversible ” when 
describing a metabolic cause of SE, e.g., hypoglycemia as this better 
describes the condition like severe hypoglycemia  
#3.Removed “phenobarbital or ketamine” from the list of anesthetic 
agents and added “with the primary intent specifically to treat 
seizures or achieve burst suppression” as phenobarbital has been 
added as an approved 2nd line IV AED counted for failure (inclusion 
criterion #4) and ketamine is generally not considered an IV 
anesthetic that can produce burst suppression or indicate SRSE if fails to control seizures  
#5. Added (e.g., directive Do Not Intubate ) at the end of the 
criterion  
#10. Added reporting unit for eGFR  
#11. Removed “ whichever is greater” when describing the use of an 
investigational product; added “ Participation in a non -
interventional clinical study does not exclude eligibility ” Synopsis (Inclusion/Exclusion Criteria); Section 4.2  
 
Synopsis (Investigational Product, Dose, 
and Mode of Administration);  
Sections 5.2.2; 6.2.6  
 
Revised timeframe for recording prior medications, including AEDs, administered from 30 for prior medications (7 for AEDs) to 14 days 
to reduce the amount of data collected for this acute indication and 
focus only on the medications that are expected to be  relevant to 
acute events  Synopsis (Methodology); Table 1 footnote u; Section 5.1  
Revised the definition for medications for the acute treatment of SE with the addition of “…or prevent imminent  recurrence of SE based 
on clinical or EEG evidence”  Synopsis (Endpoints); Section 10.4.1  
Healthcare Utilization Endpoints - removed list of discharge locations 
as they were not aligned with the case report form  Synopsis (Endpoints); Section 10.4.4  
Safety Endpoints – Removed “neurological” as this assessment is 
included in the physical examination; added “ use of concomitant  
medications, and occurrence of AEs ” to the safety analyses  Synopsis (Endpoints); Section 10.5  
Removed “and status strata (CSE or NCSE) as fixed effects” from 
logistic regression model to avoid unstable estimation of the 
regression coefficient of status strata as the majority of the participants will be NCSE  
Added “ In addi tion, the point estimate of difference of the 
proportions of participants achieving either and both of the co -
primary endpoints between two treatment arms will be provided. Synopsis (Analysis of Primary Endpoint); Section 10.4  
 
Confidential  Page 103 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
The 95% confidence interval will be provided using Clopper -
Pearson method”  to facilitate interpretation of the treatment effect 
Clinical Data 
Added findings from May 2021 breastfeeding study that have 
become available after the initial date of this protocol.  Section 1.2  
Added paragraph that describes the most common treatment 
emergent adverse events reported in the 1042- SE-2001 study Section 2.1  
Added Exploratory Objectives to align with the Synopsis  Section 2.2.3  
Restrictions  
Removed “from consuming grapefruit, Seville oranges, starfruit or 
citrus derived products” based on current DDI data; revised the 
restriction period for use of alcohol until the “ end of the 24 hour IP 
discontinuation follow -up period” based on the relatively short 
half-life of ganaxolone that is expected to be cleared from the body 
within 24 hours post discontinuation  
Clarified that breastfeeding is prohibited for 45 days after the last dose of IP  Section 4.3  
Revised duration for males to avoid causing pregnancy in their sexual partner during the study and for 30 days  after the last dose of IP  Section 4.4.2  
Added Section 4.5.1.1 Reason for IP Discontinuation   
Clarified that investigator clinical judgment should be used to determine if a participant should be discontinued from the study  
Revised participant withdrawal criteria related to ventilatory depression  Section 4.5.2  
Revised Section header to Reason for Study  Discontinuation  4.5.3  
Added details for collecting benzodiazepines, AEDs, anesthesia, and vasopressors data for prior to and concomitant treatment  Sections 5.1, 5.2  
Allocation of Participants to Treatment – clarified that randomization 
is defined as the initiation of IP infusion; provides flexibility for 
timing of randomization to avoid impact to SOC; emphasizes that IP 
administration cannot occur until eligibility cr iteria has been met  Section 6.2.2  
Clarified that IWRS will record all unblinding events and removed instruction that “code breaks must be reported to the Clinical Research Organization (CR) and Sponsor”  Section 6.2.8  
The protocol allows for additional labels to be applied to the IP to satisfy local or institution requirements; therefore, “on a case by case basis” was removed  
Removed the following paragraph “Identify the study participant by 
name…” and replaced with “Sponsor approval is not needed to make 
this change”  Section 6.3.1  
Section header revised to “Follow- up Period (24 hours following IP  
to Week 4) for clarification purposes  Section 7.1.3  
Section header revised to “Medical, Seizure or SE , and Medication 
History and added bullet “Seizure or SE Etiology” to be aligned with the data being collected  Section 7.2.3.1  
Removed “A neurological examination should be performed at the time of assent/consent is administered to the participant for continued 
participation…” as a neurological assessment is part of the physical 
examination and, therefore, no need to specify each system Section 7.2.3.2  
 
Confidential  Page 104 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
Section header revised to “ Medication Errors ” and section content 
updated to align with events that may occur when administering the 
IV formulation; removed references of “abuse, misuse or overdose”; 
added Other Reportable Information; clarified that reports of 
Medication Errors and Other Reportable  Information are subject to 
the 24- hour reporting requirement  Sections 8.1.7; 8.2.2  
Removed paragraph that states that the IB has not been updated to include the 1 mg/mL ganaxolone IV formulation as the current IB includes this information  Section 8.2.1  
Revised guidance for data entry of participant data in the electronic data capture system; removed reference to Data Management Plan (DMP) as this is an internal document  Sections 9.1 and 9.2  
Revised the Analysis Population descriptions for Enrolled, Safety, Modified Intent to Treat (mITT) and Per Protocol (PP); added Randomized  Section 10.2  
Removed “During the study, participants will receive usual SOC …” through “The comparison for statistical significance….”;  
Added “ Both co -primary efficacy endpoints must be statistically 
significant at 2 -sided 5%...”   
Added “In addition, the point estimate of difference…to align with statistical principles  Section 10.4  
Clarified which data are included in the Safety Analyses  Section 10.5  
Clarified that there is no formal interim analysis planned for this study and that the DMC is chartered to review the study data periodically without any hypothesis testing  Section 10.7  
Reference 37 and 38 added  References  
Salzburg Criteria: Illustration revised to clarify patient eligibility  Appendix 2  
Clarified that the table listing the US -Marketed Products containing 
Captisol® is not an exhaustive list  Appendix 3  
Added recording window for extraction of the 3 timepoints  Appendix 4  
Added Appendix 5 Summary of changes from Protocol Amendment 1   
Additional grammatical, typographical errors and formatting revisions have been made in the document but are not identified here   
  
 
Confidential  Page 106 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
To align with the revised inclusion criteria all references to the text in the bullets below has 
been removed or revised to align with the updated inclusion criteria:  
• “following initial benzodiazepine treatment and administration of two or more second -line IV AEDs.”  
• “after initial treatment with benzodiazepines and”  
• “Investigators should determine that doses of administered second -line AEDs 
were sufficient for treatment of SE.”  
• “Antiepileptic drug doses utilized in the treatment of SE are provided in Appendix 1.” 
In addition , the following have  been updated throughout the protocol to align with the 
update inclusion criteria : 
• References to the participants receiving any two or more of the following  agents  
for the treatment  of the current episode of SE, administered at an adequate dose 
and for a sufficient  duration, in the judgment of the investigator, based on 
investigator judgment, at an adequate dose and for a sufficient duration to 
have  demonstrated efficacy: As previously described, IP will be added to SOC 
after “initial treatment with benzodiazepines and” failure of any  two or more 
“second -line IV AEDs” antiseizure treatmen ts (benzodiazepine and one IV 
AED or two IV AEDs).  
And Benzodiazepine has been added to the list of possible treatments a participant may fail 
prior to IP initiation and IV has been added to all the 2
nd line IV AEDs  Synopsis (Investigational 
Product, Dose, and 
Mode of 
Administration), (Methodology), 
Section s 3.1, 5.2.1, 
6.2.3  
 
 
To align with the inclusion criteria, the original wording, “After meeting the criteria for SE 
(clinical and EEG) within 60 minutes prior to IP initiation, the presence of ictal activity SE 
(clinical and EEG) should be confirmed during the 30 minutes immediately prior to IP 
initiation (bolus dose). Has been updated to the following:  
The investigator will confirm that the participant meets clinical and EEG criteria for 
SE during the 60 -minute period  prior to IP initiation and will reconfirm that ongoing 
ictal activity is present within  30 minutes immediately prior to IP  initiation .  Synopsis 
(Investigational 
Product, Dose, and 
Mode of Administration), 
Section s 6.2.3 and 
7.1.2.1  
 
Moved, “ Status epilepticus cessation will be assessed by the investigator based on clinical 
and EEG features. Training will be provided to guide and help standardize decisions across 
clinical sites. In addition, a retrospective confirmatory analysis of EEGs will be performed 
by a central reader  who is blinded to treatment assignment" from the Methodology section 
to the Endpoints section as, “ SE cessation will be assessed by the investigator based on 
clinical and EEG features (see Appendix 1 for seizure cessation guide). Training will be 
provided to guide and help standardize decisions across clinical sites. In addition, a central 
reader blinded to treatment assignment  will review EEG recordings retrospectively and 
corroborate accuracy of interpretation .” And moved  to Appendix 1, “ *SE cessation will 
be determined by the investigator based on clinical and EEG findings. The criterion for time of electrographic seizure cessation will be the beginning of the first 30 -minute epoch 
of EEG in which  
The seizure burden (percent of time during which there is electrographic seizure activity) is 
<20% ”  
and 
“The seizure burden is at least 50% less than during the 30 minutes prior to IP initiation”  
to align the Endpoint section of the synopsis  to align the Endpoint s. Synopsis 
(Methodology), 
(Endpoints), Section 6.3 2, Section 10.4.1  
Expanded the Vital signs collection window from (+/ - 1 hour) to (+/- 2 hour) for 24 hours 
(+/- 1 hour) following IP discontinuation timepoint.  
Removed the 12 -hour and added a 10-hour  collection time point to better align with the 
RASS, FOUR Score, CGI-I, and PK collections.  Synopsis (Methodology), Table 1 footnote e  
 
Confidential  Page 107 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
Removed the 12 -hour and added a 10-hour  collection timepoint for the RASS and FOUR 
Score to better align with the Vital Sign , CGI-I, and PK collections.  Synopsis 
(Methodology), Table 1 footnote f  
Removed the 36 hours (+/- 1 hour) following IP initiation  for the 12 lead 
Electrocardiogram  (ECG).  Synopsis (Methodology), Table 1 footnote g  
Added clarification, concomitant AED levels only need to be collected if required per the 
standard of care.  
Removed all requirements for variable AED collections:  
Variable AED collection times based on participant response : 
Between  IP initiation and at the end of the first 24 hours of the follow -up period, 
where possible, collect sample for AED level(s):  
I. If a decision is made to intubate  
II. After initial SE cessation, AED levels should be collected at time of 
first recurrence of seizure activity or SE  Synopsis 
(Methodology), Table 1 footnote i  
Removed the weekly follow up visit Coagulation sample collection  
At the weekly follow -up visits (Week 1, 2, 3, or 4) for hospitalized participants and for 
participants who have been discharged (whenever possible).  Synopsis 
(Methodology), Table 1 footnote k  
Removed the 4, 8, and 12- hour PK collections and added a 6 and 10 hour  collections to 
make the sample collections not intersect with an infusion change.  
Increased the collection window for 10, 24, and 36 hour samples to (+/- 2 hour)  
Removed requirements I, II, and IV for variable PK collections:  
Variable PK collection times based on participant response: 
Between IP initiation and at the end of the first 24 hours of the follow -up period, 
where possible, collect a  PK sample:  
I. If a decision is made to intubate  
II. At the time of introduction of a new AED for safety/efficacy (not for AEDs given prophylactically for “transition/bridging”)  
IV. After the initial SE cessation, collect a sample at the first instance of seizure activity or 
SE relapse and does not progress to anesthesia (e.g., midazolam, propofol, thiopental, or 
pentobarbital)  Synopsis 
(Methodology), Table 2 footnote b  
Removed the 12 -hour and added a 10-hour  collection timepoint for the CGI -I to better 
align with the Vital Sign, RASS, FOUR Score, and PK collections.  Synopsis (Methodology); Table 1 footnote o  
Unified all references to mechanical or artificial ventilation to be positive pressure  
ventilation (PPV)  Synopsis (Methodology), 
(Endpoints), Sections 
7.3, 10.4.2, and 
10.4.4 
The following inclusion criteria revised:  
As the study is expanding globally #1 was updated to allow for deferred consent to be 
obtained where allowed by law.  
1. Participant, participant’s  parent, guardian,  or LAR must provide  signed 
informed  consent/assent, and once  capable  (per institution al guidelines), 
there  must be documentation of  consent/assent by the  participant 
demonstrating they are  willing and aware  of the investigational nature  of the 
study and related procedures. Where allowed by law, if the patient lacks 
the capacity to make informed decisions regarding his/her medical 
treatment options, the treating clinician may follow their deferred Synopsis 
(Inclusion/Exclusion Criteria), Section 4.1  
 
   
 
 
 
Confidential  Page 108 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
consenting practices. The clinician will make the final decision based on 
the best interests  
of the patient.  
#3 was completely deleted, and new wording added to clarify the requirement and better 
align with clinical practice of SE diagnosis  
3. SE meeting the following criteria:  
a. A diagnosis of SE with or without prominent motor features based 
on clinical and EEG findings:  
i. Diagnosis is established by:  
• For SE with prominent motor features: Clinical and EEG  
seizure activity indicative of convulsive, myoclonic or focal 
motor SE  
• For SE without prominent motor features (nonconvulsive 
SE): Appropriate clinical features and an EEG indicative of NCSE (see  modified Salzburg criteria
19 in Appendix 3)  
ii. For any type of SE:  
• At least 6 minutes of cumulative seizure activity over a 30-
minute period within the hour before IP initiation, AND  
• Seizure activity during the 30 minutes immediately prior 
to IP initiation 
b. The treating clinician(s) anticipate that IV anesthesia is likely to be 
the next treatment for SE that persists following initiation of IP  
#4 Revised to clarify the requirement and better align with clinical current practice that 
some patients may not be receiving benzodiazepines and would be started on second- line 
agents directly . “Participants must have received a benzodiazepine and two or more of the 
following second- line IV AEDs for treatment of the current episode of SE” was revised to 
“Participants must have received any two or more of the following agents for treatment 
of the current episode of SE”  
Benzodiazepine was added to the bulleted list of medications and IV was added to all the bulleted second -line IV AEDs:  
o Benzodiazepines,  
o IV Fosphenytoin/phenytoin,  
o IV Valproic  acid,  
o IV Levetiracetam,  
o IV Lacosamide,  
o IV Brivaracetam, or  
o IV Phenobarbital   
The following exclusion criteria 2, 3, 4, 8, 11 revised  
#2 added “an uncorrected”, to Anoxic brain injury or an uncorrected  rapidly reversable 
metabolic condition as the primary cause of SE (e.g., hypoglycemia <50 mg/dL or hyperglycemia >400 mg/dL).  
#3 deleted the text, “with the primary intent to treat seizures or achieve burst suppression” 
and added the bolded text below  
Participants who have received high -dose  IV anesthetics  (e.g., midazolam, 
propofol, thiopental,  or pentobarbital) during the current episode of SE for 
more than 18 hours, or who continue to have clinical or electrographic 
evidence of persistent seizures while receiving high -dose IV anesthetics . Synopsis (Inclusion/Exclusion Criteria); Section 4.2  
 
 
 
Confidential  Page 109 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
#4 and #5 were deleted and a new exclusion added:  
Clinical condition or advance directive that would NOT permit use of IV anesthesia  
The changes to exclusion #3, 4, and 5 were all made to simplify the protocol requirements 
around IV anesthetic use in this patient population.  
 
Due to the combining of exclusion #4 and 5, the remaining criteria have been renumbered.  
#7 “US -” was removed as the appendix now reflects the global marketed products 
containing Captisol® 
#8 leading to impaired synthetic liver function  was added to hepatic restrictions to better 
define the medical condition and guide the investigators  
Clarified that while the screening period is from the time consent/assent is obtained (or 
deferred, if allowed by law) to immediately prior to IP initiation (excluding pre -consent).  
Assessments collected prior to this timeframe that the investigator judges to be clinically 
relevant to the participant’s current state can be utilized in the study and do not need to be 
repeated. For medically unstable participants , screening activities (e.g., labs or vital signs) 
should be collected as close to IP initiation as possible . Synopsis  (Maximum 
Duration of 
Participant 
Involvement in the Study), Table 1 
footnote a 
Other Secondary Endpoint , Level of sedation has added agitation  to better define the 
assessment collection.  Synopsis (Endpoints), Sect
ion 10.4.3  
Added Time on positive pressure ventilation to the Healthcare Utilization Endpoints 
and moved Proportion of participants requiring positive pressure ventilation to the second 
bullet based on key opinion leader feedback of the rank of meaningful clinical response.  Synopsis (Endpoints), 
Section 10.4.4  
 
Removed “ Status epilepticus cessation will be based on investigator judgmen t, according to 
the following criteria:  
a. SE cessation of at least 30 minutes duration, and  
b. Without administration of medications for the acute treatment of SE from the 
time of IP initiation through 30 minutes following the onset of SE cessation”  
Removed  “Key secondary endpoints will be compared between ganaxolone - and placebo -
treated participants in the mITT population with a hierarchical testing process at the 5% 
level of significance. The analysis of secondary efficacy endpoints will use the order of 
endpoints listed above. Assuming that a statistically significant difference between groups was observed on both co -primary endpoints, the first key secondary endpoint will be 
compared between groups. If statistical significance is established on the first key secondary endpoint, then the testing process will proceed to the second key secondary endpoint.” And replaced it with , If the primary endpoints are statistically significant, 
the analysis of key secondary efficacy endpoints will be performed sequentially in the order as listed above. If the key secondary endpoints are statistically significant, analysis of the first healthcare utilization endpoint, time on positive pressure ventilation, will be performed.  
 
Added that the time on positive pressure ventilation endpoints will be analyzed using the 
Kaplan -Meier method.  
 
Added an Interim Analysis section to the Synopsis:  Synopsis (Statistical 
Methods), Section 
10.4.2 and 10.7 
 
 
Confidential  Page 110 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
We plan to conduct an interim analysis when two -thirds of the subjects have 
completed the study ( 41 participants per arm). The overall type I error rate (i.e., 
alpha=0.05, two -sided) will be controlled using a power family alpha spending 
function, with a two -sided nominal alpha level of 0.0293 at the interim analysis. If one 
or both primary efficacy endpoints fail to reach statistical significance at the interim 
analysis, the same testing process will be repeated at the final analysis at the nominal 
alpha l evel of 0.0343. The interim analysis will be performed by an independent 
statistician who is not involved in study operation and conduct.  
If study enrollment is proceeding at a rate that the study  would be complete or nearly 
complete by the time an interim analysis is accomplished, the Sponsor may elect not to conduct it.  
Further details will be provided in the SAP . 
Updated the exclusion criterion reference from #8 to #7 to match the renumbering. Section 5.2.2  
Removed reference to the IP formulation  and storage requirements as this information will 
be detailed in the pharmacy manual , “In addition to Captisol®, the formulation consists of 
water for injection (diluent), buffering agents (potassium phosphate, sodium phosphate) 
and sodium chloride (tonicity modifier).”  
 
To simplify the protocol and refer the reader to the Pharmacy Manual.  
 
Added, “On 01 June 2022 the Drug Enforcement Administration (DEA) issued its 
interim final rule placing ganaxolone, including its salts, in schedule V of the 
Controlled Substances Act. The DEA drug code for Ganaxolone (commercial name, 
Ztalmy) is 2401. ” 
Also removed the storage requirements as the information is detailed in Section 6.3.3 
(Storage)  Section 6.1  
The Interactive Response Technology (IRT) features are being updated, and as a result, IP 
allocation  has been added to the list of available tasks.  
The following has been deleted:  Randomization consists of two steps. The participant will first be assigned a randomization 
number and assignment of IP bottles by the IRT followed by the initiation of IP. This second step of initiation of the IP means the patient is randomized .  
The randomization number represents a unique number corresponding to IP allocated to the participant.  Section 6. 2.1, 6.2.2  

 
Confidential  Page 111 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
Individual participant treatment is automatically assigned by the IRT  
To allow for timely delivery of IP to the hospital unit, the IP bottles  may be allocated for 
use in the IRT prior to the participant meeting all eligibility criteria to avoid impact to 
SOC. Investigational product will not be administered until eligibility has been determined. 
Enrollment is defined as the initiation of IP infusion. 
Added a reminder that the investigator is responsible for complying with the DEA and CSA 
regulations now that ganaxolone is a scheduled drug, “The investigator has overall 
responsibility for ensuring that IP is stored in a secure, limited access location in accordance with applicable requirements under the Controlled Substance Act (CSA) 
and Drug Enforcement Administration (DEA) regulations.”  
Removed the temperature ranges, “The 1 mg/mL ganaxolone IV solution and placebo 
bottles should be stored at room temperature 15°C to 25°C (59°F to 77°F) until use. 
Excursions up to 30°C (86°F) that are less than or equal to 72 hours are allowed” and 
referr ed the site staff to the pharmacy manual for the storage requirements.  Section 6.3.3  
To clarify the collection requirements if a weekly follow -up visit is close to the discharge 
visit the bold sentence has been added: The follow -up period for this protocol is 
approximately 4 weeks. Week 1, 2, 3, and 4 visits may be conducted as an inpatient visit, if 
the participant is still in the hospital, or as a telephone contact, if the participant has been 
discharged. Attempts should be made to have discharged participants return for one of 
these visits to be in person. The participant/participant’s p arent/guardian/LAR, as 
appropriate, will receive a follow -up contact weekly approximately 7 ± 3, 14 ± 3, 21 ± 3, 
and 28 ± 3 days following the IP discontinuation date. If the hospital discharge visit 
corresponds to the Week 1, 2, 3, or 4 (± 3 days) visits it can take the place of the 
weekly visit.  Section 7.1.3  
Clarified that rapid EEG can be utilized to screen and enroll participations where a 
conventional EEG may not be available.  Section 7.2.2.1  
Updated blood collection volumes to 48 to 59 mL for pediatric institutions and 140.3 to 
190.4 mL for adult participants, based on the revisions to Table 1 and Table 2.  Section 7.2.4.3 
(Tables 7 and 8)  
The following text was added to the protocol to cover the expansion of the study to 
countries outside of the USA  
• For ex -US countries, the Sponsor will comply with local laws and 
requirements with  regard to SAE  reporting   
• European Public posting site, Europe’s website - Eudract.ema.europa.eu  
• All EU and UK based sites, laboratories, or entities providing support for this 
study, must, where applicable, comply with General Data Protection 
Regulation (GDPR) 2016/679 for the purposes of data protection and privacy . Section s 8.2.7, 11.1.2, 
and 11.4  
Simplified the population definitions by removing the Enrolled and Randomized population 
definitions. Additional population data can be found in the SAP.  
Enrolled: All participants who signed the ICF and received a participant number.  
Randomized: All enrolled participants who received a randomization number and met all 
inclusion criteria and none of the exclusion criteria or received IP.  Section 10.3  
Updated Reference 32 to the latest version of the investigator brochure  References  
Updated the US -Marketed Products containing Captisol® to be the Global list of marketed 
products and removed the Sponsor  Appendix 4 
Added Appendix 6 Summary of changes from Protocol Amendment 2  Appendix 6 
Additional grammatical, typographical errors and formatting revisions have been made in 
the document but are not identified here   
 
  
 
Confidential  Page 113 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
largely focused on rapid SE cessation, including initiation of drugs to terminate 
seizures and reversal of conditions that may lower seizure threshold. Potentiating 
GABAergic inhibition is a key mechanism to achieve rapid seizure cessation in both 
adults a nd children.  
Summary of nonclinical Captisol® data in rats added.  Section 1.2  
Language for secondary objective updated to “ To evaluate the sustained efficacy of 
ganaxolone IV beyond the 48 -hour treatment period as assessed by prevention of 
progression to IV anesthesia for the treatment of SE” for clarity.  
Secondary objective “Determine the effect of ganaxolone on healthcare utilization” 
changed to an exploratory objective .  Syn
opsis  (Objectives ) 
Section 2.2  
Expanded regions/sites to United States, Canada and Australia.  Synopsis (Site(s) and Region(s)) and 
Section 3.3  
Inclusion criterion #3 updated to “approximately 6 minutes” for SE diagnosis as p recise 
and prospective calculation of ictal burden by providers caring for patients at the bedside 
may result in delay of standard of care . Synopsis ( Inclusion and Exclusion 
Criteria ) 
Section 4.1  
The following exclusion criteria has been reinserted into Section 4.2 to align with the synopsis. 
11. Known or suspected history or evidence of a medical condition that, in the 
investigator’s judgment, would expose participant to an undue risk of a significant 
adverse event or would interfere with assessments of safety or efficacy during the 
study.  Section 4.2  
Inclusion of creatinine collection for urine chemistry evaluations alongside  N-acetyl -β-D-
glucosaminidase [NAG] and β2- microglobulin.  Synopsis ( Safety and Assessments ), 
Section  6.2.4 , Section 7.2.3.7  
(including Table 6 ) 
The maximum dosing for Captisol® was clarified as 50 g /day (1.25 g/kg/day in 
participants weighing <40 kg)  which corresponds to a maximum ganaxolone dose of  
833 mg/day (20.825 mg/kg/day in participants weighing <40 kg) . Synopsis (Rationale, Dose 
adjustments and interruptions ), 
Section 6.2.7  
Section 8.1.7  
Pharmacokinetic blood collection time window updated for consistency within protocol and ganaxolone and Capitsol specified to be collected.  Synopsis ( Safety and Assessments ) 
Section 7.2.4.1  
Total blood volume values corrected and assessment for IV AEDs row removed as no  
longer required per protocol.  Synopsis ( Safety and Assessments ) 
Section  7.2.4.3  and Table 8  
Updated “M arinus Safety Department or its delegate ” to Marinus Drug  Safety vendor . EMERGENCY CONTACT 
INFORMATION  
Sections 8.1.6, 8.1.7 , 8.2.2, 8.2.4  
Removed “A copy of the Pregnancy Report Form (and any applicable follow -up reports) 
must also be sent to the Medical Monitor using the details specified in the emergency 
contact information section at the beginning of the protocol. ” Section 8.1.6  
Time to SE cessation following IP initiation  designated as first k ey secondary endpoint . 
Secondary endpoint language expanded for consistency with primary endpoint to 
“Proportion of participants with no progression to IV anesthesia for 72 hours following 
IP initiation ” and other secondary endpoint clarified as “Proportion of participants 
whose treatment does not progress to  IV anesthesia for  4 weeks following IP initiation ”. Synopsis (Endpoints, Statistical 
Methods) 
Section 10.4 
Clarification added on the timing of the Healthcare Utilization endpoints  as follows:  
• Time on positive pressure ventilation after IP initiation   Synopsis ( Healthcare Utilization 
Endpoints ) 
Section 10.4.4  
 
Confidential  Page 114 of 114 IND 129433   Marinus Pharmaceuticals , Inc. 
Protocol 1042 -SE-3003   Version 6.0 
• Proportion of participants requiring positive pressure ventilation initiated during 
IP infusion  
• Length of stay in intensive care unit and in hospital after IP initiation . 
Details for the p harmacokinetic analyses  added to replace cross -reference to separate 
analysis plan.  Section 10.6  
Additional grammatical, typographical errors and formatting revisions have been made in 
the document but are not identified here . Throughout the document  
 